ANTICORPOS ANTI-PSMA, CONJUGADOS E MÉTODOS PARA USO

Abstract

Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates) thereof that bind PSMA, as well as STING agonist linker-drug conjugates and preparation thereof, are disclosed. The disclosure further relates to methods and compositions for use in the treatment of, e.g., cancer by administering the compositions provided herein.

Description

Anti-PSMA antibodies, conjugates, and methods for use.

[0001] This application claims the benefit of Provisional Application No. U.S. 63 / 487,553, filed February 28, 2023, and Provisional Application No. U.S. 63 / 557,342, filed February 23, 2024, the contents of which are incorporated by reference in their entirety.

[0002] The present disclosure relates to anti-PSMA antibodies and antigen-binding fragments thereof, as well as conjugates, such as antibody-drug conjugates (ADCs), for example, those comprising a STING agonist, and their use in the treatment and diagnosis of cancers that express PSMA and / or are amenable to treatment by modulating the STING pathway or administering a composition disclosed herein.

[0003] Prostate cancer is the second most common type of cancer and the second leading cause of cancer death in men. There are currently limited treatment options for metastatic prostate cancer, with a poor prognosis in such cases and a need to develop more effective treatments.

[0004] Prostate-specific membrane antigen (PSMA) is a cell surface antigen that is highly expressed in prostate cancer. PSMA expression levels increase along with prostate cancer progression, with high PSMA expression maintained at metastatic sites. Anti-PSMA antibodies have been previously generated, including modified antibodies with reduced immunogenicity in humans. See, for example, U.S. Patent No. 7,045,605 and U.S. Patent No. 11,059,903. Examples of antibodies that bind PSMA are J591 and deimmunized J591 (deJ591). The amino acid sequence of the variable heavy chain domain of the J591 antibody is given herein as SEQ ID NO: 40, and the corresponding variable light chain domain is given herein as SEQ ID NO: 41. However, clinical trials using this antibody have shown undesirable immunogenicity effects, including myelosuppression and liver enzyme abnormalities. See, for example. Petition 870260065905, dated 03 / 07 / 2026, page 5 / 1400 2 / 650 example, from Bono et al. (2021) Clin Cancer Res 27 (13): 3602-3609. There remains a need for PSMA antibodies, for example, those that are fully humanized to minimize immunogenicity while retaining desirable properties such as satisfactory target binding affinity, low off-target binding, and satisfactory stability.

[0005] Given the high expression of PSMA in prostate cancer, it can be used as a target for antigen-specific drug delivery approaches, for example, an antibody-mediated approach. Antibodies conjugated with cytotoxic compounds, such as chemotherapeutic agents, have also been explored to increase the cell-killing activity of antibody-based drug delivery to tumor cells. However, the need remains to provide suitable antibodies and / or ADCs, such as those that offer a combination of efficient prostate tumor targeting, on-target effects, and / or reduced off-target effects.

[0006] STING (stimulating interferon gene) is a pattern recognition receptor that detects cyclic dinucleotides in the cytosol and induces the expression of type I interferons and other inflammatory cytokines (e.g., interferon-β (IFN-β), tumor necrosis factor alpha (TNFα), Chemokine Motif Ligand CXC 10 (CXCL10), interleukin-6 (IL-6)), which in turn mediates the innate immune response to infections or diseases, e.g., cancer. STING signaling has been shown to have antitumor effects, such as modulation of the vasculature and enhancement of adaptive immunity. First-generation STING agonists, e.g., cyclic dinucleotides, often require intratumoral injection and show only modest systemic efficacy. These STING agonists are also poorly membrane permeable, which may limit their ability to bind to STING inside the cell.

[0007] Although uses of STING agonists to treat infection or disease have been reported in the art, an unmet need remains for delivery systems that would allow the Petition 870260065905, dated 03 / 07 / 2026, p. 6 / 1400 3 / 650 Systemic administration of STING agonists that specifically target tumor sites. Similarly, there remains a need in the art for improved antibodies that bind to PSMA with superior properties, for example, with respect to antigen binding and / or the ability to effectively deliver payloads, such as a STING agonist, to a target cell or tissue expressing PSMA. SUMMARY OF THE INVENTION

[0008] In several embodiments, the present disclosure provides, in part, innovative antibodies and antigen-binding fragments that have the ability to specifically bind to PSMA and can be used independently or linked to one or more additional agents (e.g., as ADCs) and administered as part of pharmaceutical compositions. In some embodiments, the antibodies, antigen-binding fragments and / or ADCs of the present disclosure can be used to delay, inhibit and / or reverse tumor growth in mammals, and may be useful for treating human cancer patients.

[0009] The present disclosure relates specifically, in several embodiments, to antibodies and antibody-drug conjugate compounds that have the ability to bind and / or kill cells expressing PSMA. In several embodiments, the compounds also have the ability to internalize into a target PSMA-expressing cell after binding. Anti-PSMA-ADC compounds comprising a linker that links a chemical moiety of STING agonist, for example, Formula (III), Formula (IV), or a compound from Table 16, for example, Compound 1, to an anti-PSMA antibody chemical moiety are disclosed. An anti-PSMA antibody chemical moiety can be a full-length antibody or antigen-binding fragment.

[0010] In various embodiments, the present disclosure provides a humanized anti-prostate membrane antigen-specific antibody (PSMA) or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment specifically binds to human PSMA, and Petition 870260065905, dated 03 / 07 / 2026, p. 7 / 1400 4 / 650 wherein the antibody or antigen-binding fragment comprises (i) three HCDRs comprising amino acid sequences of SEQ ID NO: 21 (HCDR1), SEQ ID NO: 22 (HCDR2) and SEQ ID NO: 27 (HCDR3); and three LCDRs comprising SEQ ID NO: 32 (LCDR1), SEQ ID NO: 35 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the Kabat numbering system; or (ii) three HCDRs comprising amino acid sequences of SEQ ID NO: 21 (HCDR1), SEQ ID NO: 22 (HCDR2) and SEQ ID NO: 27 (HCDR3); and three LCDRs comprising SEQ ID NO: 33 (LCDR1), SEQ ID NO: 36 (LCDR2), and SEQ ID NO: 37 (LCDR3), as defined by the Kabat numbering system; or (iii) three HCDRs comprising amino acid sequences of SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2), and SEQ ID NO: 30 (HCDR3); and three LCDRs comprising SEQ ID NO: 38 (LCDR1), SEQ ID NO: 39 (LCDR2), and SEQ ID NO: 37 (LCDR3), as defined by the IMGT numbering system.

[0011] In some embodiments, the anti-PSMA antibody or antigen-binding fragment comprises three HCDRs comprising amino acid sequences of SEQ ID NO: 21 (HCDR1), SEQ ID NO: 22 (HCDR2) and SEQ ID NO: 27 (HCDR3); and three LCDRs comprising SEQ ID NO: 32 (LCDR1), SEQ ID NO: 35 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the Kabat numbering system; or three HCDRs comprising amino acid sequences of SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2) and SEQ ID NO: 30 (HCDR3); and three LCDRs comprising SEQ ID NO: 38 (LCDR1), SEQ ID NO: 39 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the IMGT numbering system.

[0012] In some embodiments, the anti-PSMA antibody or antigen-binding fragment comprises a variable heavy chain region comprising an amino acid sequence of SEQ ID NO: 1 and a variable light chain region comprising an amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-PSMA antibody or antigen-binding fragment comprises a variable heavy chain region comprising an amino acid sequence of SEQ ID NO: Petition 870260065905, dated 03 / 07 / 2026, page 8 / 1400 5 / 650 and a variable light chain region comprising an amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-PSMA antibody or antigen-binding fragment comprises a variable heavy chain region comprising an amino acid sequence of SEQ ID NO: 3 and a variable light chain region comprising an amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-PSMA antibody or antigen-binding fragment comprises a variable heavy chain region comprising an amino acid sequence of SEQ ID NO: 14 and a variable light chain region comprising an amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-PSMA antibody or antigen-binding fragment comprises a variable heavy chain region comprising an amino acid sequence of SEQ ID NO: 14 and a variable light chain region comprising an amino acid sequence of SEQ ID NO: 19.

[0013] In some embodiments, the anti-PSMA antibody or antigen-binding fragment comprises a constant region of human IgG1 heavy chain. In some embodiments, the anti-PSMA antibody or antigen-binding fragment comprises a constant region of human Ig kappa light chain.

[0014] In some embodiments, the anti-PSMA antigen-binding fragment has a melting temperature (Tm) > 80 °C. In some embodiments, the antigen-binding fragment is a Fab.

[0015] In some embodiments, the anti-PSMA antibody or antigen-binding fragment is linked to at least one ligand. In some embodiments, at least one ligand is cleavable. In some embodiments, at least one ligand is conjugated with a cytotoxic agent or detectable reagent.

[0016] In several embodiments, the present disclosure also provides, in part, innovative binder-payload conjugates. The present disclosure relates specifically, in several embodiments, to conjugates Petition 870260065905, dated 03 / 07 / 2026, p. 9 / 1400 6 / 650 ligand-payload comprising a ligand that links a STING agonist chemical moiety, for example, Formula (III), Formula (IV), or a compound from Table 16, for example, Compound 1, to an anti-PSMA antibody moiety.

[0017] In various embodiments, the present disclosure provides a ligand-payload conjugate comprising LD, where L is a ligand covalently bonded to D, where D comprises a compound according to one of the following formulas: Formula (UI). Formula (IV), an isomer thereof, a deuterated derivative of the compound or isomer; or a salt of the compound, isomer or deuterated derivative; wherein, independently for each occurrence, each of Pa and Pb, when not racemic, is independently selected from stereochemistry (R) and stereochemistry (S); Each of Qa and Qb is independently selected from NH and O; Each of Va and Vb is independently selected from F and OH; W is selected from H and NH2; Each of Xa and Xb is independently selected from OH and SH; Each of Ya and Yb is independently selected from O and S; Each Za and Zb is independently selected from CH2, O and Petition 870260065905, dated 03 / 07 / 2026, page 10 / 1400 7 / 650 NH; e = means that the bond is selected from a single bond (—), a double bond (=) of configuration (E) or (Z), or a triple bond ( =); provided that at least one of Zae Zb is NH or at least one of Xa and Xb is SH.

[0018] In some embodiments, Pa is of configuration (S) and Pb is of configuration (R). In some embodiments, Pa is of configuration (R) and Pb is of configuration (R). In some embodiments, Q and Qb are O. In some embodiments, Va and Vb are OH. In some embodiments, Va and Vb are F. In some embodiments, W is H. In some embodiments, at least one of Za and Zb is NH. In some embodiments, Za and Zb are NH. In some embodiments, it comprises a double bond (=) of configuration (E) or (Z). In some embodiments, the bridge has structure h or H. In some embodiments, at least one of Ya and Yb is O. In some embodiments, Ya and Yb are O. In some embodiments, at least one of X and Xb is SH. In some embodiments, X and Xb are SH. In some embodiments, D comprises a compound of Formula (III).

[0019] In some embodiments, D comprises a compound of Formula (III) selected from: Compound 1 Petition 870260065905, dated 03 / 07 / 2026, p. 11 / 1400 8 / 650 Compound 2 Petition 870260065905, dated 03 / 07 / 2026, p. 12 / 1400 9 / 650 and you leave the same.

[0020] In some embodiments, D comprises a compound of Formula (III) selected from: Compound 1 Compound 2 and its salts.

[0021] In some forms, D comprises Compound 1.

[0022] In some forms, D comprises Compound 2.

[0023] In some embodiments, at least one of Xa and Xb is SH and L is linked to D through a sulfur atom on sulfur S-2 or sulfur S-14. In some embodiments, Xb is SH and L is linked to D on sulfur S-2. In some embodiments, Xa is SH and L is linked to D on sulfur S-14.

[0024] In some embodiments, at least one of Za and Zb is NH and L is linked to D through a nitrogen atom on nitrogen N-34 or nitrogen N-39. In some embodiments, Zb is NH and L is linked to D on nitrogen N-34. In some embodiments, Za is NH and L is linked to D on nitrogen N-39.

[0025] In some embodiments, L is a cleavable ligand. In Petition 870260065905, dated 03 / 07 / 2026, p. 13 / 1400 In some embodiments, the cleavable linker comprises a cleavable peptide chemical portion. In some embodiments, the cleavable peptide chemical portion is cleavable by a protease, optionally wherein the protease is a cathepsin or a legumein. In some embodiments, the cleavable peptide chemical portion comprises an amino acid unit. In some embodiments, the amino acid unit comprises Val-Ala, Val-Cit, Val-Lys, Ala-Ala-Asn, Ala-(NMe)Ala-Asn, Asn, Gly-Gly-Phe-Gly (SEQ ID NO: 141), GluVal-Ala, or Gly-Val-Ala. In some embodiments, the cleavable linker comprises Val-Cit. In some embodiments, the cleavable linker comprises Val-Ala.

[0026] In some embodiments, the linker comprises a maleimide (Mal) chemical moiety. In some embodiments, the Mal chemical moiety comprises maleimidocaproyl (MC). In some embodiments, the Mal chemical moiety is linked to an antibody or antigen-binding fragment via a cysteine ​​residue on the antibody or antigen-binding fragment.

[0027] In some embodiments, the binder further comprises at least one spacer unit. In some embodiments, the at least one spacer unit comprises at least one polyethylene glycol (PEG) chemical moiety. In some embodiments, the at least one PEG chemical moiety comprises -(PEG)m- where m is an integer from 1 to 10. In some embodiments, m is an integer from 2 to 8. In some embodiments, m is an integer from 2 to 5. In some embodiments, m is 2. In some embodiments, the at least one spacer unit comprises PEG2-Lys(s-PEGs-OMe)-PEG2.

[0028] In some embodiments, at least one spacer unit comprises θ. In some embodiments, at least one spacer unit comprises Formula (II). Petition 870260065905, dated 03 / 07 / 2026, p. 14 / 1400 11 / 650

[0029] In some embodiments, the linker additionally comprises at least one self-immolating unit. In some embodiments, the linker comprises a first self-immolating unit. In some embodiments, the linker has the ability to be removed from D after cleavage of the linker by self-immolation of the first self-immolating unit. In some embodiments, the first self-immolating unit comprises a p-aminobenzyl (pAB) optionally substituted with 1-3 substituents chosen from methyl, fluorine, chlorine, trifluoromethyl, aryl, and heteroaryl. In some embodiments, the first self-immolating unit comprises a p-aminobenzyl (pAB). In some embodiments, the linker comprises MC-Val-Ala-pAB.

[0030] In some embodiments, the first self-immolating unit comprises a p-aminobenzyloxycarbonyl (pABC).

[0031] In some embodiments, the ligand additionally comprises a second self-immolating unit. In some embodiments, the ligand has the ability to be removed from D after ligand cleavage by self-immolation of the first self-immolating unit and / or self-immolation of the second self-immolating unit. In some embodiments, the ligand is removed from D after ligand cleavage in a stepwise manner by self-immolation of the first self-immolating unit and then self-immolation of the second self-immolating unit.

[0032] In some embodiments, the linker comprises a cleavable linker, a first self-immolating unit, and a second self-immolating unit. In some embodiments, the cleavable linker comprises Val-Ala. In some embodiments, the cleavable linker comprises Val-Cit. In some embodiments, the cleavable linker comprises Formula (II).

[0033] In some embodiments, the second self-immolating unit comprises one of the following chemical portions: Petition 870260065905, dated 03 / 07 / 2026, page 15 / 1400 12 / 650 Table 1. Chemical portions of the second autoimmolating unit Second Self-Immolating Unit Chemical Structure Unit 1 (MEC) I o Unit 2 - / -Z 0 Unit 3 | 0 Unit 4 I 0 Unit 5 I 0 Unit 6 kV I / \ II 0 Unit 7 '4^ IH -°Ύ\' 0 Unit 8 / o Unit 9 N—( / / * 0 Unit 10 F ^N—< o Petition 870260065905, dated 03 / 07 / 2026, page 16 / 1400 13 / 650 Table 1. Chemical portions of the second self-immolating unit (continued) Second Self-Immolating Unit Chemical Structure Unit 11 so Unit 12 N—( o Unit 13 u. °^° LL / \ O / . or an isomer of the same.

[0034] In some embodiments, the cleavable linker comprises Val-Ala and wherein the second self-immolating unit comprises one of the following chemical portions: Table 2. Chemical portions of the second autoimmolating unit. Second Self-Immolating Unit Chemical Structure Unit 1 (MEC) -4- 1 o Unit 2 - / -Z o Unit 3 1 0 Unit 4 1 0 Unit 5 1 0 Petition 870260065905, dated 03 / 07 / 2026, page 17 / 1400 14 / 650 Table 2. Chemical portions of the second self-immolating unit (continued) Unit 6 1 L 0 Unit 7 1 H 0 Unit 8 / x 0 Unit 9 N—\ / r 0 Unit 10 FN—\ lí5 O Unit 11 FF ,N—\ Vo Unit 12 XF N—\ 0 Unit 13 V —F Άι0 or an isomer of the same.

[0035] In some embodiments, the second self-immolating unit comprises a chemical portion of Unit 1 (MEC). In some Petition 870260065905, dated 03 / 07 / 2026, page 18 / 1400 In some embodiments, the second self-immolating unit comprises a chemical portion of Unit 8. In some embodiments, the second self-immolating unit comprises a chemical portion of Unit 11. In some embodiments, the second self-immolating unit comprises a chemical portion of Unit 9.

[0036] In some embodiments, the ligand comprises the chemical portion of Val-Ala-pABC-MEC. In some embodiments, the ligand comprises the chemical portion of MC-Val-Ala-pABC-MEC.

[0037] In some modalities, LD comprises LP1: or LP2:

[0038] In some embodiments, the ligand comprises the chemical portion of Val-Cit-pABC-MEC. In some embodiments, the ligand comprises the chemical portion of MC-Val-Cit-pABC-MEC. In some embodiments, MCVal-Cit-pABC-MEC-Compound 1.

[0039] In some embodiments, the ligand comprises the chemical portion of Val-Ala-pABC-Unit 8. In some embodiments, the ligand comprises the chemical portion of MC-Val-Ala-pABC-Unit 8.

[0040] In some modalities, LD comprises LP16: Petition 870260065905, dated 03 / 07 / 2026, page 19 / 1400 16 / 650

[0041] In some embodiments, the ligand comprises the chemical portion of Val-Cit-pABC-Unit 8. In some embodiments, the ligand comprises the chemical portion of MC-Val-Cit-pABC-Unit 8. In some embodiments, the LD comprises MC-Val-Cit-pABC-Unit 8-Compound 1.

[0042] In some embodiments, the ligand comprises the chemical portion of Val-Ala-pABC-Unit 11. In some embodiments, the ligand comprises the chemical portion of MC-Val-Ala-pABC-Unit 11.

[0043] In some modalities, LD comprises LP28: the

[0044] In some embodiments, the ligand comprises the chemical portion of Val-Cit-pABC-Unit 11. In some embodiments, the ligand comprises the chemical portion of MC-Val-Cit-pABC-Unit 11. In some embodiments, the LD comprises MC-Val-Cit-pABC-Unit 11-Compound 1.

[0045] In some embodiments, the ligand comprises the chemical portion of Val-Ala-pABC-Unit 9. In some embodiments, the ligand Petition 870260065905, dated 03 / 07 / 2026, page 20 / 1400 17 / 650 comprises the chemical portion of MC-Val-Ala-pABC-Unit 9.

[0046] In some modalities, LD comprises LP20:

[0047] In some embodiments, the ligand comprises the chemical portion of Val-Cit-pABC-Unit 9. In some embodiments, the ligand comprises the chemical portion of MC-Val-Cit-pABC-Unit 9. In some embodiments, the LD comprises MC-Val-Cit-pABC-Unit 9-Compound 1.

[0048] In some embodiments, the ligand comprises Formula (II)-Val-Cit-pABC. In some embodiments, the ligand comprises the chemical portion of Formula (II)-Val-Cit-pABC-MEC. In some embodiments, the ligand comprises the chemical portion of Mal-Formula (II)-Val-Cit-pABC-MEC. In some embodiments, the LD comprises Mal-Formula (II)-Val-Cit-pABC-MECCompound 1. In some embodiments, the ligand comprises the chemical portion of Formula (II)-Val-Cit-pABC-Unit 8. In some embodiments, the ligand comprises the chemical portion of Mal-Formula (II)-Val-Cit-pABC-Unit 8. In some embodiments, the LD comprises Mal-Formula (II)-Val-Cit-pABCUnit 8-Compound 1. In some embodiments, the ligand comprises the chemical portion of Formula (II)-Val-Cit-pABC-Unit 11. In some embodiments, the ligand comprises the chemical portion of Mal-Formula (II)-ValCit-pABC-Unit 11. In some embodiments, the LD comprises Mal-Formula (II)-Val-Cit-pABC-Unit 11-Compound 1.In some embodiments, the ligand comprises the chemical moiety of Formula (II)-Val-Cit-pABC-Unit 9. In some embodiments, the ligand comprises the chemical moiety of Mal. Petition 870260065905, dated 03 / 07 / 2026, page 21 / 1400 18 / 650 Formula (II)-Val-Cit-pABC-Unit 9. In some embodiments, the LD comprises Mal-Formula (II)-Val-Cit-pABC-Unit 9-Compound 1.

[0049] In some embodiments, the ligand comprises Formula (II)-Val-Ala-pABC. In some embodiments, the ligand comprises the chemical portion of Formula (II)-Val-Ala-pABC-MEC. In some embodiments, the ligand comprises the chemical portion of Mal-Formula (II)-Val-Ala-pABC-MEC. In some embodiments, the LD comprises Mal-Formula (II)-Val-Ala-pABC-MECCompound 1. In some embodiments, the ligand comprises the chemical portion of Formula (II)-Val-Ala-pABC-Unit 8. In some embodiments, the ligand comprises the chemical portion of Mal-Formula (II)-Val-Ala-pABC-Unit 8. In some embodiments, the LD comprises Mal-Formula (II)-Val-Ala-pABCUnit 8-Compound 1. In some embodiments, the ligand comprises the chemical portion of Formula (II)-Val-Ala-pABC-Unit 11. In some embodiments, the ligand comprises the chemical portion of Mal-Formula (II)-ValAla-pABC-Unit 11. In some embodiments, the LD comprises Mal-Formula (II)-Val-Ala-pABC-Unit 11-Compound 1.In some embodiments, the ligand comprises the chemical portion of Formula (II)-Val-Ala-pABC-Unit 9. In some embodiments, the ligand comprises the chemical portion of MalFormula (II)-Val-Ala-pABC-Unit 9. In some embodiments, the LD comprises Mal-Formula (II)-Val-Ala-pABC-Unit 9-Compound 1.

[0050] In some embodiments, the ligand comprises Formula (II)-Val-Cit-pAB. In some embodiments, the ligand comprises the chemical portion of Formula (II)-Val-Cit-pAB-Unit 9. In some embodiments, the ligand comprises Mal-Formula (II)-Val-Cit-pAB. In some embodiments, the ligand comprises the chemical portion of Mal-Formula (II)-Val-Cit-pAB-Unit 9. In some embodiments, the LD comprises Mal-Formula (II)-Val-Cit-pAB-Unit 9-Compound 1.

[0051] In some embodiments, the ligand comprises Formula (II)-Val-Ala-pAB. In some embodiments, the ligand comprises the chemical portion of Formula (II)-Val-Ala-pAB-Unit 9. In some embodiments, the Petition 870260065905, dated 03 / 07 / 2026, p. 22 / 1400 19 / 650 The ligand comprises Mal-Formula (II)-Val-Ala-pAB. In some embodiments, the ligand comprises the chemical portion of Mal-Formula (II)-Val-Ala-pAB-Unit 9.

[0052] In some modalities, LD comprises LP25: THE

[0053] In some embodiments, the ligand comprises the chemical portion of Formula (II)-Val-Cit-pAB-Unit 11. In some embodiments, the ligand comprises the chemical portion of Mal-Formula (II)-Val-Cit-pAB-Unit 11. In some embodiments, the LD comprises Mal-Formula (II)-Val-Cit-pAB-Unit 11-Compound 1.

[0054] In some embodiments, the ligand comprises the chemical portion of Formula (II)-Val-Ala-pAB-Unit 11. In some embodiments, the ligand comprises the chemical portion of Mal-Formula (II)-Val-Ala-pAB-Unit 11.

[0055] In some modalities, LD comprises LP26:

[0056] In several embodiments, the present disclosure provides an antibody-drug conjugate of Formula (I): Ab-(LD) p (I) Petition 870260065905, dated 03 / 07 / 2026, p. 23 / 1400 20 / 650 where Ab is an anti-PSMA antibody or antigen-binding fragment thereof disclosed in this document; LD is a ligand-payload conjugate disclosed in this document; ep is an integer from 1 to 20.

[0057] In some modalities, p is an integer from 1 to 12. In some modalities, p is an integer from 2 to 8. In some modalities, p is an integer from 2 to 4. In some modalities, p is 2. In some modalities, p is 4.

[0058] In some embodiments, the cleavable ligand comprises a cleavable chemical portion that is positioned so that no part of the ligand or antibody or antigen-binding fragment remains attached to D upon cleavage.

[0059] In some embodiments, the ligand-payload conjugate binds to the antibody or antigen-binding fragment via a Mal chemical moiety. In some embodiments, the Mal chemical moiety is attached to the antibody or antigen-binding fragment via a cysteine ​​residue on the antibody or antigen-binding fragment. In some embodiments, the cysteine ​​residue is on the light chain of the antibody or antigen-binding fragment. In some embodiments, the cysteine ​​residue is on the heavy chain of the antibody or antigen-binding fragment.

[0060] In some embodiments, the antibody or antigen-binding fragment comprises three HCDRs comprising amino acid sequences of SEQ ID NO: 21 (HCDR1), SEQ ID NO: 22 (HCDR2) and SEQ ID NO: 27 (HCDR3); and three LCDRs comprising amino acid sequences of SEQ ID NO: 32 (LCDR1), SEQ ID NO: 34 (LCDR2) and SEQ ID NO: 36 (LCDR3), as defined by the Kabat numbering system.

[0061] In some embodiments, the antibody or antigen-binding fragment comprises three HCDRs comprising amino acid sequences of SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2) and SEQ ID NO: 30 (HCDR3); and three LCDRs comprising amino acid sequences Petition 870260065905, dated 03 / 07 / 2026, p. 24 / 1400 21 / 650 of SEQ ID NO: 37 (LCDR1), SEQ ID NO: 38 (LCDR2) and SEQ ID NO: 36 (LCDR3), as defined by the IMGT numbering system.

[0062] In some embodiments, the antibody or antigen-binding fragment comprises a variable heavy chain region comprising an amino acid sequence of SEQ ID NO: 14 and a variable light chain region comprising an amino acid sequence of SEQ ID NO: 19.

[0063] In some modalities, LD comprises LP16, LP20, LP26 or LP28.

[0064] In some modalities, LD comprises LP16:

[0065] In some modalities, LD comprises LP20:

[0066] In some modalities, LD comprises LP26: Petition 870260065905, dated 03 / 07 / 2026, p. 25 / 1400 22 / 650

[0067] In some modalities, LD comprises LP28: the

[0068] In various embodiments, the present disclosure provides a pharmaceutical formulation comprising an anti-PSMA ADC, antibody, antigen-binding fragment thereof, or ligand-payload conjugate as disclosed herein and a pharmaceutically acceptable carrier.

[0069] In various embodiments, the present disclosure provides a composition comprising multiple copies of an antibody-drug conjugate of Formula (I): Ab-(LD) p (I) where Ab is an anti-PSMA antibody or antigen-binding fragment as disclosed in this document; LD is a bonding-payload conjugate as disclosed in this document; and Petition 870260065905, dated 03 / 07 / 2026, p. 26 / 1400 23 / 650 p is the average number of LD chemical moieties per Ab, where the average op of antibody-drug conjugates in the composition is about 2 to about 8.

[0070] In some embodiments, the antibody or antigen-binding fragment comprises three HCDRs comprising amino acid sequences of SEQ ID NO: 21 (HCDR1), SEQ ID NO: 22 (HCDR2) and SEQ ID NO: 27 (HCDR3); and three LCDRs comprising SEQ ID NO: 32 (LCDR1), SEQ ID NO: 35 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the Kabat numbering system; or three HCDRs comprising amino acid sequences of SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2) and SEQ ID NO: 30 (HCDR3); and three LCDRs comprising SEQ ID NO: 38 (LCDR1), SEQ ID NO: 39 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the IMGT numbering system; and LD includes LP16:

[0071] In some embodiments, the antibody or antigen-binding fragment comprises three HCDRs comprising amino acid sequences of SEQ ID NO: 21 (HCDR1), SEQ ID NO: 22 (HCDR2) and SEQ ID NO: 27 (HCDR3); and three LCDRs comprising SEQ ID NO: 32 (LCDR1), SEQ ID NO: 35 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the Kabat numbering system; or three HCDRs comprising amino acid sequences of SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2) and SEQ ID NO: 30 (HCDR3); and three LCDRs comprising SEQ ID NO: 38 (LCDR1), Petition 870260065905, dated 03 / 07 / 2026, p. 27 / 1400 24 / 650 SEQ ID NO: 39 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the IMGT numbering system; and the LD comprises LP20:

[0072] In some embodiments, the antibody or antigen-binding fragment comprises three HCDRs comprising amino acid sequences of SEQ ID NO: 21 (HCDR1), SEQ ID NO: 22 (HCDR2) and SEQ ID NO: 27 (HCDR3); and three LCDRs comprising SEQ ID NO: 32 (LCDR1), SEQ ID NO: 35 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the Kabat numbering system; or three HCDRs comprising amino acid sequences of SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2) and SEQ ID NO: 30 (HCDR3); and three LCDRs comprising SEQ ID NO: 38 (LCDR1), SEQ ID NO: 39 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the IMGT numbering system; and the LD comprises LP26:

[0073] In some embodiments, the antibody or antigen-binding fragment comprises three HCRs comprising sequences of Petition 870260065905, dated 03 / 07 / 2026, p. 28 / 1400 25 / 650 amino acids from SEQ ID NO: 21 (HCDR1), SEQ ID NO: 22 (HCDR2), and SEQ ID NO: 27 (HCDR3); and three LCDRs comprising SEQ ID NO: 32 (LCDR1), SEQ ID NO: 35 (LCDR2), and SEQ ID NO: 37 (LCDR3), as defined by the Kabat numbering system; or three HCDRs comprising amino acid sequences from SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2), and SEQ ID NO: 30 (HCDR3); and three LCDRs comprising SEQ ID NO: 38 (LCDR1), SEQ ID NO: 39 (LCDR2), and SEQ ID NO: 37 (LCDR3), as defined by the IMGT numbering system; and the LD comprises LP28: the

[0074] In some embodiments, the antibody or antigen-binding fragment comprises a variable heavy chain region comprising an amino acid sequence of SEQ ID NO: 14 and a variable light chain region comprising an amino acid sequence of SEQ ID NO: 19.

[0075] In various embodiments, the present disclosure provides methods for treating a patient who has or is at risk of having cancer, comprising administering to the patient a therapeutically effective amount of an anti-PSMA ADC, antibody, antigen-binding fragment thereof, or ligand-payload conjugate as disclosed herein. In various embodiments, the present disclosure provides methods for reducing or inhibiting the growth of cancer, comprising administering a therapeutically effective amount of an anti-PSMA ADC, antibody, antigen-binding fragment, or ligand-payload conjugate as disclosed herein. Petition 870260065905, dated 03 / 07 / 2026, page 29 / 1400 26 / 650 to the antigen of the same, or ligand-payload conjugate as disclosed herein. In some embodiments, the cancer expresses PSMA. In some embodiments, the cancer is prostate cancer.

[0076] In several embodiments, the present disclosure provides the use of an anti-PSMA ADC, antibody, antigen-binding fragment thereof, or ligand-payload conjugate as disclosed herein in the treatment of cancer. In some embodiments, the cancer expresses PSMA. In some embodiments, the cancer is prostate cancer.

[0077] In various embodiments, the present disclosure provides methods for producing an anti-PSMA ADC, comprising reacting an antibody or antigen-binding fragment thereof as disclosed herein with a ligand-payload conjugate as disclosed herein. In various embodiments, the present disclosure provides methods for producing an antibody-drug conjugate, wherein the method comprises conjugating an antibody or antigen-binding fragment as disclosed herein with a ligand-payload conjugate as disclosed herein under suitable binding conditions.

[0078] In various embodiments, the present disclosure provides methods for producing an LD(V) conjugate: Petition 870260065905, dated 03 / 07 / 2026, p. 30 / 1400 27 / 650 the method comprising reacting a compound of Formula (III) as disclosed in this document: or a salt thereof with an activated ligand comprising a suitable ligand having the following structure: to produce the LD(V) conjugate, where Zb is NH.

[0079] In some embodiments, Pb has (S) configuration, and the activated ligand reacts with Zb preferentially. In some embodiments, the compound of Formula (III) is Compound 1.

[0080] In several embodiments, the present disclosure provides methods for producing an LD (VI) conjugate: the method comprising reacting a compound of Formula (III) Petition 870260065905, dated 03 / 07 / 2026, p. 31 / 1400 28 / 650 as revealed in this document: or a salt thereof with an activated ligand comprising a suitable ligand having the following structure: Binder to produce the LD (VI) conjugate, where Zb is NH.

[0081] In some embodiments, Pb has (S) configuration, and the activated ligand reacts with Zb preferentially. In some embodiments, the compound of Formula (III) is Compound 1.

[0082] In several embodiments, the present disclosure provides compositions comprising a binder-payload conjugate as disclosed herein. In some embodiments, the present disclosure provides a composition comprising a binder-payload conjugate produced in accordance with the methods disclosed herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0083] Figure 1 shows the alignment of J591 VH and VL with human germline sequences. Underlined residues are human-specific residues, residues in lowercase are mouse-specific residues.

[0084] Figure 2 shows an in silico model of J591 Fv that was Petition 870260065905, dated 03 / 07 / 2026, page 32 / 1400 Figure 29 / 650 was generated using BioLuminate software. CDR residues are shown as space-filling framework residues that differ between mouse and HCzu1-Lczu1. Residues adjacent to CDRs are shown as sphere-rod. Residue numbering follows Kabat.

[0085] Figure 3 shows similar PSMA binding for humanized heavy chain (HC) variants 1-10 paired with Lczu1. Hczu1-10 were paired with LCzu1 and analyzed for PSMA binding by ELISA.

[0086] Figure 4 shows the superhumanization of J591. The resulting PSMA antibodies have strong binding affinity. The humanized J591 variants were analyzed for PSMA binding by ELISA.

[0087] Figure 5A shows the thermal stability of deJ591. Figure 5B shows the thermal stability of humanized J591 variants HC1-LC1, HC2-LC1, HC3-LC1, HC14-LC1, and HC14-LC5 compared to deJ591. Figure 5C shows the thermal stability of IgG1 HC14-LC5 (H14L5) antibodies modified to include site-specific conjugation residues compared to deJ591 and J591.

[0088] Figure 6A shows immunogenicity prediction scores for 9mer peptide sequences in the variable heavy chain domain of J591. Figure 6B shows immunogenicity prediction scores for 9mer peptide sequences in the variable heavy chain domain of J591. Figure 6C shows immunogenicity prediction scores for 9mer peptide sequences in the variable heavy chain domain of zuJ591-H14.

[0089] Figure 7A shows immunogenicity prediction scores for 9mer peptide sequences in the variable light chain domain of J591. Figure 7B shows immunogenicity prediction scores for 9mer peptide sequences in the variable light chain domain of J591. Figure 7C shows immunogenicity prediction scores for 9mer peptide sequences in the variable light chain domain of zuJ591-L5. Petition 870260065905, dated 03 / 07 / 2026, page 33 / 1400 30 / 650

[0090] Figure 8 shows the specific anti-PSMA binding to LNCaP cells expressing PSMA.

[0091] Figure 9 shows PSMA-dependent ADCP activity as assessed by flow cytometry. The percentage of macrophages that ingested at least one target cell is shown.

[0092] Figure 10 shows target cell dependence of anti-PSMA ADC internalization as measured by flow cytometry.

[0093] Figure 11 shows the production of IFNe dependent on ADCP due to anti-PSMA ADC treatment.

[0094] Figure 12 shows the ADCP-dependent activation of myeloid cells by anti-PSMA ADC treatment.

[0095] Figure 13 shows in vivo antitumor activity of anti-PSMA ADC in a PSMA-positive LNCaP xenograft model.

[0096] Figure 14A shows a heat map of Type 1 Interferon gene expression as assessed by RNA-seq in an LNCaP xenograft model treated with anti-PSMA antibody (PSMA Control), anti-PSMA-LP3 ADC, or negative control (anti-SEB-LP3). Figure 14B shows that cytokines specific to the STING pathway were modulated by anti-PSMA-LP3 ADC treatment. Figure 14C shows macrophage polarization shift from M2 to M1 in the tumor microenvironment when treated with anti-PSMA-LP3 ADC.

[0097] Figure 15A shows tumor volume (left) and percentage change in body weight (right) in 22RV1 human prostate cancer xenograft mice (castrated) following treatment with anti-PSMA antibody or anti-PSMA ADC. Figure 15B shows tumor volume (left) and percentage change in body weight (right) in 22RV1 human prostate cancer xenograft mice (non-castrated) following treatment with anti-PSMA antibody or anti-PSMA ADC. Sp = thiophosphate ligand binding site S in Compound 1; Rp = thiophosphate ligand binding site R in Compound 1. Petition 870260065905, dated 03 / 07 / 2026, page 34 / 1400 31 / 650

[0098] Figure 16A shows an in vivo efficacy model of anti-PSMA ADCs in a 22RV1 xenoenerget model. Figure 16B shows the concentration of mouse TNFα (left) or IFNε (right) in plasma 6 h post-injection with anti-PSMA ADC.

[0099] Figure 17 shows the percentage change in DAR of anti-PSMA ADCs.

[0100] Figures 18A, 18B and 18C show the change in DAR over time for S-linked ligands.

[0101] Figures 19A, 19B and 19C show the free Compound 1 over time for S-linked ligands.

[0102] Figures 20A, 20B and 20C show the percentage of monomers over time for S-linked ligands.

[0103] Figures 21A, 21B, 21C, 21D, 21E, 21F and 21G show the change in DAR over time for N-linked ligands.

[0104] Figures 22A, 22B, 22C, 22D, 22E, 22F and 22G show the free Compound 1 over time for N-linked ligands.

[0105] Figures 23A, 23B, 23C, 23D, 23E, 23F and 23G show the percentage of monomers over time for N-linked ligands.

[0106] Figure 24A shows the percentage of Compound 1 release from anti-PSMA ADCs in mouse plasma over time. Figure 24B shows the mean DAR of anti-PSMA ADCs in mouse plasma over time. Figure 24C shows the percentage change from initial DAR of anti-PSMA ADCs in mouse plasma. Figure 24D shows free Compound 1 in mouse plasma over time.

[0107] Figure 25 shows the mouse plasma stability of S-linked Compound 1 anti-PSMA ADCs.

[0108] Figure 26 shows structures of Compound 1 and monophosphate forms of Compound 1.

[0109] Figure 27A shows average LP3 DAR of anti-PSMA ADC Petition 870260065905, dated 03 / 07 / 2026, page 35 / 1400 32 / 650 (random DAR4 and RESPECT-L DAR4). Figure 27B shows the metabolism of random DAR4 from anti-PSMA ADC LP3. Figure 27C shows the metabolism of RESPECT-L DAR4 from anti-PSMA ADC LP3.

[0110] Figure 28A shows the stability of N-linked anti-PSMA ADCs in mouse plasma after 10 days of treatment. Figure 28B shows the stability of N-linked anti-PSMA ADCs in mouse plasma on day 7.

[0111] Figure 29 shows the DAR of N-linked Compound 1 antiPSMA ADCs in mouse plasma on Day 7 / 10.

[0112] Figure 30 shows the production of hIFN-β in C4-2 / THP1 coculture following treatment with anti-PSMA ADCs.

[0113] Figure 31 shows the mean tumor volume and percentage of body weight in xenograft tumors treated with anti-PSMA ADCs.

[0114] Figure 32 shows antitumor activity of AntiPSMA-LP ADCs in the 22Rv1 xenograft model (Cohort 1). Mean tumor growth and mean body weight change are shown.

[0115] Figure 33 shows serum cytokine analysis for PSMA-LP ADCs in the 22Rv1 xenograft model (Cohort 1). n = 3; each point represents an individual value. Data are represented as mean ± SEM.

[0116] Figure 34 shows antitumor activity of antiPSMA-LP ADCs in the 22Rv1 xenograft model (Cohort 2). Mean tumor growth and mean body weight change are shown.

[0117] Figure 35 shows serum cytokine analysis for PSMA-LP ADCs in the 22Rv1 xenograft model (Cohort 2). n = 3; each point represents an individual value. Data are represented as mean ± SEM.

[0118] Figure 36 shows antitumor activity of antiPSMA-LP ADCs in the 22Rv1 xenograft model (Cohort 3). Mean tumor growth and mean body weight change are shown.

[0119] Figure 37 shows serum cytokine analysis for ADCs Petition 870260065905, dated 03 / 07 / 2026, page 36 / 1400 33 / 650 PSMA-LP in the 22Rv1 xenograft model (Cohort 3). n = 3; each point represents an individual value. Data are represented as mean ± SEM.

[0120] Figure 38 shows antitumor activity of antiPSMA-LP ADCs in the C4-2 xenograft model. Mean tumor growth and mean body weight change are shown.

[0121] Figure 39 shows serum cytokine analysis for PSMA-LP ADCs in the 22Rv1 xenograft model (Cohort 3). n = 3; each point represents an individual value. Data are represented as mean ± SEM.

[0122] Figure 40 shows the ADC pharmacokinetics of LP3 antiPSMA (random DAR4) in normal mice at an IV dose of 1 mpk.

[0123] Figure 41 shows the ADC pharmacokinetics of LP3 antiPSMA (RESPECT-L DAR2) in mice bearing C4-2 tumors at IV doses of 3 and 9 mg / kg.

[0124] Figure 42 shows Compound 1 levels in plasma from mice bearing C4-2 tumors measured with anti-PSMA LP3 ADC (RESPECT-L DAR2) or anti-PSMA LP1 ADC (RESPECT-L DAR4).

[0125] Figure 43 shows intratumoral levels of Compound 1 in mice bearing C4-2 tumors measured with anti-PSMA LP3 ADC (RESPECT-L DAR2) or anti-PSMA LP1 ADC (RESPECT-L DAR4).

[0126] Figure 44 shows tumor PK parameters of mice bearing C4-2 tumors measured with anti-PSMA LP3 ADC (RESPECT-L DAR2) and anti-PSMA LP1 ADC (RESPECT-L DAR4).

[0127] Figure 45 shows a schematic of a two-stage payload release test. LP2 is shown as an example.

[0128] Figure 46 shows IFN-β release in vitro after treatment with anti-PSMA S-binding ADCs. Panels identified with A (left column) show IFN-β release from THP-1 monoculture and panels identified with B (right column) show IFN-β release from C4-2 and THP-1 coculture.

[0129] Figure 47 shows the release of IFN-β in vitro after the Petition 870260065905, dated 03 / 07 / 2026, page 37 / 1400 34 / 650 treatment with anti-PSMA N-binding ADCs. Panels identified with A (left column) show IFN-β release from THP-1 monoculture and panels identified with B (right column) show IFN-β release from C4-2 and THP-1 coculture. DETAILED DESCRIPTION

[0130] The compositions and methods disclosed can be more readily understood by reference to the following detailed description considered in conjunction with the accompanying Figures, which form part of this disclosure.

[0131] Throughout this text, descriptions refer to compositions and methods of use of said compositions. When the disclosure describes or claims a feature or modality associated with a composition, such feature or modality is equally applicable to methods of use of said composition. Similarly, when the disclosure describes or claims a feature or modality associated with a method of use of a composition, such feature or modality is equally applicable to the composition.

[0132] When a range of values ​​is expressed, it includes modalities that use any specific value within the range. Furthermore, the reference to the values ​​indicated in the ranges includes each of the values ​​within that range. All ranges include their endpoint parameters and are combinable. When values ​​are expressed as approximations, by using the antecedent “about”, it will be understood that the specific value forms another modality. The reference to a given numerical value includes at least that specific value, except where the context clearly indicates otherwise.

[0133] All references cited in this document are incorporated by reference for any purpose. Where a reference and the descriptive report conflict, the descriptive report shall prevail. Petition 870260065905, dated 03 / 07 / 2026, page 38 / 1400 35 / 650

[0134] It should be considered that certain features of the disclosed compositions and methods which are, for clarity, described herein in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, several features of the disclosed compositions and methods which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any subcombination. Definitions

[0135] Several terms relating to aspects of the description are used throughout the descriptive report and claims. Such terms shall have their common meaning in the art, except where otherwise indicated. Other specifically defined terms shall be interpreted in a manner consistent with the definitions provided herein.

[0136] As used in this document, the singular forms “a”, “an”, “the” and “the” include plural forms, unless the context clearly indicates otherwise.

[0137] The terms “about” or “approximately” in the context of numerical values ​​and ranges refer to values ​​or ranges that approach or are close to the values ​​or ranges mentioned, so that the embodiment can perform as intended, such as having a desired amount of nucleic acids or polypeptides in a reaction mixture, as is evident to one skilled in the art from the teachings contained in this document. In some embodiments, “about” means plus or minus 10% of a numerical quantity.

[0138] The term “agent” is used in this document to refer to a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract produced from biological materials. The term “therapeutic agent,” “drug,” or “drug chemical portion” refers to an agent that has the capacity to modulate a biological process and / or has biological activity. Petition 870260065905, dated 03 / 07 / 2026, p. 39 / 1400 36 / 650

[0139] As used in this document, the term “aliphatic” or “aliphatic group” means a linear (i.e., unbranched) or branched hydrocarbon chain, substituted or unsubstituted, that is fully saturated or that contains one or more unsaturation units. In some embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 4 aliphatic carbon atoms.

[0140] As used in this document, the term “ambient conditions” means ambient temperature, open air condition and uncontrolled humidity condition. The terms “ambient temperature” and “ambient temperature” mean 15 °C to 30 °C.

[0141] The terms “antibody-drug conjugate”, “antibody conjugate”, “conjugate”, “immunoconjugate”, and “ADC” are used interchangeably, and refer to a compound or derivative thereof that is linked to an antibody (e.g., an anti-PSMA antibody) and can be defined by the generic formula: Ab-(LD)p (Formula I), where Ab = an antibody chemical moiety (i.e., antibody or antigen-binding fragment), L = a ligand chemical moiety, D = a drug chemical moiety, and p = the number of drug chemical moieties per antibody chemical moiety. In some embodiments, the ligand L may include a cleavable chemical moiety between the antibody or antigen-binding fragment and the therapeutic compound. In some embodiments, the L ligand may include a cleavable chemical moiety that can be linked to one or both of the antibody or antigen-binding fragment and the therapeutic compound, for example, by spacer unit(s).Exemplary cleavable ligands are described and exemplified in this document.

[0142] The term “antibody” is used in its broadest sense to refer to an immunoglobulin molecule that recognizes and binds Petition 870260065905, dated 03 / 07 / 2026, p. 40 / 1400 37 / 650 specifically targets a protein, polypeptide, carbohydrate, polynucleotide, lipid, or combinations thereof, through at least one antigen recognition site within the variable region of the immunoglobulin molecule. The heavy chain (HC) of an antibody is composed of a variable heavy chain domain (VH) and a constant heavy chain region (CH). The light chain (LC) is composed of a variable light chain domain (VL) and a constant light chain domain (CL). As used in this document, the terms “domain” and “region” may be used interchangeably (e.g., the term “variable domain” may be used interchangeably with the term “variable region” and understood as referring to the same part of the antibody).For the purposes of this application, mature heavy-chain and light-chain variable domains each comprise three complementarity-determining regions (CDR1, CDR2, and CDR3; also referred to as “hypervariable regions”) within four framework regions (FR1, FR2, FR3, and FR4) arranged from the N-terminal to the C-terminal: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. CDRs can be identified according to the Kabat and / or IMGT numbering systems (Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991); International ImMunoGeneTics Information System (IMGT®)). An “antibody” can be naturally occurring or artificially occurring, such as monoclonal antibodies produced by conventional hybridoma technology. The term “antibody” includes full-length monoclonal antibodies and full-length polyclonal antibodies, as well as antibody fragments such as Fab, Fab', F(ab')2, Fv, and single-chain antibodies.An antibody can be one of the five main classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, or subclasses thereof (e.g., IgG1, IgG2, IgG3, IgG4 isotypes). An antibody of any of the aforementioned classes or subclasses can also comprise one of two functionally similar classes of light chains: κ (also referred to herein as "Ig kappa" or "kappa") and λ (also referred to herein as "Ig. Petition 870260065905, dated 03 / 07 / 2026, p. 41 / 1400 38 / 650 lambda” or “lambda”). The term “antibody” also encompasses human antibodies, chimeric antibodies, humanized antibodies, and any modified immunoglobulin molecule containing an antigen recognition site, provided it demonstrates the desired biological activity.

[0143] The term “chimeric antibody,” as used in this document, refers to antibodies in which the amino acid sequence of the immunoglobulin molecule is derived from two or more species. In some cases, the variable regions of both heavy and light chains correspond to the variable regions of antibodies derived from one species with desired specificity, affinity, and activity characteristics, while the constant regions are homologous to antibodies derived from another species (e.g., human) to minimize an immune response in the latter species.

[0144] The term “human antibody”, as used in this document, refers to an antibody produced by a human being or an antibody that has an amino acid sequence of an antibody produced by a human being.

[0145] As used in this document, the term “humanized antibody” refers to antibody forms that contain sequences of non-human (e.g., murine) antibodies as well as human antibodies. Such antibodies are chimeric antibodies containing a minimal sequence derived from non-human immunoglobulin. In general, the humanized antibody will comprise substantially all or at least one, and typically two, variable domains, wherein all or substantially all hypervariable regions correspond to those of a non-human immunoglobulin and all or substantially all framework (FR) regions are those of a human immunoglobulin sequence. The humanized antibody will also optionally comprise at least a portion of an immunoglobulin constant (Fc) region, typically that of a human immunoglobulin. The humanized antibody may be further modified by Petition 870260065905, dated 03 / 07 / 2026, page 42 / 1400 39 / 650 residue substitution, in the Fv framework region and / or within the substituted non-human residues to refine and optimize the specificity, affinity, and / or activity of the antibody. The humanized antibody can also be further modified by substituting residues in the Fc domain to reduce its binding to various cellular receptors, such as an Fcy receptor (FcyR), and other immune molecules.

[0146] The term “monoclonal antibody,” as used in this document, refers to an antibody obtained from a substantially homogeneous population of antibodies, that is, the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in small quantities. Monoclonal antibodies are highly specific, being directed against a single antigenic epitope. In contrast, conventional antibody preparations (polyclonal) typically include a variety of antibodies directed against (or specific for) different epitopes. The modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and should not be interpreted as requiring the production of the antibody by any specific method.For example, the monoclonal antibodies to be used according to the present disclosure may be produced by the hybridoma method first described by Kohler et al. (1975) Nature 256:495, or may be produced by recombinant DNA methods. See, for example, US Patent No. 4,816,567. Monoclonal antibodies may also be isolated from phage antibody libraries using the techniques described in, for example, Clackson et al. (1991) Nature 352:624-8, and Marks et al. (1991) J. Mol. Biol. 222:581-97.

[0147] The monoclonal antibodies described in this document specifically include “chimeric” antibodies, in which a portion of the heavy and / or light chain is identical or homologous to the corresponding sequences in an antibody derived from a specific species or belonging to a specific antibody class or subclass, while the Petition 870260065905, dated 03 / 07 / 2026, p. 43 / 1400 40 / 650 of the remaining chain(s) is identical or homologous to the corresponding sequences in an antibody derived from another species or belonging to another class or subclass of antibodies, as well as fragments of such antibodies, provided that they bind specifically to the target antigen and / or exhibit the desired biological activity.

[0148] The term “antigen-binding fragment” or “antigen-binding portion” of an antibody, as used herein, refers to one or more fragments of an antibody that retain the ability to bind specifically to an antigen (e.g., PSMA). Antigen-binding fragments also preferentially retain the ability to internalize into an antigen-expressing cell. In some embodiments, antigen-binding fragments also retain immune effector activity. It has been shown that fragments of a full-length antibody can perform the antigen-binding function of a full-length antibody.Examples of binding fragments encompassed by the term “antigen-binding fragment” or “antigen-binding portion” of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL, and CH1 domains; (ii) an F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge in the hinge region; (iii) an Fd fragment consisting of the VH and CH1 domains; (iv) an Fv fragment consisting of the VL and VH domains of a single arm of an antibody; (v) a dAb fragment, comprising a single variable domain, for example, a VH domain (see, for example, Ward et al. (1989) Nature 341:544-6; and Winter et al., paper no. WO 90 / 05144); and (vi) an isolated complementarity-determining region (CDR).Furthermore, although the two domains of the Fv fragment, VL and VH, are encoded by separate genes, they can be joined using recombinant methods, by a synthetic linker that allows them to be produced as a single protein chain in which the VL and VH regions pair up to form molecules. Petition 870260065905, dated 03 / 07 / 2026, page 44 / 1400 41 / 650 monovalent (known as single-chain Fv (scFv)). See, for example, Bird et al. (1988) Science 242:423-6; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-83. Such single-chain antibodies are also intended to be encompassed by the term “antigen-binding fragment” or “antigen-binding portion” of an antibody and are known in the art as an exemplary type of binding fragment that can internalize into cells by binding. See, for example, Zhu et al. (2010) 9:2131-41; He et al. (2010) J. Nucl. Med. 51:427-32; and Fitting et al. (2015) MAbs 7:390-402. In certain embodiments, the molecules of scFv can be incorporated into a fusion protein.Diabodies are bispecific bivalent antibodies in which the VH and VL domains are expressed on a single polypeptide chain. However, a ligand that is too short to allow pairing between the two domains on the same chain is used, thus inducing pairing of the domains with complementary domains on another chain and creating two antigen-binding sites. (See, for example, Holliger et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-8; and Poljak et al. (1994) Structure 2:1121-3). Antigen-binding fragments are obtained using conventional techniques known to those skilled in the art, and the binding fragments are analyzed for utility (e.g., binding affinity, internalization) in the same way as intact antibodies. Antigen-binding fragments can be prepared, for example, by cleaving the intact protein, for example, by protease or chemical cleavage.

[0149] The term “anti-PSMA antibody” or “antibody that specifically binds to PSMA” refers to any form of antibody or fragment thereof that specifically binds to PSMA and includes monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, and biologically functional antibody fragments, provided that they specifically bind to PSMA. Preferably, the anti-PSMA antibody used in the ADCs disclosed herein is an antibody of Petition 870260065905, dated 03 / 07 / 2026, p. 45 / 1400 42 / 650 internalization or internalization antibody fragment. As used in this document, the terms “specific,” “specifically binds,” and “specifically binds” refer to the selective binding of the antibody to the target antigen or epitope by alternative antigens or epitopes. Antibodies can be tested for binding specificity by comparing binding to a suitable antigen with binding to an irrelevant antigen or antigen mixture under a given set of conditions. If the antibody binds to the appropriate antigen with at least 2 times, or preferably at least 50 times, at least 100 times, or at least 1000 times, greater affinity than an irrelevant antigen or antigen mixture, then it is considered specific, for example, as measured by surface plasmon resonance, e.g., BIAcore® analysis.In one embodiment, a specific antibody is one that binds to the PSMA antigen but does not bind (or exhibits minimal binding) to other antigens.

[0150] The term “aryl” refers to a group or substituent derived from an aromatic ring and encompasses monocyclic aromatic rings and bicyclic, tricyclic, and fused ring systems that have a total of six to fourteen ring members, wherein at least one ring in the system is aromatic. An aryl group may be optionally replaced by one or more substituents.

[0151] The term “heteroaryl” refers to a cyclic group comprising at least one ring atom that is a heteroatom, such as O, N, or S. Heteroaryl groups encompass monocyclic, bicyclic, and tricyclic ring systems that have a total of five to fourteen ring members, wherein at least one ring in the system is aromatic, at least one ring in the system contains one or more heteroatoms, and wherein each ring in the system contains three to seven ring members.

[0152] The term “at least one” refers to one or more.

[0153] The term “bridge” refers to a cluster of atoms in a STING agonist compound in a macrocycle bridge of development that extends from a first nucleic acid base in the agonist compound of Petition 870260065905, dated 03 / 07 / 2026, p. 46 / 1400 43 / 650 STING-bridge macrocycle linkage to a second nucleic acid base in the STING-bridge macrocycle agonist compound.

[0154] The term “cancer” refers to the physiological condition in mammals in which a population of cells is characterized by unregulated cell growth. Examples of cancers include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia.More specific examples of such cancers include squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, squamous cell carcinoma of the lung, bile duct cancer (e.g., cholangiocarcinoma), esophageal cancer, nasopharyngeal cancer, peritoneal cancer, hepatocellular carcinoma (e.g., hepatocellular carcinoma), gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, osteosarcoma, skin cancer (e.g., melanoma), colon cancer, colorectal cancer, endometrial or uterine cancer, ovarian cancer, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer (e.g., advanced prostate cancer, metastatic castration-resistant prostate cancer), vulvar cancer, thyroid cancer, liver carcinoma, bone cancer, and various types of head and neck cancers.

[0155] The terms “cancer cell” and “tumor cell” refer to individual cells or the total population of cells derived from a tumor, including both non-tumorigenic cells and cancer stem cells. As used in this document, the term “tumor cell” will be modified by the term “non-tumorigenic” when referring only to tumor cells without the capacity for renewal and differentiation to distinguish these tumor cells from cancer stem cells.

[0156] The terms “tumor” and “neoplasm” refer to any mass of tissue resulting from excessive growth or proliferation of cells, whether benign or malignant, including precancerous lesions.

[0157] The term “chemotherapeutic agent” or “anticancer agent” is Petition 870260065905, dated 03 / 07 / 2026, page 47 / 1400 44 / 650 used in this document refers to a chemical compound that is effective in the treatment of cancer, regardless of the mechanism of action. Inhibition of metastasis or angiogenesis is frequently a property of a chemotherapeutic agent. Stimulation of an antitumor immune response may also be a property of a chemotherapeutic agent. Non-limiting examples of chemotherapeutic agents include stimulatory agents, for example, STING agonists. In addition, chemotherapeutic agents include antibodies, biological molecules, and small molecules. A chemotherapeutic agent may be a cytotoxic or cytostatic agent.

[0158] The term “cytotoxic agent” refers to a substance that causes cell death by interfering with the expression and / or functioning of a cell or by stimulating a response that causes cell death, for example, an immune response. Examples of cytotoxic agents include, but are not limited to, STING agonists, such as Compound 1.

[0159] An “effective amount” of an ADC, as disclosed herein, is an amount sufficient to accomplish a specifically stated purpose, for example, to produce a therapeutic effect after administration, such as a reduction in tumor growth rate or tumor volume, a reduction in a cancer symptom, or some other indication of treatment efficacy. An effective amount may be routinely determined in relation to the stated objective. The term “therapeutically effective amount” refers to an amount of an ADC effective in treating a disease or disorder in an individual. In the case of cancer, a therapeutically effective amount of ADC may reduce the number of cancer cells, reduce tumor size, inhibit (e.g., slow or stop) tumor metastasis, inhibit (e.g., slow or stop) tumor growth, and / or alleviate one or more symptoms.A "prophylactically effective amount" refers to an amount that is effective, in dosages and during the time intervals required, to achieve the desired prophylactic result. Typically, a prophylactic dose is used in individuals before or at a later stage. Petition 870260065905, dated 03 / 07 / 2026, page 48 / 1400 45 / 650 initial stage of the disease, the prophylactically effective amount will be less than the therapeutically effective amount.

[0160] The term “epitope” refers to the portion of an antigen capable of being recognized and specifically bound by an antibody. When the antigen is a polypeptide, epitopes can be formed from contiguous amino acids or non-contiguous amino acids juxtaposed by tertiary folding of the polypeptide. The antibody-bound epitope can be identified using any epitope mapping technique known in the art, including X-ray crystallography for epitope identification by direct visualization of the antigen-antibody complex, as well as monitoring antibody binding to fragments or mutated variations of the antigen or monitoring solvent accessibility of different parts of the antibody and antigen.Exemplary strategies used to map antibody epitopes include, but are not limited to, matrix-based oligopeptide screening, limited proteolysis, site-directed mutagenesis, high-throughput mutagenesis mapping, hydrogen-deuterium exchange, and mass spectrometry. See, for example, Gershoni et al. (2007) 21:145-56; and HagerBraun and Tomer (2005) Expert Rev. Proteomics 2:745-56).

[0161] The term “Compound 1”, as used herein, refers to the structure of Compound 1 shown below, or a salt thereof: Compound 1.

[0162] Compound 1 is a macrocycle bridge sting agonist (MBSA) with a bioactive locked U-shaped conformation of Petition 870260065905, dated 03 / 07 / 2026, page 49 / 1400 46 / 650 cyclic dinucleotides comprising a transannular macrocyclic bridge between nucleic acid bases. As used in this document, “Compound 1” may include salts of Compound 1, for example, diammonium salt and / or sodium salt of Compound 1. The term “chemical moiety of Compound 1”, “E7766”, “E7766 agonist chemical moiety” or “E7766 chemical moiety” refers to the component of an ADC that has the structure of Compound 1, and is linked to the ADC ligand, for example, through its N-34 nitrogen, N-39 nitrogen, S-2 sulfur or S-14 sulfur of the chemical moiety of Compound 1. Compositions and methods for inhibiting tumor growth in patients comprising administering Compound 1 are disclosed in document no. WO 2018 / 152450, which is incorporated herein by reference in its entirety for all Compound 1 structures and methods for synthesizing those structures.

[0163] The atoms in Compound 1, as referred to in this document, can be numbered as shown below:

[0164] The term “Compound 2”, as used herein, refers to the structure of Compound 2 shown below, or a salt thereof: Petition 870260065905, dated 03 / 07 / 2026, p. 50 / 1400 47 / 650 Compound 2.

[0165] The atoms in Compound 2, as referred to in this document, can be numbered as shown below: 024 THE 019 C230180 C17 016 0' S14 I (S) C46 N47 / =N l, kiN45 \C48 Π C20 N39~ -P21Nχ N F N43 N41 F22 C31 N30.. C37 C35 — --UM34 F10 N32 R C9 dc33 OS2 P1 IIS2—P-SH (R)\ P 04 ?C5 C6 C38C36NC2^T N'C8'qHN^ / N2507 N27 C26 C11 θO12 THE 015

[0166] In various embodiments of the disclosure, “nitrogen N-34”, “nitrogen N-39”, “sulfur S-2” or “sulfur S-14” may be used to refer to nitrogen or sulfur atoms in other STING agonists that correspond to the numbered nitrogen or sulfur atoms in Compound 1 or Compound 2, regardless of whether the atoms are numbered otherwise according to nomenclature convention. In some cases, for compounds of Formula (III), Formula (IV), or Table 20, for example, Compound 1 or Compound 2, an LD conjugate bonded to nitrogen N-34 may be designated as “Rn” or “RN” and an LD conjugate bonded to nitrogen N-39 may be designated as “Sn” or “SN”.

[0167] “The Fcy receptor”, “Fc-gamma receptor” or “FcyR” refers to a cell surface protein commonly found on immune cells of various types, for example, neutrophils. The binding of an Fc region of a Petition 870260065905, dated 03 / 07 / 2026, p. 51 / 1400 48 / 650 antibody to an Fcy receptor can induce different effector functions, for example antibody-dependent cellular cytotoxicity (ADCC) or antibody-dependent cellular phagocytosis (ADCP).

[0168] As used in this document, the term “halogen” or “halo” means F, Cl, Br or I.

[0169] The term “homologous” refers to a molecule that exhibits homology to another molecule, for example, that has sequences of chemical residues that are identical or similar in corresponding positions.

[0170] The terms “IgG1 Fc”, “IgG1 Fc domain” or “antibody containing IgG1 Fc” as used herein refers to an antibody that has at least one IgG1 CH2 and CH3 domain, as identified by SEQ ID NO: 70 and SEQ ID NO: 71, respectively.

[0171] “Wild-type IgG1 Fc domain” refers to a human IgG1 Fc domain comprising the amino acid sequence SEQ ID NO: 69 or a fragment thereof.

[0172] The term “inhibit” or “inhibition of”, as used in this document, means to reduce by a measurable amount and may include, but does not require, complete prevention or inhibition.

[0173] “Internalizing”, as used in this document in reference to an antibody or antigen-binding fragment, refers to an antibody or antigen-binding fragment that has the ability to be transported across the lipid bilayer membrane of the cell to an internal compartment (i.e., “internalized”) by binding to the cell, preferably in a degrading compartment in the cell. For example, an internalizing anti-PSMA antibody is one that has the ability to be obtained in the cell after binding to PSMA in the cell membrane.

[0174] The term “KD” refers to the equilibrium dissociation constant of a particular antibody-antigen interaction. KD is calculated by ka / kd. The ratio can be determined using standard assays, such as a BIAcore® assay or ELISA. Petition 870260065905, dated 03 / 07 / 2026, page 52 / 1400 49 / 650

[0175] The term kon or ka refers to the association rate constant for an antibody to associate with an antigen to form the antibody / antigen complex. The rate can be determined using standard assays, such as a BIAcore® or ELISA assay.

[0176] The term “koff” or “kd” refers to the dissociation rate constant for the dissociation of an antibody from the antibody / antigen complex. The rate can be determined using standard assays, such as a BIAcore® assay or ELISA.

[0177] A “ligand” or “linking chemical moiety” is any chemical moiety that has the capacity to covalently bind to a compound, usually a chemical moiety of a drug such as a chemotherapeutic agent, or to another chemical moiety such as an antibody chemical moiety. Ligands may be susceptible or substantially resistant to acid-induced cleavage, peptidase-induced cleavage, light-based cleavage, esterase-induced cleavage, and / or disulfide bond cleavage, under conditions in which the compound or antibody remains active. A “cleavable ligand” is any ligand that comprises a cleavable chemical moiety and may thus be susceptible to cleavage. A cleavable chemical moiety may be a cleavable peptide chemical moiety. The term "cleavable peptide chemical portion" refers to any chemical bond linking amino acids (derived from natural or synthetic amino acids) that can be cleaved by an agent present in the intracellular environment.

[0178] The use of “ou” will mean “and / or” except where the specific context of its use indicates otherwise.

[0179] The term “p” or “antibody:drug ratio” or “drug-to-antibody ratio” or “DAR” refers to the number of drug chemical moieties per antibody chemical moiety, i.e., drug loading, or the number of LD chemical moieties per antibody or antigen-binding fragment (Ab) in Formula I ADCs. In compositions comprising multiple copies of Formula I ADCs, “p” refers to the average number of Petition 870260065905, dated 03 / 07 / 2026, p. 53 / 1400 50 / 650 chemical moieties LD per antibody or antigen-binding fragment, also called drug loading medium.

[0180] A pharmaceutical composition refers to a preparation that is in a form to permit administration and subsequently deliver the intended biological activity of the active ingredient (or active ingredients) and / or to achieve a therapeutic effect, and that does not contain additional components that are unacceptably toxic to an individual to whom the formulation would be administered. The pharmaceutical composition may be sterile.

[0181] A “pharmaceutical excipient” comprises a material such as an adjuvant, a carrier, pH adjusting and buffering agents, tonicity adjusting agents, humectants, preservatives and the like.

[0182] “Pharmaceutically acceptable” means approved or approvable by a federal or state government regulatory agency, or mentioned in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia, for use in animals and more particularly in humans.

[0183] As used in this document, the term “pi bond” means a covalent bond formed by the p orbitals of adjacent atoms. Pi bonds exist when there is a multiple bond, that is, a double or triple bond, between two atoms. For example, a carbon-carbon double bond consists of one pi bond, and a carbon-carbon triple bond consists of two pi bonds.

[0184] The term “prostate-specific limb antigen” or “PSMA,” as used herein, refers to any native form of human PSMA. The term encompasses full-length PSMA (e.g., NCBI Reference Sequence: NP_004467.1; SEQ ID NO: 67), as well as any form of human PSMA resulting from cellular processing. The term may also encompass naturally occurring variants of PSMA, including, but not limited to, splice variants, allelic variants, and isoforms. An antibody that binds PSMA may not bind all variants, as will be Petition 870260065905, dated 03 / 07 / 2026, p. 54 / 1400 51 / 650 readily apparent to an individual skilled in the art. PSMA can be isolated from a human, or it can be produced recombinantly or by synthetic methods. The terms “PSMA” and “prostate-specific membrane antigen” are interchangeable with “glutamate carboxypeptidase II (GCPII)”, “folate hydrolase 1”, “N-acetylated alpha-linked acid dipeptidase I (NAALADase I)” and any other name for FOLH1-encoded proteins known in the art.

[0185] The term “protecting group”, as used in this document, refers to any chemical group introduced into a molecule by chemical modification of a functional group to achieve chemoselectivity in a subsequent chemical reaction.

[0186] Methods for adding (a process generally referred to as “protection”) and removing (a process generally referred to as “deprotection”) are well known in the art and available, for example, in PJ Kocienski, Protecting Groups, 3rd edition (Thieme, 2005), and in Greene and Wuts, Protective Groups in Organic Synthesis, 4th edition (John Wiley & Sons, New York, 2007), both of which are readily incorporated by reference in their entirety.

[0187] Non-limiting examples of useful protecting groups for amines that can be used in this disclosure include monovalent protecting groups, for example, t-butyloxycarbonyl (Boc), benzyl (Bn), 9-fluorenylmethyloxycarbonyl (Fmoc), benzyloxycarbonyl (Cbz), formyl, acetyl (Ac), trifluoroacetyl (TFA), and p-toluenesulfonyl (Ts); and divalent protecting groups, for example, benzylidene, N-phthalimide, N-dithiasuccinimide, N-2,3-diphenylmaleimide, N-2,3-dimethylmaleimide, and N-2,5-dimethylpyrrole.

[0188] Non-limiting examples of useful protecting groups for alcohols that may be used in this disclosure include, for example, acetyl (Ac), benzoyl (Bz), benzyl (Bn), β-methoxyethoxymethyl (MEM), dimethoxytrityl (DMT), methoxymethyl (MOM), methoxytrityl (MMT), p-methoxybenzyl (PMB), pivaloyl (Piv), tetrahydropyranyl (THP), trityl (Tr), 4-nitrophenyl carbonate, Petition 870260065905, dated 03 / 07 / 2026, page 55 / 1400 52 / 650 trimethylsilyl (TMS), triethylsilyl (TES), tri-isopropylsilyl (TIPS), t-butyldimethylsilyl (TBS) and t-butyldiphenylsilyl (TBDPS).

[0189] Non-limiting examples of useful protecting groups for carboxylic acids that may be used in this disclosure include, for example, methyl or ethyl esters, substituted alkyl esters such as 9-fluorenylmethyl, methoxymethyl (MOM), tetrahydropyranyl (THP), tetrahydrofuranyl, β-methoxyethoxymethyl (MEM), 2-(trimethylsilyl)ethoxymethyl (SEM), benzyloxymethyl (BOM), acetyl (Ac), phenacyl, substituted phenacyl esters, t-butyl, allyl, phenyl (Ph), silyl esters, benzyl and substituted benzyl esters, 2,6-dialkylphenyl and pentafluorophenyl (PFP).

[0190] Non-limiting examples of amine bases that may be used in this disclosure include, for example, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), N-methylmorpholine (NMM), triethylamine (Et3N; TEA), diisopropylethylamine (i-Pr2EtN; DIPEA), pyridine, 2,2,6,6-tetramethylpiperidine, 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD), 7-methyl-1,5,7-triazabicyclo[4.4.0]dec-5-ene (MTBD), t-butetramethylguanidine, 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), lithium bis(trimethylsilyl)amide (LiHMDS) and potassium bis(trimethylsilyl)amide (KHMDS).

[0191] Non-limiting examples of carbonate bases that may be used in this disclosure include, for example, sodium carbonate (Na2CO3), potassium carbonate (K2CO3), cesium carbonate (Cs2CO3), lithium carbonate (Li2CO3), sodium bicarbonate (NaHCO3), and potassium bicarbonate (KHCO3).

[0192] Non-limiting examples of phosphate bases that can be used in this disclosure include, for example, tribasic sodium phosphate (Na3PO4), tribasic potassium phosphate (K3PO4), dibasic potassium phosphate (K2HPO4) and monobasic potassium phosphate (KH2PO4).

[0193] Non-limiting examples of acids that may be used in this disclosure include, for example, acetic acid (AcOH), trifluoroacetic acid (TFA), hydrochloric acid (HCl), camphorsulfonic acid (CSA), methanesulfonic acid (MsOH), formic acid (FA), phosphoric acid (H3PO4) and acid Petition 870260065905, dated 03 / 07 / 2026, page 56 / 1400 53 / 650 sulfuric acid (H2SO4).

[0194] Non-limiting examples of peptide coupling reagents include, for example, N,N'-dicyclohexylcarbodiimide (DCC), 1-ethyl-3[3-(dimethylamino)propyl]carbodiimide (EDCI), 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-io chloride (DMT-MM), 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), 1-3-hexafluorophosphate oxide [bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium (HATU),1hydroxybenzotriazole (HOBT), and N, N, N, N '-tetramethyl-O -(N succinimidyl)uronium tetrafluoroborate (TSTU).

[0195] For amino acid sequences, sequence identity and / or similarity can be determined using standard techniques known in the art, including, but not limited to, the local sequence identity algorithm of Smith and Waterman (1981) Adv. Appl. Math. 2:482, the sequence identity alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, the similarity search method of Pearson and Lipman (1988) Proc. Nat. Acad. Sci. USA 85:2444, computerized implementations of these algorithms (GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, Wis.), the Best Fit sequence program described by Devereux et al. (1984) Nucl. Acid Res. 12:387-95, preferably using the default settings or by inspection.Preferably, the identity percentage is calculated by FastDB based on the following parameters: divergence penalty of 1; gap penalty of 1; gap size penalty of 0.33; and join penalty of 30. See “Current Methods in Sequence Comparison and Analysis”, Macromolecule Sequencing and Synthesis, Selected Methods and Applications, pages 127-149 (1988), Alan R. Liss, Inc.

[0196] An example of a useful algorithm is PILEUP. PILEUP creates a multi-sequence alignment from a group of related sequences using forward pairwise alignments. The same also Petition 870260065905, dated 03 / 07 / 2026, page 57 / 1400 54 / 650 can plot a tree showing the grouping relationships used to create the alignment. PILEUP uses a simplification of the forward alignment method of Feng & Doolittle (1987) J. Mol. Evol. 35:351-360; the method is similar to that described by Higgins and Sharp (1989) CABIOS 5:151-3. Useful PILEUP parameters include a standard gap weight of 3.00, a standard gap length weight of 0.10, and weighted end gaps.

[0197] Another example of a useful algorithm is the BLAST algorithm. See, for example, Altschul et al. (1990) J. Mol. Biol. 215:403-10; Altschul et al. (1997) Nucleic Acids Res. 25:3389-402; and Karin et al. (1993) Proc. Natl. Acad. Sci. USA 90:5873-87. A particularly useful BLAST program is the WU-BLAST-2 program which was obtained from Altschul et al. (1996) Methods in Enzymology 266:460-80. WU-BLAST-2 uses several search parameters, most of which are set to default values. The adjustable parameters are set with the following values: overlap amplitude = l, overlap fraction = 0.125, word threshold (T) = II. The HSP S and HSP S2 parameters are dynamic values ​​and are set by the program itself depending on the composition of the specific sequence and the composition of the specific database against which the sequence of interest is being searched; however, the values ​​can be adjusted to increase sensitivity.

[0198] An additional useful algorithm is gap-based BLAST, as reported by Altschul et al. (1993) Nucl. Acids Res. 25:3389-402. Gap-based BLAST uses BLOSUM-62 replacement scores; threshold parameter T set to 9; the two-hit method for triggering gapless extensions, carries ka-cost gap lengths of 10+k; Xu set to 16 and Xg set to 40 for the database search stage and 67 for the output stage of the algorithms. Gap alignments are triggered by a score corresponding to approximately 22 bits.

[0199] In general, the proteins disclosed in this document and variants thereof (e.g., variants that retain the function of the original protein), including PSMA variants and variable domain variants of Petition 870260065905, dated 03 / 07 / 2026, page 58 / 1400 55 / 650 antibodies (including individual variant CDRs) have amino acid homology, similarity, or identity of at least 80%, and more typically homologies or identities of at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, and nearly 100% or 100%.

[0200] Similarly, “percentage (%) of nucleic acid sequence identity” with respect to the nucleic acid sequence of antibodies and other proteins identified in this document is defined as the percentage of nucleotide residues in a candidate sequence that is identical to the nucleotide residues in the coding sequence of the antigen-binding protein. A specific method uses the BLASTN module of WU-BLAST-2 defined for the standard parameters, with overlap amplitude and chemical overlap portion defined as 1 and 0.125, respectively.

[0201] The term “stable”, as used herein, refers to compounds that are not substantially altered when subjected to conditions that allow their production, detection and preferably their recovery, purification and use for one or more of the purposes disclosed herein.

[0202] The terms “individual” and “patient” are used interchangeably in this document to refer to any animal, such as any mammal, including, but not limited to, humans, non-human primates, rodents and the like. In some embodiments, the mammal is a mouse. In some embodiments, the mammal is a human being.

[0203] The term “target negative” or “negative for target antigen” refers to the absence of target antigen expression by a cell or tissue. The term “target positive” or “positive for target antigen” refers to the presence of target antigen expression. For example, a cell or cell line that does not express a target antigen can be described as target negative, while a cell or cell line that expresses a target antigen can be described as target positive. Petition 870260065905, dated 03 / 07 / 2026, page 59 / 1400 56 / 650

[0204] As used in this document, the term “solvent” refers to any liquid in which the product is at least partially soluble (product solubility > 1 g / l).

[0205] As used in this document, the term “isomer” refers to compounds with identical molecular formula but different spatial arrangements of atoms or bonds. Isomers include stereoisomers, cis-trans isomers, atropisomers, and tautomers.

[0206] As used in this document, the term “stereoisomer” refers to both enantiomers and diastereomers.

[0207] It will be observed that certain compounds of this invention may exist as separate stereoisomers or enantiomers and / or mixtures of these stereoisomers or enantiomers. As used in the chemical structures disclosed herein, a “wedge” (^) or “hatched” ('') linkage to a stereogenic atom indicates a chiral center of known absolute stereochemistry (i.e., a stereoisomer). As used herein, a stereogenic atom that is denoted with an (R) or (S) indicates the stereochemical designation of the stereogenic atom under the Cahn-Ingold-Prelog convention. As used in the chemical structures disclosed herein, a (“linear”) linkage to a stereogenic atom indicates whether there is a mixture (e.g., a racemate or enrichment). As used herein, two (“linear”) linkages to a double-bonded carbon indicate that the double bond has the E / Z stereochemistry as drawn.

[0208] Certain compounds disclosed in this document may exist as tautomers and both tautomeric forms are intended, although only a single tautomeric structure is represented.

[0209] The revelation also provides processes for preparing salts of the revelation compounds.

[0210] A salt of a compound of this revelation is formed between Petition 870260065905, dated 03 / 07 / 2026, page 60 / 1400 57 / 650 an acid and basic group(s) of the compound, such as an amino functional group, or a base and acidic group(s) of the compound, such as a carboxyl functional group. Depending on the ratio between the basic or acidic group(s) in the compound and the valence of the acid or base, a compound may form a salt with one or more molecular units of the acid / base, or multiple units of the compound may form a salt with one unit of the acid / base. In some embodiments, the salt is a sodium salt. In some embodiments, the salt is a diammonium salt. In some embodiments, the salt is a dialkylammonium salt. In some embodiments, the salt is a bis(triethylammonium) salt.

[0211] The term “interferon gene stimulator” or “STING,” as used herein, refers to any native form of human STING. The term encompasses full-length STING (e.g., NCBI Reference Sequence: NP_938023.1; SEQ ID NO: 68), as well as any form of human STING resulting from cellular processing. The term also encompasses naturally occurring variants of STING, including, but not limited to, splice variants, allelic variants, and isoforms. STING may be isolated from a human, or it may be produced recombinantly or by synthetic methods.

[0212] As used in this document, “treat” or “therapeutic” and grammatically related terms refer to any improvement of any consequence of the disease, such as prolonged survival, less morbidity, and / or decreased side effects that are byproducts of an alternative therapeutic modality. As readily noted in the art, complete eradication of disease is preferred, although not a requirement for an act of treatment. “Treatment” or “treat,” as used in this document, refers to the administration of a described ADC or antibody to an individual, for example, a patient. Treatment may be to cure, alleviate, attenuate, alter, remedy, improve, palliate, enhance, or affect the disorder, the symptoms of the disorder, or the predisposition to the disorder, for example, cancer. Petition 870260065905, dated 03 / 07 / 2026, page 61 / 1400 58 / 650

[0213] As used in this document, the term “unsaturated” means that a chemical moiety has one or more unsaturation units. Anti-PSMA Antibodies and Antigen-Binding Fragments

[0214] The present disclosure provides antibodies that bind specifically to PSMA and can be used independently, for example, formulated as therapeutic or diagnostic antibody compositions, for example, for use in the treatment or detection of PSMA-expressing cancers. The antibodies can be supplied packaged or prepared for therapeutic use as antibodies, antigen-binding fragments thereof, or as portions of ADCs.

[0215] The antibodies disclosed herein can bind to PSMA with a dissociation constant (KD) of < 1 mM, < 100 nM or < 10 nM, or any amount in between, as measured by, for example, BIAcore® analysis. In some embodiments, the KD is 500 pM at 1 nM, or 1 nM at 10 nM. In some embodiments, the KD is < 10 nM, < 5 nM, < 1 nM or < 0.5 nM.

[0216] In some embodiments, the antibodies are four-chain antibodies (also referred to as an immunoglobulin), comprising two heavy chains and two light chains. In some embodiments, the antibodies are two-chain half-bodies (one light chain and one heavy chain), or antigen-binding fragments of an immunoglobulin.

[0217] In some embodiments, the antibodies are internalizing antibodies or antigen-binding fragments thereof. In some embodiments, the internalizing antibodies bind to PSMA expressed on the surface of a cell and enter the cell by or after binding. In some embodiments, the drug chemical portion of the ADC is released from the antibody chemical portion of the ADC after the ADC enters and is present in a cell expressing PSMA (i.e., after the ADC has been Petition 870260065905, dated 03 / 07 / 2026, page 62 / 1400 59 / 650 internalized). In some embodiments, internalizing antibodies bind to PSMA expressed on the cell surface of a cell and the cell is subsequently phagocytosed (e.g., antibody-dependent cellular phagocytosis occurs). In some embodiments, the drug chemical portion of the ADC is released from the antibody chemical portion of the ADC after the ADC enters and is present in the phagocytic cell (e.g., macrophage, dendritic cell).

[0218] The antibodies disclosed herein that specifically bind a PSMA protein may comprise three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) having amino acid sequences selected from the HC CDRs listed in Tables 3 and / or 5 below, as defined by the Kabat numbering system, and three light chain CDRs (LCDR1, LCDR2 and LCDR3) having amino acid sequences selected from the LC CDRs listed in Tables 3 and / or 5 below, as defined by the Kabat numbering system. In some embodiments, the antibodies comprise three heavy chain CDRs (HCDR1, HCDR2, and HCDR3) that have amino acid sequences selected from the HC CDRs listed in Table 7 below, as defined by the IMGT numbering system, and three light chain CDRs (LCDR1, LCDR2, and LCDR3) that have amino acid sequences selected from the LC CDRs listed in Table 7 below, as defined by the IMGT numbering system.

[0219] In some embodiments, an antibody disclosed herein comprises a VH domain having an amino acid sequence selected from the SEQ ID NOs: 1-14 listed in Tables 4 and / or 9 below. In some embodiments, the antibody comprises a VL domain having an amino acid sequence selected from the SEQ ID NOs: 1520 listed in Tables 4 and / or 9 below.

[0220] In some embodiments, an antigen-binding fragment disclosed herein retains PSMA binding. In some embodiments, the antigen-binding fragment retains PSMA binding. Petition 870260065905, dated 03 / 07 / 2026, p. 63 / 1400 60 / 650 comprising three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) comprising amino acid sequences selected from the HC CDRs listed in Tables 3 and / or 5 below, as defined by the Kabat numbering system, and three light chain CDRs (LCDR1, LCDR2 and LCDR3) comprising amino acid sequences selected from the LC CDRs listed in Tables 3 and / or 5 below, as defined by the Kabat numbering system. In some embodiments, the antigen-binding fragment comprises three heavy chain CDRs (HCDR1, HCDR2, and HCDR3) comprising amino acid sequences selected from the HC CDRs listed in Table 7 below, as defined by the IMGT numbering system, and three light chain CDRs (LCDR1, LCDR2, and LCDR3) comprising amino acid sequences selected from the LC CDRs listed in Table 7 below, as defined by the IMGT numbering system.In some embodiments, the antigen-binding fragments disclosed herein may retain PSMA binding comprising a VH domain comprising an amino acid sequence selected from SEQ ID NOs: 1-14 listed in Tables 4 and / or 9 below, and a VL domain comprising an amino acid sequence selected from SEQ ID NOs: 15-20 listed in Tables 4 and / or 9 below.

[0221] In some embodiments, the anti-PSMA antibody or antigen-binding fragment comprises three HCDRs comprising amino acid sequences of SEQ ID NO: 21 (HCDR1), SEQ ID NO: 44 (HCDR2), and SEQ ID NO: 27 (HCDR3); and three LCDRs comprising SEQ ID NO: 45 (LCDR1), SEQ ID NO: 46 (LCDR2), and SEQ ID NO: 37 (LCDR3) as defined by the Kabat numbering system. In some embodiments, the antibody or antigen-binding fragment comprises a variable heavy chain region comprising an amino acid sequence of SEQ ID NO: 42 and a variable light chain region comprising an amino acid sequence of SEQ ID NO: 43. In some embodiments, the antibody or antigen-binding fragment comprises an IgG1 domain. Petition 870260065905, dated 03 / 07 / 2026, page 64 / 1400 61 / 650

[0222] In some embodiments, the anti-PSMA antibody or antigen-binding fragment comprises three HCDRs comprising amino acid sequences of SEQ ID NO: 21 (HCDR1), SEQ ID NO: 22 (HCDR2) and SEQ ID NO: 27 (HCDR3); and three LCDRs comprising SEQ ID NO: 32 (LCDR1), SEQ ID NO: 35 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the Kabat numbering system; or three HCDRs comprising amino acid sequences of SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2) and SEQ ID NO: 30 (HCDR3); and three LCDRs comprising SEQ ID NO: 38 (LCDR1), SEQ ID NO: 39 (LCDR2), and SEQ ID NO: 37 (LCDR3), as defined by the IMGT numbering system. In some embodiments, the antibody or antigen-binding fragment comprises a variable heavy chain region comprising an amino acid sequence of SEQ ID NO: 14 and a variable light chain region comprising an amino acid sequence of SEQ ID NO: 19.In some forms, the antibody or antigen-binding fragment comprises an IgG1 domain.

[0223] In some embodiments, the anti-PSMA antibodies and antigen-binding fragments disclosed in this document have favorable thermal stability. In some embodiments, the anti-PSMA antibodies or antigen-binding fragments disclosed in this document have a melting point (Tm) > 70 °C, > 75 °C, or > 80 °C. In some embodiments, the anti-PSMA antibodies or antigen-binding fragments disclosed in this document have a melting point (Tm) > 80 °C. In some embodiments, the anti-PSMA antibodies or antigen-binding fragments disclosed in this document have a higher melting point (Tm) than anti-PSMA antibodies, for example, J591 and deJ591. See, for example, U.S. Patent No. 11,059,903 and U.S. Patent No. 7,045,605.

[0224] An anti-PSMA antibody or antigen-binding fragment may be selected to enhance or retain a variety of factors, including retaining target binding affinity, enhancing thermal stability, and / or minimizing immunogenicity. In some embodiments, an anti-PSMA antibody Petition 870260065905, dated 03 / 07 / 2026, page 65 / 1400 62 / 650 is selected to exhibit superiority in more than one category. In some modalities, an anti-PSMA antibody is selected to exhibit improvement in more than one category, even if not necessarily the best antibody in a category.

[0225] In some embodiments, an anti-PSMA antibody or antigen-binding fragment comprising three HCDRs comprising amino acid sequences of SEQ ID NO: 21 (HCDR1), SEQ ID NO: 22 (HCDR2) and SEQ ID NO: 27 (HCDR3); and three LCDRs comprising SEQ ID NO: 32 (LCDR1), SEQ ID NO: 35 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the Kabat numbering system; or three HCDRs comprising amino acid sequences of SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2) and SEQ ID NO: 30 (HCDR3); and three LCDRs comprising SEQ ID NO: 38 (LCDR1), SEQ ID NO: 39 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the IMGT numbering system, is selected to exhibit retained target binding affinity, enhanced thermal stability and minimized immunogenicity compared to other anti-PSMA antibodies, e.g., J591 and / or deJ591.In some embodiments, an anti-PSMA antibody or antigen-binding fragment comprising three HCDRs comprising amino acid sequences of SEQ ID NO: 21 (HCDR1), SEQ ID NO: 22 (HCDR2) and SEQ ID NO: 27 (HCDR3); and three LCDRs comprising SEQ ID NO: 32 (LCDR1), SEQ ID NO: 35 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the Kabat numbering system; or three HCDRs comprising amino acid sequences of SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2) and SEQ ID NO: 30 (HCDR3); and three LCDRs comprising SEQ ID NO: 38 (LCDR1), SEQ ID NO: 39 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the IMGT numbering system, is selected to exhibit retained target binding affinity and minimized immunogenicity compared to other anti-PSMA antibodies, for example, J591, deJ591 and / or anti-PSMA antibodies disclosed in this document.

[0226] In some forms, an anti-PSMA antibody or Petition 870260065905, dated 03 / 07 / 2026, p. 66 / 1400 A 63 / 650 antigen-binding fragment comprising a variable heavy chain region comprising an amino acid sequence of SEQ ID NO: 14 and a variable light chain region comprising an amino acid sequence of SEQ ID NO: 19 is selected to exhibit retained target binding affinity, enhanced thermal stability, and minimized immunogenicity compared to other anti-PSMA antibodies, e.g., J591 and / or deJ591. In some embodiments, an anti-PSMA antibody or antigen-binding fragment comprising a variable heavy chain region comprising an amino acid sequence of SEQ ID NO: 14 and a variable light chain region comprising an amino acid sequence of SEQ ID NO: 19 is selected to exhibit retained target binding affinity and minimized immunogenicity compared to other anti-PSMA antibodies, e.g., J591, deJ591, and / or anti-PSMA antibodies disclosed herein.

[0227] In some embodiments, the antibodies disclosed herein may comprise an IgG constant domain, for example, an IgG1 domain, or an IgG1 domain that has been modified to reduce binding to an Fc receptor, for example, an Fcy receptor (FcyR), compared with an antibody containing a wild-type constant domain (for example, an antibody containing wild-type IgG1). The reduced binding to an Fc receptor, for example, an FcyR, can be measured as a comparison to the binding of the antibody without modification to the same receptor. The reduced binding can be at least about 10-fold, and preferably at least about 100-fold compared with the antibody containing the unmodified constant domain. The reduced binding can be measured using any assay known in the art. For example, the reduced binding can be measured using a fluorescence resonance energy transfer (FRET) assay.

[0228] In some embodiments, the antibodies disclosed in this document may comprise a constant IgG domain, for Petition 870260065905, dated 03 / 07 / 2026, p. 67 / 1400 64 / 650 For example, an IgG1 domain or an IgG1 domain that has been modified to increase binding to an Fc receptor, for example, an Fcy receptor (FcyR), compared to an antibody containing a wild-type constant domain (for example, an antibody containing wild-type IgG1). The increased binding to an Fc receptor, for example, an FcyR, can be measured as a comparison to the binding of the antibody without modification to the same receptor. The increased binding can be at least about 5-fold, and preferably at least about 10-fold compared to the antibody containing the unmodified constant domain. The increased binding can be measured using a fluorescence resonance energy transfer (FRET) assay. In some embodiments, the modified IgG constant domain is modified by Fc genetic modification and / or glycan modification, for example, afucosylation.

[0229] In some embodiments, an antibody disclosed in this document may comprise an IgG1 domain comprising the L234A, L235A, P238S, H268Q, and / or K274Q mutations (e.g., comprising all of these mutations) according to Kabat EU numbering. See, for example, Wang et al. (2017) Protein Cell 9(1):63-73; Vafa et al. (2014) Methods 1;65(1):114-26; and Tam et al. (2017) Antibodies 1 6(3):12. Without adhering to theory, these mutations may reduce antibody binding to an Fcy receptor (FcyR), which may reduce non-antigen-mediated uptake of antibodies or ADCs by immune cells such as neutrophils, thus reducing neutropenia. Reduced neutropenia can be measured using any assay known in the art. For example, reduced neutropenia can be measured using a flow cytometry assay.

[0230] In some embodiments, an antibody that specifically binds a PSMA protein comprises a heavy chain having an amino acid sequence selected from the SEQ ID NOs: 47-60 listed in Table 10 below and / or comprising a set of CDRs and / or a variable domain of the amino acid sequences in Table 10. In some Petition 870260065905, dated 03 / 07 / 2026, p. 68 / 1400 65 / 650 modalities, an antibody that specifically binds a PSMA protein comprises a light chain having an amino acid sequence selected from the SEQ ID NOs: 61-66 listed in Table 10, below, and / or comprising a set of CDRs and / or a variable domain of the amino acid sequences in Table 10.

[0231] The amino acid and nucleic acid sequences of exemplary antibodies of the present disclosure are shown in Tables 3-11. The monoclonal antibody Kabat CDR and variable region consensus sequences (Tables 3 and 4, respectively) reflect the alignment of the heavy and light chain variable region sequences represented by SEQ ID NOs: 1-20 (Figure 1). Residues that differ between clones are represented by “X” in SEQ ID NOs: 42-46. An anti-PSMA antibody or antigen-binding fragment as described herein may be defined by the consensus CDR sequences from Table 3 in combination with the CDR sequences from Table 5, for example, by selecting a CDR2 from HC, CDR1 from LC and / or LCDR2 sequence from Table 3 and a CDR1 from HC, CDR2 from HC, CDR3 from HC, CDR1 from LC, CDR2 from LC and / or CDR3 from LC from Table 5 to describe an antibody by its three heavy chain and three light chain CDR sequences. Table 3. Amino Acid Sequences of Kabat CDRs from Consensus mAbs IgG Chain SEQ ID NO Amino Acid Sequence Heavy Chain CDRs HC CDR2 44 NINPNNGGTTYX1X2KFX3X4 Light Chain CDRs LC CDR1 45 X5ASQDVGTAX6X7 LC CDR2 46 WASTRHX8 X1= A or N; X2= E or Q; X3= Q or E; X4= G or D; X5= R or K; X6= V or L; X7 = D or N; and X8 = S or T Petition 870260065905, dated 03 / 07 / 2026, p. 69 / 1400 66 / 650 Table 4. Amino Acid Sequences of Variable Regions of Consensus mAb IgG Chain SEQ ID NO Variable Region Amino Acid Sequence Heavy Chain 42 EVQLVQSGAEVKKPGATVKISCKX9S GYTFTEYTIHWV QQAPGKGLEWX10GNINPNNGGTTYX11X12KFX13X14RV TITX15DX16STX17TAYM ELSSLRS EDTAVYYCAX18GWN FDYWGQGTLLTVSS Light Chain 43 DIQMTQSPSSLSASVGDRVTITCX19ASQDVGTAX20X21 WYQQKPGKAPKLLIYWASTRHX22GVPSRFSGSGSGT DFTLTISSLQPEDFATYYCQQYNSYPLTFGQGTKLEIK X9 = V or T; X10= M or I; X11= A or N; X12= E or Q; X13= Q or E; X14= G or D; X15= A or V; X16= T or K; X17= D or S; X18= T or A; X19= R or K; X20= L or V; X21= N or D; and X22= S or T Table 5. Amino Acid Sequences of Kabat CDRs of mAb IgG Chain SEQ ID NO Amino Acid Sequence Heavy Chain CDRs HC CDR1 21 EYTIH HC CDR2 22 NINPNNGGGTTYAEKFQG 23 NINPNNGGTTYNEKFQG 24 NINPNNGGTTYNQKFQG 25 NINPNNGGTTYNQKFEG 26 NINPNNGGTTYNQKFED HC CDR3 27 GWNFDY Petition 870260065905, dated 03 / 07 / 2026, p. 70 / 1400 67 / 650 Table 5. Amino Acid Sequences of Kabat CDRs from mAb (continued) IgG Chain SEQ ID NO Amino Acid Sequence Light Chain CDRs LC CDR1 32 RASQDVGTAVD 33 KASQDVGTAVD 34 RASQDVGTALN LC CDR2 35 WASTRHS 36 WASTRHT LC CDR3 37 QQYNSYPLT Table 6. Nucleic acid sequences encoding Kabat CDRs of mAb IgG Chain SEQ ID NO Nucleic Acid Sequence Heavy Chain CDRs HC CDR1 74 GAGTACACCATTCAC HC CDR2 75 AACATCAACCCCAACAACGGCGGCACCACCTAC GCCGAAAATTCCAGGGC 76 AACATCAACCCCAACAACGGCGGCACCACCTAC AACGAAAAATTCCAGGGC 77 AACATCAACCCCAACAACGGCGGCACCACCTAC AACCAGAAATTCCAGGGC 78 AACATCAACCCCAACAACGGCGGCACCACCTAC AACCAGAAATTCGAGGGC 79 AACATCAACCCCAACAACGGCGGCACCACCTAC AACCAGAAATTCGAGGAC HC CDR3 80 GGCTGGAACTTCGACTAC Petition 870260065905, dated 03 / 07 / 2026, p. 71 / 1400 68 / 650 Table 6. Nucleic acid sequences encoding Kabat CDRs of mAb (continued) IgG Chain SEQ ID NO Nucleic Acid Sequence Light Chain CDRs LC 81 AGAGCCAGCCAGGATGTGGGCACCGCTGTTGAC 82 AAGGCCAGCCAGGATGTGGGCACCGCTGTTGAC 83 AGAGCCAGCCAGGATGTGGGCACCGCTCTGAAC LC 84 TGGGCCAGCACAAGACACAGC 85 TGGGCCAGCACAAGACACACA LC 86 CAGCAGTACAACAGCTACCCTCTGACC Table 7. Amino acid sequences of CDRs of IMGT mAb IgG Chain SEQ ID NO Amino Acid Sequence Heavy Chain CDRs HC CDR1 28 GYTFTEYT HC CDR2 29 INPNNGGT HC CDR3 30 ATGWNFDY 31 AAGWNFDY Light Chain CDRs LC CDR1 38 QDVGTA LC CDR2 39 WAS LC CDR3 37 QQYNSYPLT Petition 870260065905, dated 03 / 07 / 2026, p. 72 / 1400 69 / 650 Table 8. Nucleic acid sequences encoding mAb IMGT CDRs IgG Chain SEQ ID NO Nucleic Acid Sequence Heavy Chain CDRs HC CDR1 87 GGCTACACCTTCACCGAGTACACC HC CDR2 88 ATCAACCCCAACAACGGCGGCACC HC CDR3 89 GCCACCGGCTGGAACTTCGACTAC 90 GCCGCCGGCTGGAACTTCGACTAC Light Chain CDRs LC CDR1 91 CAGGATGTGGGCACCGCT LC CDR2 92 TGGGCCAGC LC CDR3 86 CAGCAGTACAACAGCTACCCTCTGACC Table 9. Amino acid sequences of variable regions of mAb SEQ ID NO Target Name Fv Variable Region Amino Acid Sequence 1 VhZu1 Human PSMA Vh EVQLVQSGAEVKKPGATVKISC KVSGYTFTEYTIHWVQQAPGKG LEWMGNINPNNGGTTYNQKFE DRVTITADTSTDTAYMELSSLRS EDTAVYYCATGWNFDYWGQGT LVTVSS 2 VhZu2 Human PSMA Vh EVQLVQSGAEVKKPGATVKISC KTSGYTFTEYTIHWVQQAPGKG LEWMGNINPNNGGTTYNQKFE DRVTITADTSTDTAYMELSSLRS EDTAVYYCATGWNFDYWGQGT LVTVSS Petition 870260065905, dated 03 / 07 / 2026, page 73 / 1400 70 / 650 Table 9. Amino acid sequences of variable regions of mAb (continued) SEQ ID NO Target Name Fv Variable Region Amino Acid Sequence 3 VhZu3 Human PSMA Vh EVQLVQSGAEVKKPGATVKISC KVSGYTFTEYTIHWVQQAPGKG LEWIGNINPNNGGTTYNQKFED RVTITADTSTDTAYMELSSLRSSE DTAVYYCATGWNFDYWGQGTL VTVSS 4 VhZu4 Human PSMA Vh EVQLVQSGAEVKKPGATVKISC KVSGYTFTEYTIHWVQQAPGKG LEWMGNINPNNGGTTYNQKFE DRVTITVDTSTDTAYMELSSLRS EDTAVYYCATGWNFDYWGQGT LVTVSS 5 VhZu5 Human PSMA Vh EVQLVQSGAEVKKPGATVKISC KVSGYTFTEYTIHWVQQAPGKG LEWMGNINPNNGGTTYNQKFE DRVTITADKSTDTAYMELSSLRS EDTAVYYCATGWNFDYWGQGT LVTVSS 6 VhZu6 Human PSMA Vh EVQLVQSGAEVKKPGATVKISC KVSGYTFTEYTIHWVQQAPGKG LEWMGNINPNNGGTTYNQKFE DRVTITADTSTSTAYMELSSLRS EDTAVYYCATGWNFDYWGQGT LVTVSS Petition 870260065905, dated 03 / 07 / 2026, page 74 / 1400 71 / 650 Table 9. Amino acid sequences of variable regions of mAb (continued) SEQ ID NO Target Name Fv Variable Region Amino Acid Sequence 7 VhZu7 Human PSMA Vh EVQLVQSGAEVKKPGATVKISC KVSGYTFTEYTIHWVQQAPGKG LEWMGNINPNNGGTTYNQKFE DRVTITADTSTDTAYMELSSLRS EDTAVYYCAAGWNFDYWGQG TLVTVSS 8 VhZu8 Human PSMA Vh EVQLVQSGAEVKKPGATVKISC KVSGYTFTEYTIHWVQQAPGKG LEWIGNINPNNGGTTYNQKFED RVTITADTSTDTAYMELSSLRSE DTAVYYCAAGWNFDYWGQGTL VTVSS 9 VhZu9 Human PSMA Vh EVQLVQSGAEVKKPGATVKISC KTSGYTFTEYTIHWVQQAPGKG LEWIGNINPNNGGTTTYNQKFED RVTITADKSTSTAYMELSSLRSE DTAVYYCAAGWNFDYWGQGTL VTVSS 10 VhZu10 Human PSMA Vh EVQLVQSGAEVKKPGATVKISC KTSGYTFTEYTIHWVQQAPGKG LEWIGNINPNNGGTTTYNQKFED RVTITADTSTTDTAYMELSSLRSE DTAVYYCAAGWNFDYWGQGTL VTVSS Petition 870260065905, dated 03 / 07 / 2026, page 75 / 1400 72 / 650 Table 9. Amino acid sequences of variable regions of mAb (continued) SEQ ID NO Target Name Fv Variable Region Amino Acid Sequence 11 VhZu11 Human PSMA Vh EVQLVQSGAEVKKPGATVKISC KVSGYTFTEYTIHWVQQAPGKG LEWMGNINPNNGGTTYNQKFE GRVTITADTSTDTAYMELSSLRS EDTAVYYCATGWNFDYWGQGT LVTVSS 12 VhZu12 Human PSMA Vh EVQLVQSGAEVKKPGATVKISC KVSGYTFTEYTIHWVQQAPGKG LEWMGNINPNNGGTTYNQKFQ GRVTITADTSTDTAYMELSSLRS EDTAVYYCATGWNFDYWGQGT LVTVSS 13 VhZu13 Human PSMA Vh EVQLVQSGAEVKKPGATVKISC KVSGYTFTEYTIHWVQQAPGKG LEWMGNINPNNGGTTYNEKFQ GRVTITADTSTTDTAYMELSSLRS EDTAVYYCATGWNFDYWGQGT LVTVSS 14 VhZu14 Human PSMA Vh EVQLVQSGAEVKKPGATVKISC KVSGYTFTEYTIHWVQQAPGKG LEWMGNINPNNGGTTYAEKFQ GRVTITADTSTTDTAYMELSSLRS EDTAVYYCATGWNFDYWGQGT LVTVSS Petition 870260065905, dated 03 / 07 / 2026, page 76 / 1400 73 / 650 Table 9. Amino acid sequences of variable regions of mAb (continued) SEQ ID NO Target Name Fv Variable Region Amino Acid Sequence 15 VkZu1 Human PSMA Vk DIQMTQSPSSLSASVGDRVTITC KASQDVGTAVDWYQQKPGKA PKLLIYWASTRHTGVPSRFSGS GSGTDFTLTISSLQPEDFATYYC QQYNSYPLTFGQGTKLEIK 16 VkZu2 Human PSMA Vk DIQMTQSPSSLSASVGDRVTITC RASQDVGTAVD WYQQKPGKA PKLLIYWASTRHTGVPSRFSGS GSGTDFTLTISSLQPEDFATYYC QQYNSYPLTFGQGTKLEIK 17 VkZu3 Human PSMA Vk DIQMTQSPSSLSASVGDRVTITC RASQDVGTALN WYQQKPGKAP KLLIYWASTRHTGVPSRFSGSG SGTDFTLTISSLQPEDFATYYCQ QYNSYPLTFGQGTKLEIK 18 VkZu4 Human PSMA Vk DIQMTQSPSSLSASVGDRVTITC KASQDVGTAVD WYQQKPGKA PKLLIYWASTRHSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYC QQYNSYPLTFGQGTKLEIK Petition 870260065905, dated 03 / 07 / 2026, page 77 / 1400 74 / 650 Table 9. Amino acid sequences of variable regions of mAb (continued) SEQ ID NO Target Name Fv Variable Region Amino Acid Sequence 19 VkZu5 Human PSMA Vk DIQMTQSPSSLSASVGDRVTITC RASQDVGTAVD WYQQKPGKA PKLLIYWASTRHSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYC QQYNSYPLTFGQGTKLEIK 20 VkZu6 Human PSMA Vk DIQMTQSPSSLSASVGDRVTITC RASQDVGTALN WYQQKPGKAP KLLIYWASTRHSGVPSRFSGSG SGTDFTLTISSLQPEDFATYYCQ QYNSYPLTFGQGTKLEIK 40 deJ591 Vh Human PSMA Vh EVQLVQSGPEVKKPGATVKISC KTSGYTFTEYTIHWVKQAPGKG LEWIGNINPNNGGTTYNQKFED KATLTVDKSTDTAYMELSSLRS EDTAVYYCAAGWNFDYWGQG TLLTVSS 41 deJ591 Vk Human PSMA Vk DIQMTQSPSSLSTSVGDRVTLT CKASQDVGTAVDWYQQKPGP SPKLLIYWASTRHTGIPSRFSGS GSGTDFTLTISSLQPEDFADYYC QQYNSYPLTFGPGTKVDIK Petition 870260065905, dated 03 / 07 / 2026, page 78 / 1400 75 / 650 Table 9. Amino acid sequences of variable regions of mAb (continued) SEQ ID NO Target Name Fv Variable Region Amino Acid Sequence 72 J591 Vh Human PSMA Vh EVQLQQSGPELKKPGTSVRISC KTSGYTFTEYTIHWVKQSHGKS LEWIGNINPNNGGTTYNQKFED KATLTVDKSSSTAYMELRSLTS EDSAVYYCAAGWNFDYWGQG TTLTVSS 73 J591 Vk Human PSMA Vk DIVMTQSHKFMSTSVGDRVSIIC KASQDVGTAVDWYQQKPGQSP KLLIYWASTRHTGVPDRFTGSG SGTDFTLIIINVQSEDLADYFC QQYNSYPLTFGAGTMLDLK The bold text indicates the amino acid positions corresponding to the CDR sequences according to the Kabat system; the underlined text indicates amino acid positions corresponding to the CDR sequences according to the IMGT system. The text that is not bold or underlined corresponds to the structural regions. Petition 870260065905, dated 03 / 07 / 2026, p. 79 / 1400 76 / 650 Table 10. Nucleic acid sequences encoding variable regions of mAb SEQ ID NO Name Target Fv Variable region nucleic acid sequence 93 VhZu1 Human PSMA Vh GAAGTTCAACTTGTTCAGAGCGGAGCC GAAGTGAAGAAACCCGGCGCTACAGT CTGGAATGGATGGGCAACATCAACCCC AACAACGGCGGCACCACCTACAACCA GAAATTCGAGGACAGAGTGACCATCAC CGCCGACACCAGCACCGATACAGCCT ACATGGAACTGAGCAGCCTGAGAAGC GAGGACACCGCCGTGTTATTGTGCC ACAGGGCACACTGGTCACCGTTAGCTC T 94 VhZu2 PSMA human Vh GAAGTTCAACTTGTTCAGAGCGGAGCC GAAGTGAAGAAACCCGGCGCTACAGT GAAGATCAGCTGCAAGACCTCCGGCTA CACCTTCACCGAGTACACCATTCACTG GGTGCAGCAGGCAAGCGACCTT TGGAATGGATGGGCAACATCAACCCCA ACAACGGCGGCACCACCTACAACCAG AAATTCGAGGACAGAGTGACCATCACC GCCGACACCAGCACCGATACAGCCTA CATGGAACTGAGCAGCCTGAGAAGCG AGGACACCGCCGTTATTGTGCCA CCGGCTGGAACCTGGGGAGGA CAGGGCACACTGGTCACCGTTAGCTCT Petition 870260065905, of 03 / 07 / 2026, p. 80 / 1400 77 / 650 Table 10. Nucleic acid sequences encoding variable regions of mAb (continued) SEQ ID NO Target Name Fv Variable Region Nucleic Acid Sequence 95 VhZu3 Human PSMA Vh GAAGTTCAACTTGTTCAGAGCGGAGCC GAAGTGAAGAAACCCGGCGCTACAGT GAAGATCAGCTGCAAGGTGTCCGGCT ACACCTTCACCGAGTACACCATTCACT GGGTGCAGCAGGCCCCTGGCAAAGGA CTGGAATGGATCGGCAACATCAACCCC AACAACGGCGGCACCACCTACAACCA GAAATTCGAGGACAGAGTGACCATCAC CGCGACACCAGCACCGATACAGCCT ACATGGAACTGAGCAGCCTGAGAAGC GAGGACACCGCCGTGTATTATTGTGCC ACCGCTGGAACTTCGACTACTGGGG ACAGGGCACACTGGTCACCGTTAGCTC T 96 VhZu4 Human PSMA Vh GAAGTTCAACTTGTTCAGAGCGGAGCC GAAGTGAAGAAACCCGGCGCTACAGT GAAGATCAGCTGCAAGGTGTCCGGCT ACACCTTCACCGAGTACACCATTCACT GGGTGCAGCAGGCCCCTGGCAAAGGA CTGGAATGGATGGGCAACATCAACCCC AACAACGGCGGCACCACCTACAACCA GAAATTCGAGGACAGAGTGACCATCAC CGTGGACACCAGCACCGATACAGCCT ACATGGAACTGAGCAGCCTGAGAAGC GAGGACACCGCCGTGTATTATTGTGCC ACCGGCTGGAACTTCGACTACTGGGG Petition 870260065905, dated 03 / 07 / 2026, p. 81 / 1400 78 / 650 Table 10. Nucleic acid sequences encoding variable regions of mAb (continued) SEQ ID NO Target Name Fv Variable Region Nucleic Acid Sequence ACAGGGCACACTGGTCACCGTTAGCTC T 97 VhZu5 Human PSMA Vh GAAGTTCAACTTGTTCAGAGCGGAGCC GAAGTGAAGAAACCCGCGGCTACAGT GAAGATCAGCTGCAAGGTGTCCGGCT ACACCTTCACCGAGTACACCATTCACT GGGTGCAGCAGGCCCCTGGCAAAGGA CTGGAATGGATGGGCAACATCAACCCC AACAACGGCGGCACCACCTACAACCA GAAATTCGAGGACAGAGTGACCATCAC CGCCGACAAGAGCACCGATACAGCCT ACATGGAACTGAGCAGCCTGAGAAGC GAGGACACCGCCGTGTATTATTGTGCC ACCGCTGGAACTTCGACTACTGGGG ACAGGGCACACTGGTCACCGTTAGCTC T 98 VhZu6 Human PSMA Vh GAAGTTCAACTTGTTCAGAGCGGAGCC GAAGTGAAGAAACCCGGCGCTACAGT GAAGATCAGCTGCAAGGTGTCCGGCT ACACCTTCACCGAGTACACCATTCACT GGGTGCAGCAGGCCCCTGGCAAAGGA CTGGAATGGATGGGCAACATCAACCCC AACAACGGCGGCACCACCTACAACCA GAAATTCGAGGACAGAGTGACCATCAC CGCCGACACCAGCACCAGCACAGCCT Petition 870260065905, dated 03 / 07 / 2026, p. 82 / 1400 79 / 650 Table 10. Nucleic acid sequences encoding variable regions of mAb (continued) SEQ ID NO Target Name Fv Variable Region Nucleic Acid Sequence ACATGGAACTGAGCAGCCTGAGAAGC GAGGACACCGCCGTGTATTATTGTGCC ACCGCTGGAACTTCGACTACTGGGG ACAGGGCACACTGGTCACCGTTAGCTC T 99 VhZu7 Human PSMA Vh GAAGTTCAACTTGTTCAGAGCGGAGCC GAAGTGAAGAAACCCGCGCTACAGT GAAGATCAGCTGCAAGGTGTCCGGCT ACACCTTCACCGAGTACACCATTCACT GGGTGCAGCAGGCCCCTGGCAAAGGA CTGGAATGGATGGGCAACATCAACCCC AACAACGGCGGCACCACCTACAACCA GAAATTCGAGGACAGAGTGACCATCAC CGCGCACCACCAGCACCGATACAGCCT ACATGGAACTGAGCAGCCTGAGAAGC GAGGACACCGCCGTGTATTATTGTGCC GCCGGCTGGAACTTCGACTACTGGGG ACAGGGCACACTGGTCACCGTTAGCTC T 100 VhZu8 human PSMA Vh GAAGTTCAACTTGTTCAGAGCGGAGCC GAAGTGAAGAAACCCGGCGCTACAGT GAAGATCAGCTGCAAGGTGTCCGGCT ACACCTTCACCGAGTACACCATTCACT GGGTGCAGCAGGCCCCTGGCAAAGGA CTGGAATGGATCGGCAACATCAACCCC AACAACGGCGGCACCACCTACAACCA Petition 870260065905, dated 03 / 07 / 2026, p. 83 / 1400 80 / 650 Table 10. Nucleic acid sequences encoding variable regions of mAb (continued) SEQ ID NO Target Name Fv Variable Region Nucleic Acid Sequence GAAATTCGAGGACAGTGACCATCAC CGCGACACCAGCACCGATACAGCCT ACATGGAACTGAGCAGCCTGAGAAGC GAGGACACCGCCGTGTATTATTGTGCC GCCGGCTGGAACTTCGACTACTGGGG ACAGGGCACACTGGTCACCGTTAGCTC T 101 VhZu9 Human PSMA Vh GAAGTTCAACTTGTTCAGAGCGGAGCC GAAGTGAAGAAACCCGCGCGTACAGT GAAGATCAGCTGCAAGACCTCCGGCTA CACCTTCACCGAGTACACCATTCACTG GGTGCAGCAGGCCCCTGGCAAAGGAC TGGAATGGATCGGCAACATCAACCCCA ACAACGGCGGCACCACCTACAACCAG AAATTCGAGGACAGAGTGACCATCACC GCCGACAAGAGCACCAGCACAGCCTA CATGGAACTGAGCAGCCTGAGAAGCG AGGACACCGCCGTGTATTATTGTGCCG CCGGCTGGAACTTCGACTACTGGGGA CAGGGCACACTGGTCACCGTTAGCTCT 102 VhZu10 Human PSMA Vh GAAGTTCAACTTGTTCAGAGCGGAGCC GAAGTGAAGAAACCCGGCGCTACAGT GAAGATCAGCTGCAAGACCTCCGGCTA CACCTTCACCGAGTACACCATTCACTG GGTGCAGCAGGCCCCTGGCAAAGGAC TGGAATGGATCGGCAACATCAACCCCA Petition 870260065905, dated 03 / 07 / 2026, p. 84 / 1400 81 / 650 Table 10. Nucleic acid sequences encoding variable regions of mAb (continued) SEQ ID NO Name Target Fv Variable region nucleic acid sequence ACAACGGCGGCACCACCTACAACCAG AAATTCGAGGACAGAGTGACCATCACC GCCGACACCAGCACCGATACAGCCTA CATGGAACTGAGCAGCCTGAGAAGCG AGGACACCGCCGTGTATTATTGTGCCG CCGGCTGGAACTTCGACTACTGGGGA CAGGGCACACTGGTCACCGTTAGCTCT 103 VhZu11 Human PSMA CGCCGACACCAGCACCGATACAGCCT ACATGGAACTGAGCAGCCTGAGAAGC GAGGACACCGCCGTGTATTATTGTGCC ACCGGCTGGAACTTCGACTACTGGGG ACAGGGCACACTGGTCACCGTTAGCTC T 104 VhZu12 Human PSMA Vh GAAGTTCAACTTGTTCAGAGCGGAGCC GAAGTGAAGAAACCCGGCGCTACAGT GAAGATCAGCTGCAAGGTGTCCGGCT ACACCTTCACCGAGTACACCATTCACT GGGTGCAGCAGGCCCCTGGCAAAGGA Petition 870260065905, dated 03 / 07 / 2026, p. 85 / 1400 82 / 650 Table 10. Nucleic acid sequences encoding variable regions of mAb (continued) SEQ ID NO Name Target Fv Variable region nucleic acid sequence CTGGAATGGATGGGCAACATCAACCCC AACAACGGCGGCACCACCTACAACCA GAAATTCCAGGGCAGAGTGACCATCAC CGCCGACACCAGCACCGATACAGCCT ACATGGAACTGAGCAGCCTGAGAAGC GAGGACACCGCCGTGTATTATTGTGCC ACCGGCTGGAACTTCGACTACTGGGG ACAGGGCACACTGGTCACCGTTAGCTC T 105 VhZu13 human PSMA Vh GAAGTTCAACTTGTTCAGAGCGGAGCC GAAGTGAAGAAACCCGGCGCTACAGT GAAGATCAGCTGCAAGGTGTCCGGCT ACACCTTCACCGAGTACACCATTCACT GGGTGCAGCAGGCCCCTGGCAAAGGA CTGGAATGGATGGGCAACATCAACCCC AACAACGGCGGCACCACCTACAACGA AAAATTCCAGGGCAGAGTGACCATCAC CGCCGACCAGCACCGATACAGCCT ACATGGAACTGAGCAGCCTGAGAAGC GAGGACACCGCCGTGTATTATTGTGCC ACCGGCTGGAACTTCGACTACTGGGG ACAGGGCACACTGGTCACCGTTAGCTC T 106 VhZu14 human PSMA Vh GAAGTTCAACTTGTTCAGAGCGGAGCC GAAGTGAAGAAACCCGGCGCTACAGT GAAGATCAGCTGCAAGGTGTCCGGCT Petition 870260065905, dated 03 / 07 / 2026, p. 86 / 1400 83 / 650 Table 10. Nucleic acid sequences encoding variable regions of mAb (continued) SEQ ID NO Target Name Fv Variable Region Nucleic Acid Sequence ACACCTTCACCGAGTACACCATTCACT GGGTGCAGCAGGCCCCTGGCAAAGGA CTGGAATGGATGGGCAACATCAACCCC AACAACGGCGGCACCACCTACGCCGA AAAATTCCAGGGCAGAGTGACCATCAC CGCGACACCAGCACCGATACAGCCT ACATGGAACTGAGCAGCCTGAGAAGC GAGGACACCGCCGTGTATTATTGTGCC ACCGCTGGAACTTCGACTACTGGGG ACAGGGCACACTGGTCACCGTTAGCTC T 107 VkZu1 Human PSMA Vk GATATTCAGATGACACAGCCCTAGC AGCCTGAGCGCCTCTGTGGGCGATAG AGTGACAATCACATGCAAGGCCAGCCA GGATGTGGGCACCGCTGTTGACTGGT ATCAGCAGAAGCCTGGCAAGGCCCCT AAGCTGCTGATCTACTGGGCCAGCACA AGACACACAGGCGTGCCAAGCAGATTT TCTGGCAGCGGCTCTGGCACCGACTT CACCCTGACCATTTCTAGCCTCCAGCC TGAGGACTTCGCCACCTACTACTGTCA GCAGTACAACAGCTACCCTCTGACCTT TGGCCAGGGCACCAAGCTGGAAATCA AA 108 VkZu2 Human PSMA Vk GATATTCAGATGACACAGAGCCCTAGC AGCCTGAGCGCCTCTGTGGGCGATAG Petition 870260065905, dated 03 / 07 / 2026, p. 87 / 1400 84 / 650 Table 10. Nucleic acid sequences encoding variable regions of mAb (continued) SEQ ID NO Target Name Fv Variable Region Nucleic Acid Sequence AGTGACAATCACATGCAGAGCCAGCCA GGATGTGGGCACCGCTGTTGACTGGT ATCAGCAGAAGCCTGGCAAGGCCCCT AAGCTGCTGATCTACTGGGCCAGCACA AGACACACAGGCGTGCCAAGCAGATTT TCTGGCAGCGGCTCTGGCACCGACTT CACCCTGACCATTTCTAGCCTCCAGCC TGAGGACTTCGCCACCTACTACTGTCA GCAGTACAACAGCTACCCTCTGACCTT TGGCCAGGGCACCAAGCTGGAAATCA AA 109 VkZu3 Human PSMA Vk GATATTCAGATGACACAGCCCTAGC AGCCTGAGCGCCTCTGTGGGCGATAG AGTGACAATCACATGCAGAGCCAGCCA GGATGTGGGCACCGCTCTGAACTGGT ATCAGCAGAAGCCTGGCAAGGCCCCT AAGCTGCTGATCTACTGGGCCAGCACA AGACACACAGGCGTGCCAAGCAGATTT TCTGGCAGCGGCTCTGGCACCGACTT CACCCTGACCATTTCTAGCCTCCAGCC TGAGGACTTCGCCACCTACTACTGTCA GCAGTACAACAGCTACCCTCTGACCTT TGGCCAGGGCACCAAGCTGGAAATCA AA 110 VkZu4 Human PSMA Vk GATATTCAGATGACACAGAGCCCTAGC AGCCTGAGCGCCTCTGTGGGCGATAG Petition 870260065905, dated 03 / 07 / 2026, p. 88 / 1400 85 / 650 Table 10. Nucleic acid sequences encoding variable regions of mAb (continued) SEQ ID NO Target Name Fv Variable Region Nucleic Acid Sequence AGTGACAATCACATGCAAGGCCAGCCA GGATGTGGGCACCGCTGTTGACTGGT ATCAGCAGAAGCCTGGCAAGGCCCCT AAGCTGCTGATCTACTGGGCCAGCACA AGACACAGCGGCGTGCCAAGCAGATT TTCTGGCAGCGGCTCTGGCACCGACTT CACCCTGACCATTTCTAGCCTCCAGCC TGAGGACTTCGCCACCTACTACTGTCA GCAGTACAACAGCTACCCTCTGACCTT TGGCCAGGGCACCAAGCTGGAAATCA AA 111 VkZu5 Human PSMA Vk GATATTCAGATGACACAGAGCCCTAGC AGCCTGAGCGCCTCTGTGGGCGATAG AGTGACAATCACATGCAGAGCCAGCCA GGATGTGGGCACCGCTGTTGACTGGT ATCAGCAGAAGCCTGGCAAGGCCCT AAGCTGCTGATCTACTGGGCCAGCACA AGACACAGCGGCGTGCCAAGCAGATT TTCTGGCAGCGGCTCTGGCACCGACTT CACCCTGACCATTTCTAGCCTCCAGCC TGAGGACTTCGCCACCTACTACTGTCA GCAGTACAACAGCTACCCTCTGACCTT TGGCCAGGGCACCAAGCTGGAAATCA AA 112 VkZu6 Human PSMA Vk GATATTCAGATGACACAGAGCCCTAGC AGCCTGAGCGCCTCTGTGGGCGATAG Petition 870260065905, dated 03 / 07 / 2026, p. 89 / 1400 86 / 650 Table 10. Nucleic acid sequences encoding variable regions of mAb (continued) SEQ ID NO Target Name Fv Variable Region Nucleic Acid Sequence AGTGACAATCACATGCAGAGCCAGCCA GGATGTGGGCACCGCTCTGAACTGGT ATCAGCAGAAGCCTGGCAAGGCCCCT AAGCTGCTGATCTACTGGGCCAGCACA AGACACAGCGGCGTGCCAAGCAGATT TTCTGGCAGCGGCTCTGGCACCGACTT CACCCTGACCATTTCTAGCCTCCAGCC TGAGGACTTCGCCACCTACTACTGTCA GCAGTACAACAGCTACCCTCTGACCTT TGGCCAGGGCACCAAGCTGGAAATCA AA 113 deJ591 Vh human PSMA Vh GAAGTTCAACTTGTGCAGAGCGGCCCT GAAGTGAAGAAACCTGGCGCTACCGT GAAGATCAGCTGCAAGACCAGCGGCT ACACCTTCACCGAGTACACCATCCACT GGGTTAAGCAGGCCCCTGGCAAAGGC CTGGAATGGATCGGCAACATCAACCCC AACAACGGCGGCACCACCTACAACCA GAAGTTCGAGGATAAGGCCACACTGAC CGTGGACAAGAGCACCGACACAGCCT ACATGGAACTGAGCAGCCTGAGAAGC GAGGACACCGCCGTGTATTATTGTGCC GCCGGATGGAACTTCGACTACTGGGG ACAGGGCACCCTGCTGACAGTCTCTTC T Petition 870260065905, dated 03 / 07 / 2026, p. 90 / 1400 87 / 650 Table 10. Nucleic acid sequences encoding variable regions of mAb (continued) SEQ ID NO Target Name Fv Variable Region 114 Nucleic Acid Sequence ofJ591 Vk Human PSMA GACACACAGGCATCCCTAGCAGATTTT CTGGCAGCGGCTCTGGCACCGACTTC ACCCTGACCATTTCTAGCCTCCAGCCT GAGGACTTCGCCGACTACTACTGCCAG CAGTACAACAGCTACCCTCTGACATTC GGCCCTGGCACCAAGGTGGACATCAA A 139 J591 Vh human PSMA Vh GAAGTTCAACTTCAGCAGTCTGGCCCC GAGCTGAAGAAACCTGGAACAAGCGT GCGGATCAGCTGCAAGACCAGCGGCT ACACCTTCACCGAGTACACCATCCACT GGGTCAAGCAGAGCCACGGCAAGTCT CTGGAATGGATCGGCAACATCAACCCC AACAACGGCGGCACCACCTACAACCA GAAGTTCGAGGATAAGGCCACACTGAC CGTGGACAAGAGCAGCAGCACAGCCT ACATGGAACTGAGAAGCCTGACCAGC GAGGACAGCGCCGTGTATTATTGTGCC GCCGGATGGAACTTCGACTACTGGGG ACAGGGCACAACCCTGACCGTTAGCTC Petition 870260065905, dated 03 / 07 / 2026, p. 91 / 1400 88 / 650 Table 10. Nucleic acid sequences encoding variable regions of mAb (continued) SEQ ID NO Target Name Fv Variable Region Nucleic Acid Sequence T 140 J591 Vk Human PSMA Vk GATATTGTGATGACCCAGAGCCACAAG TTCATGAGCACCAGCGTGGGCGACAG AGTGTCCATCATCTGCAAGGCCTCTCA GGATGTGGGCACCGCCGTTGACTGGT ATCAGCAGAAACCTGGACAGAGCCCC AAGCTGCTGATCTACTGGGCCTCTACA AGACACACAGGCGTGCCCGATAGATTC ACAGGCTCTGGCAGCGGCACCGACTT TACCCTGACCATCACAAACGTGCAGAG CGAGGACCTGGCCGACTACTTCTGCC AGCAGTACAACAGCTACCCTCTGACCT TTGGAGCCGGCACCATGCTGGATCTTA AA Petition 870260065905, dated 03 / 07 / 2026, p. 92 / 1400 89 / 650 Table 11. Amino acid sequences of full-length mAb Ig chains. SEQ ID NO Target Name Ig Chain Full-length mAb Ig chain amino acid sequence 47 zuJ591- H1 Human PSMA Human IgG1 EVQLVQSGAEVKKPGATVKISCK VS GYTFTEYTIH WVQQAPGKGL EWMGNINPNNGGTTYNQKFED RVTITADTSTDTAYMELSSLRSE DTAVYYCATGWNFDYWGQGTL VTVSSASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYICNV NHKPSNTKVDKKVEPKSCDKTH TCPPCPAPELLGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVS NKAL PAPIEKTIS KAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSF FLYSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK Petition 870260065905, dated 03 / 07 / 2026, page 93 / 1400 90 / 650 Table 11. Amino acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig chain amino acid sequence 48 zuJ591- H2 Human PSMA Human IgG1 EVQLVQSGAEVKKPGATVKISCK TS GYTFTEYTIH WVQQAPGKGL EWMGNINPNNGGTTYNQKFED RVTITADTSTDTAYMELSSLRSE DTAVYYCATGWNFDYWGQGTL VTVSSASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYICNV NHKPSNTKVDKKVEPKSCDKTH TCPPCPAPELLGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK 49 zuJ591- H3 Human PSMA Human IgG1 EVQLVQSGAEVKKPGATVKISCK VS GYTFTEYTIH WVQQAPGKGL EWIGNINPNNGGTTTYNQKFEDR Petition 870260065905, dated 03 / 07 / 2026, page 94 / 1400 91 / 650 Table 11. Amino acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence VTITADTSTDTAYMELSSLRSED TAVYYCATGWNFDYWGQGTLV TVSSASTKGPSVFPLAPSSKSTS GGTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTQTYICNVN HKPSNTKVDKKVEPKSCDKTHT CPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDP EVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLN GKEYKCKVS NKALPAPIEKTISKA KGQPREPQVYTLPPSRDELTKN QVS LTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFL YSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK 50 zuJ591- H4 Human PSMA Human IgG1 EVQLVQSGAEVKKPGATVKISCK VS GYTFTEYTIH WVQQAPGKGL EWMGNINPNNGGTTYNQKFED RVTITVDTSTTDTAYMELSSLRSE DTAVYYCATGWNFDYWGQGTL VTVSSASTKGPSVFPLAPSSKST Petition 870260065905, dated 03 / 07 / 2026, page 95 / 1400 92 / 650 Table 11. Amino acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig chain amino acid sequence SGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYICNV NHKPSNTKVDKKVEPKSCDKTH TCPPCPAPELLGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK 51 zuJ591- H5 Human PSMA Human IgG1 EVQLVQSGAEVKKPGATVKISCK VSGYTFTEYTIHWVQQAPGKGL EWMGNINPNNGGTTYNQKFED RVTITADKSTDTAYMELSSLRSE DTAVYYCATGWNFDYWGQGTL VTVSSASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYICNV Petition 870260065905, dated 03 / 07 / 2026, page 96 / 1400 93 / 650 Table 11. Amino acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence NHKPSNTKVDKKVEPKSCDKTH TCPPCPAPELLGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK 52 zuJ591- H6 Human PSMA Human IgG1 EVQLVQSGAEVKKPGATVKISCK VSGYTFTEYTIHWVQQAPGKGL EWMGNINPNNGGTTYNQKFED RVTITADTSTSTAYMELSSLRSE DTAVYYCATGWNFDYWGQGTL VTVSSASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYICNV NHKPSNTKVDKKVEPKSCDKTH TCPPCPAPELLGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSHED Petition 870260065905, dated 03 / 07 / 2026, page 97 / 1400 94 / 650 Table 11. Amino acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig chain amino acid sequence PEVKFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK 53 zuJ591- H7 Human PSMA IgG1 Human EVQLVQSGAEVKKPGATVKISCK VS GYTFTEYTIH WVQQAPGKGL EWMGNINPNNGGTTYNQKFED RVTITADTSTDTAYMELSSLRSE DTAVYYCAAGWNFDYWGQGTL VTVSSASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYICNV NHKPSNTKVDKKVEPKSCDKTH TCPPCPAPELLGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISK Petition 870260065905, dated 03 / 07 / 2026, page 98 / 1400 95 / 650 Table 11. Amino acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence AKGQPREPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK 54 zuJ591- H8 Human PSMA Human IgG1 EVQLVQSGAEVKKPGATVKISCK VSGYTFTEYTIHWVQQAPGKGL EWIGNINPNNGGTTYNQKFEDR VTITADTSTDTAYMELSSLRSED TAVYYCAAGWNFDYWGQGTLV TVSSASTKGPSVFPLAPSSKSTS GGTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTQTYICNVN HKPSNTKVDKKVEPKSCDKTHT CPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDP EVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLN GKEYKCKVS NKALPAPIEKTISKA KGQPREPQVYTLPPSRDELTKN QVS LTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFL Petition 870260065905, dated 03 / 07 / 2026, page 99 / 1400 96 / 650 Table 11. Amino acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence YSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK 55 zuJ591- H9 Human PSMA Human IgG1 EVQLVQSGAEVKKPGATVKISCK TS GYTFTEYTIH WVQQAPGKGL EWIGNINPNNGGTTYNQKFEDR VTITADKSTSTAYMELSSLRSED TAVYYCAAGWNFDYWGQGTLV TVSSASTKGPSVFPLAPSSKSTS GGTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTQTYICNVN HKPSNTKVDKKVEPKSCDKTHT CPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDP EVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLN GKEYKCKVS NKALPAPIEKTISKA KGQPREPQVYTLPPSRDELTKN QVS LTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFL YSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK Petition 870260065905, dated 03 / 07 / 2026, pages 100 / 1400 97 / 650 Table 11. Amino acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig chain amino acid sequence 56 zuJ591- H10 Human PSMA Human IgG1 EVQLVQSGAEVKKPGATVKISCK TS GYTFTEYTIH WVQQAPGKGL EWIGNINPNNGGTTYNQKFEDR VTITADTSTDTAYMELSSLRSED TAVYYCAAGWNFDYWGQGTLV TVSSASTKGPSVFPLAPSSKSTS GGTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTQTYICNVN HKPSNTKVDKKVEPKSCDKTHT CPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDP EVKFNWYVDGVEVHNAKTKPRE 57 zuJ591- H11 PSMA human IgG1 human EVQLVQSGAEVKKPGATVKISCK VS GYTFTEYTIH WVQQAPGKGL EWMGNINPNNGGTTYNQKFEG Petition 870260065905, dated 03 / 07 / 2026, page 101 / 1400 98 / 650 Table 11. Amino acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence RVTITADTSTDTAYMELSSLRSE DTAVYYCATGWNFDYWGQGTL VTVSSASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYICNV NHKPSNTKVDKKVEPKSCDKTH TCPPCPAPELLGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK 58 zuJ591- H12 Human PSMA Human IgG1 EVQLVQSGAEVKKPGATVKISCK VS GYTFTEYTIH WVQQAPGKGL EWMGNINPNNGGTTYNQKFQG RVTITADTSTTDTAYMELSSLRSE DTAVYYCATGWNFDYWGQGTL VTVSSASTKGPSVFPLAPSSKST Petition 870260065905, dated 03 / 07 / 2026, page 102 / 1400 99 / 650 Table 11. Amino acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig chain amino acid sequence SGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYICNV NHKPSNTKVDKKVEPKSCDKTH TCPPCPAPELLGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK 59 zuJ591- H13 Human PSMA IgG1 human EVQLVQSGAEVKKPGATVKISCK VSGYTFTEYTIHWVQQAPGKGL EWMGNINPNNGGTTYNEKFQG RVTITADTSTTDTAYMELSSLRSE DTAVYYCATGWNFDYWGQGTL VTVSSASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYICNV Petition 870260065905, dated 03 / 07 / 2026, page 103 / 1400 100 / 650 Table 11. Amino acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence NHKPSNTKVDKKVEPKSCDKTH TCPPCPAPELLGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK 60 zuJ591- H14 Human PSMA Human IgG1 EVQLVQSGAEVKKPGATVKISCK VSGYTFTEYTIHWVQQAPGKGL EWMGNINPNNGGTTYAEKFQG RVTITADTSTTDTAYMELSSLRSE DTAVYYCATGWNFDYWGQGTL VTVSSASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYICNV NHKPSNTKVDKKVEPKSCDKTH TCPPCPAPELLGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSHED Petition 870260065905, dated 03 / 07 / 2026, page 104 / 1400 101 / 650 Table 11. Amino acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence PEVKFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK 61 zuJ591- L1 PSMA human igK human DIQMTQSPSSLSASVGDRVTITC KASQDVGTAVDWYQQKPGKAP KLLIYWASTRHTGVPSRFSGSG SGTDFTLTISSLQPEDFATYYCQ QYNSYPLTFGQGTKLEIKRTVAA PSM KLLIYWASTRHTGVPSRFSGSG SGTDFTLTISSLQPEDFATYYCQ QYNSYPLTFGQGTKLEIKRTVAA Petition 870260065905, dated 03 / 07 / 2026, page 105 / 1400 102 / 650 Table 11. Amino acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain PSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSG NSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC 63 zuJ591- L3 human PSMA human igK DIQMTQSPSSLSASVGDRVTITC RASQDVGTALN WYQQKPGKAP KLLIYWASTRHTGVPSRFSGSG SGTDFTLTISSLQPEDFATYYCQ QYNSYPLTFGQGTKLEIKRTVAA PSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSG NSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC 64 zuJ591- L4 Human PSMA Human IgK DIQMTQSPSSLSASVGDRVTITC KASQDVGTAVDWYQQKPGKAP KLLIYWASTRHSGVPSRFSGSG SGTDFTLTISSLQPEDFATYYCQ QYNSYPLTFGQGTKLEIKRTVAA PSVFIFPPSDEQLKSGTASVVCL Petition 870260065905, dated 03 / 07 / 2026, page 106 / 1400 103 / 650 Table 11. Amino acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence LNNFYPREAKVQWKVDNALQSG NSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC 65 zuJ591- L5 Human PSMA Human IgK DIQMTQSPSSLSASVGDRVTITC RASQDVGTAVDWYQQKPGKAP KLLIYWASTRHSGVPSRFSGSG SGTDFTLTISSLQPEDFATYYCQ QYNSYPLTFGQGTKLEIKRTVAA PSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSG NSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC 66 zuJ591- L6 Human PSMA Human IgK DIQMTQSPSSLSASVGDRVTITC RASQDVGTALN WYQQKPGKAP KLLIYWASTRHSGVPSRFSGSG SGTDFTLTISSLQPEDFATYYCQ QYNSYPLTFGQGTKLEIKRTVAA PSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSG Petition 870260065905, dated 03 / 07 / 2026, page 107 / 1400 104 / 650 Table 11. Amino acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig chain amino acid sequence NSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC 115 deJ591- HC Human PSMA Human IgG1 EVQLVQSGPEVKKPGATVKISCK TSGYTFTEYTIHWVKQAPGKGLE WIGNINPNNGGTTYNQKFEDKA TLTVDKSTDTAYMELSSLRSEDT AVYYCAAGWNFDYWGQGTLLT VSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPE PVTVSWN SGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSSLGTQTYICNVNHK PSNTKVDKKVEPKSCDKTHTCP PCPAPELLGGPSVFLFPPKPKDT LMIS RTP EVTCVVVDVS HEDPEV KFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSRDELTKNQV SLTCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYS KLTVDKSRWQQGNVFSCSVMH Petition 870260065905, dated 03 / 07 / 2026, page 108 / 1400 105 / 650 Table 11. Amino acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain EALHNHYTQKSLSLSPGK 116 deJ591- LC human PSMA human igK DIQMTQSPSSLSTSVGDRVTLTC KASQDVGTAVDWYQQKPGPSP KLLIYWASTRHTGIPSRFSGSGS GTDFTLTISSLQPEDFADYYCQQ YNSYPLTFGPGTKVDIKRTVAAP SVFIFPPSDEQLKSGTASVVCLL NNFYPREAKVQWKVDNALQSG NSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC The bold text indicates the amino acid positions corresponding to the CDR sequences according to the Kabat system; the underlined text indicates amino acid positions corresponding to the CDR sequences according to the IMGT system. The text that is not bold or underlined corresponds to the structural regions. Petition 870260065905, dated 03 / 07 / 2026, p. 109 / 1400 106 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains. SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain 117 zuJ591- H1 Human PSMA Human IgG1 GAAGTTCAACTTGTTCAGAGCG GAGCCGAAGTGAAGAAACCCG GCGCTACAGTGAAGATCAGCT GCAAGGTGTCCGGCTACACCT TCACCGAGTACACCATTCACTG GGTGCAGCAGGCCCCTGGCAA AGGACTGGAATGGATGGGCAA CATCAACCCCAACAACGGCGG CACCACCTACAACCAGAAATTC GAGGACAGAGTGACCATCACC GCCGACACCAGCACCGATACA GCCTACATGGAACTGAGCAGC CTGAGAAGCGAGGACACCGCC GTGTATTATTGTGCCACCGGCT GGAACTTCGACTACTGGGGAC AGGGCACACTGGTCACCGTTA GCTCTGCATCCACCAAGGGCC CATCGGTCTTCCCCCTGGCAC CCTCCTCCAAGAGCACCTCTG GGGGCACAGCGGCCCTGGGC TGCCTGGTCAAGGACTACTTC CCCGAACCGGTGACGGTGTCG TGGAACTCAGGCGCCCTGACC AGCGGCGTGCACACCTTCCCG Petition 870260065905, dated 03 / 07 / 2026, p. 110 / 1400 107 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Amino acid sequence of full-length mAb Ig chain GCTGTCCTACAGTCCTCAGGA CTCTACTCCCTCAGCAGCGTG GTGACCGTGCCCTCCAGCAGC TTGGGCACCCAGACCTACATCT GCAACGTGAATCACAAGCCCA GCAACACCAAGGTGGACAAGA AAGTTGAGCCCAAATCTTGTGA CAAAACTCACACATGCCCACC GTGCCCAGCACCTGAACTCCT GGGGGGACCGTCAGTCTTCCT CTTCCCCCCAAAACCCAAGGA CACCCTCATGATCTCCCGGAC CCCTGAGGTCACATGCGTGGT GGTGGACGTGAGCCACGAAGA CCCTGAGGTCAAGTTCAACTG GTACGTGGACGGCGTGGAGGT GCATAATGCCAAGACAAAGCC GCGGGAGGAGCAGTACAACAG CACGTACCGTGTGGTCACGGT CCTCACCGTCCTGCACCAGGGA CTGGCTGAATGGCAAGGAGTA CAAGTGCAAGGTCTCCAACAAA GCCCTCCCAGCCCCCATCGAG AAAACCATCTCCAAAGCCAAAG Petition 870260065905, dated 03 / 07 / 2026, p. 111 / 1400 108 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence GGCAGCCCCGAGAACCACAGG TGTACACCCTGCCCCCATCCC GGGATGAGCTGACCAAGAACC AGGTCAGCCTGACCTGCCTGG TCAAAGGCTTCTATCCCAGCGA CATCGCCGTGGAGTGGGAGAG CAATGGGCAGCCGGAGAACAA CTACAAGACCACGCCTCCCGT GCTGGACTCCGACGGCTCCTT CTTCTTATATTCAAAGCTCACC GTGGACAAGAGCAGGTGGCAG CAGGGGAACGTCTTCTCATGC TCCGTGATGCATGAGGCTCTG CACAACCACTACACGCAGAAG AGCCTCTCCCTGTCTCCCCGGG AAATGA 118 zuJ591- H2 PSMA human IgG1 human GAAGTTCAACTTGTTCAGAGCG GAGCCGAAGTGAAGAAACCCG GCGCTACAGTGAAGATCAGCT GCAAGACCTCCGGCTACACCT TCACCGAGTACACCATTCACTG GGTGCAGCAGGCCCCTGGCAA AGGACTGGAATGGATGGGCAA CATCAACCCCAACAACGGCGG Petition 870260065905, dated 03 / 07 / 2026, p. 112 / 1400 109 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain CACCACCTACAACCAGAAATTC GAGGACAGAGTGACCATCACC GCCGACACCAGCACCGATACA GCCTACATGGAACTGAGCAGC CTGAGAAGCGAGGACACCGCC GTGTATTATTGTGCCACCGGCT GGAACTTCGACTACTGGGGAC AGGGCACACTGGTCACCGTTA GCTCTGCATCCACCAAGGGCC CATCGGTCTTCCCCCTGGCAC CCTCCTCCAAGAGCACCTCTG GGGGCACAGCGGCCCTGGGC TGCCTGGTCAAGGACTACTTCC CCGAACCGGTGACGGTGTCGT GGAACTCAGGCGCCCTGACCA GCGGCGTGCACACCTTCCCGG CTGTCCTACAGTCCTCAGGACT CTACTCCCTCAGCAGCGTGGT GACCGTGCCCTCCAGCAGCTT GGGCACCCAGACCTACATCTG CAACGTGAATCACAAGCCCAG CAACACCAAGGTGGACAAGAA AGTTGAGCCCAAATCTTGTGAC AAAACTCACACATGCCCACCGT Petition 870260065905, dated 03 / 07 / 2026, p. 113 / 1400 110 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Amino acid sequence of full-length mAb Ig chain GCCCAGCACCTGAACTCCTGG GGGGACCGTCAGTCTTCCTCT TCCCCCCAAAACCCAAGGACA CTGAGGTCAAGTTCAACTGGTA CGTGGACGGCGTGGAGGTGCA TAATGCCAAGACAAAGCCG GGAGGAGCAGTACAACAGCCAC GTACCGTGTGGTCAGCGTCCT CACCGTCCTGCACCAGGACTG GCTGAATGGCAAGGAGTCAAA GTGCAAGGTCTCCAACCAACCAAGCAACCATCC AACCATCTCCAAAGCCAAAGG GCAGCCCCGAGAACCACAGGT GTACACCCTGCCCCCATCCCG GGATGAGCTGACCAAGAACCA GGTCAGCCTGACCTGCCTGGT CAAAGGCTTCTATCCCAGCGA CATCGCCGTGGAGTGGGAGAG CAATGGGCAGCCGGAGAACAA CTACACCAGTCCCAG Petition 870260065905, of 03 / 07 / 2026, p. 114 / 1400 111 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain GCTGGACTCCGACGGCTCCTT CTTCTTATATTCAAAGCTCACC GTGGACAAGAGCAGGTGGCAG CAGGGGAACGTCTTCTCATGC TCCGTGATGCATGAGGCTCTG CACAACCACTACACGCAGAAG AGCCTCTCCCTGTCTCCCGGG AAATGA 119 zuJ591- H3 Human PSMA Human IgG1 GAAGTTCAACTTGTTCAGAGCG GAGCCGAAGTGAAGAAACCCG GCGCTACAGTGAAGATCAGCT GCAAGGTGTCCGGCTACACCT TCACCGAGTACACCATTCACTG GGTGCAGCAGGCCCCTGGCAA AGGACTGGAATGGATCGGCAA CATCAACCCCAACAACGGCGG CACCACCTACAACCAGAAATTC GAGGACAGAGTGACCATCACC GCCGACACCAGCACCGATACA GCCTACATGGAACTGAGCAGC CTGAGAAGCGAGGACACCGCC GTGTATTATTGTGCCACCGGCT GGAACTTCGACTACTGGGGAC AGGGCACACTGGTCACCGTTA Petition 870260065905, dated 03 / 07 / 2026, p. 115 / 1400 112 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain GCTCTGCATCCACCAAGGGCC CATCGGTCTTCCCCCTGGCAC CCTCCTCCAAGAGCACCTCTG GGGGCACAGCGGCCCTGGGC TGCCTGGTCAAGGACTACTTCC CCGAACCGGTGACGGTGTCGT GGAACTCAGGCGCCCTGACCA GCGGCGTGCACACCTTCCCGG CTGTCCTACAGTCCTCAGGACT CTACTCCCTCAGCAGCGTGGT GACCGTGCCCTCCAGCAGCTT GGGCACCCAGACCTACATCTG CAACGTGAATCACAAGCCCAG CAACACCAAGGTGGACAAGAA AGTTGAGCCCAAATCTTGTGAC AAAACTCACACATGCCCACCGT GCCCAGCACCTGAACTCCTGG GGGGACCGTCAGTCTTCCTCT TCCCCCCAAAACCCAAGGACA CCCTCATGATCTCCCGGACCC CTGAGGTCACATGCGTGGTGG TGGACGTGAGCCACGAAGACC CTGAGGTCAAGTTCAACTGGTA CGTGGACGGCGTGGAGGTGCA Petition 870260065905, dated 03 / 07 / 2026, p. 116 / 1400 113 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain TAATGCCAAGACAAAGCCGCG GGAGGAGCAGTACAACAGCAC GTACCGTGTGGTCAGCGTCCT CACCGTCCTGCACCAGGACTG GCTGAATGGCAAGGAGTACAA GTGCAAGGTCTCCAACAAAGC CCTCCCAGCCCCCATCGAGAA AACCATCTCCAAAGCCAAAGG GCAGCCCCGAGAACCACAGGT GTACACCCTGCCCCCATCCCG GGATGAGCTGACCAAGAACCA GGTCAGCCTGACCTGCCTGGT CAAAGGCTTCTATCCCAGCGA CATCGCCGTGGAGTGGGAGAG CAATGGGCAGCCGGAGAACAA CTACAAGACCACCGCCTCCCGT GCTGGACTCCGACGGCTCCTT CTTCTTATATTCAAAGCTCACC GTGGACAAGAGCAGGTGGCAG CAGGGGAACGTCTTCTCATGC TCCGTGATGCATGAGGCTCTG CACAACCACTACACGCAGAAG AGCCTCTCCCTGTCTCCCGGG AAATGA Petition 870260065905, dated 03 / 07 / 2026, p. 117 / 1400 114 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain 120 zuJ591- H4 Human PSMA Human IgG1 GAAGTTCAACTTGTTCAGAGCG GAGCCGAAGTGAAGAAACCCG GCGCTACAGTGAAGATCAGCT GCAAGGTGTCCGGCTACACCT TCACCGAGTACACCATTCACTG GGTGCAGCAGGCCCCTGGCAA AGGACTGGAATGGATGGGCAA CATCAACCCCAACAACGGCGG CACCACCTACAACCAGAAATTC GAGGACAGAGTGACCATCACC GTGGACACCAGCACCGATACA GCCTACATGGAACTGAGCAGC CTGAGAAGCGAGGACACCGCC GTGTATTATTGTGCCACCGGCT GGAACTTCGACTACTGGGGAC AGGGCACACTGGTCACCGTTA GCTCTGCATCCACCAAGGGCC CATCGGTCTTCCCCCTGGCAC CCTCCTCCAAGAGCACCTCTG GGGGCACAGCGGCCCTGGGC TGCCTGGTCAAGGACTACTTCC CCGAACCGGTGACGGTGTCGT GGAACTCAGGCGCCCTGACCA GCGGCGTGCACACCTTCCCGG Petition 870260065905, dated 03 / 07 / 2026, p. 118 / 1400 115 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain CTGTCCTACAGTCCTCAGGACT CTACTCCCTCAGCAGCGTGGT GACCGTGCCCTCCAGCAGCTT GGGCACCCAGACCTACATCTG CAACGTGAATCACAAGCCCAG CAACACCAAGGTGGACAAGAA AGTTGAGCCCAAATCTTGTGAC AAAACTCACACATGCCCACCGT GCCCAGCACCTGAACTCCTGG GGGGACCGTCAGTCTTCCTCT TCCCCCCAAAACCCAAGGACA CCCTCATGATCTCCCGGACCC CTGAGGTCACATGCGTGGTGG TGGACGTGAGCCACGAAGACC CTGAGGTCAAGTTCAACTGGTA CGTGGACGGCGTGGAGGTGCA TAATGCCAAGACAAAGCCGCG GGAGGAGCAGTACAACAGCAC GTACCGTGTGGTCAGCGTCCT CACCGTCCTGCACCAGGACTG GCTGAATGGCAAGGAGTACAA GTGCAAGGTCTCCAACAAAGC CCTCCCAGCCCCCATCGAGAA AACCATCTCCAAAGCCAAAGG Petition 870260065905, dated 03 / 07 / 2026, p. 119 / 1400 116 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence GCAGCCCCGAGAACCACAGGT GTACACCCTGCCCCCATCCCG GGATGAGCTGACCAAGAACCA GGTCAGCCTGACCTGCCTGGT CAAAGGCTTCTATCCCAGCGA CATCGCCGTGGAGTGGGAGAG CAATGGGCAGCCGGAGAACAA CTACAAGACCACGCCTCCCGT GCTGGACTCCGACGGCTCCTT CTTCTTATATTCAAAGCTCACC GTGGACAAGAGCAGGTGGCAG CAGGGGAACGTCTTCTCATGC TCCGTGATGCATGAGGCTCTG CACAACCACTACACGCAGAAG AGCCTCTCCCTGTCTCCCCGGG AAATGA 121 zuJ591- H5 PSMA human IgG1 human GAAGTTCAACTTGTTCAGAGCG GAGCCGAAGTGAAGAAACCCG GCGCTACAGTGAAGATCAGCT GCAAGGTGTCCGGCTACACCT TCACCGAGTACACCATTCACTG GGTGCAGCAGGCCCCTGGCAA AGGACTGGAATGGATGGGCAA CATCAACCCCAACAACGGCGG Petition 870260065905, dated 03 / 07 / 2026, pp. 120 / 1400 117 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence CACCACCTACAACCAGAAATTC GAGGACAGAGTGACCATCACC GCCGACAAGAGCACCCGATACA GCCTACATGGAACTGAGCAGC CTGAGAAGCGAGGACACCGCC GTGTATTATTGTGCCACCGGCT GGAACTTCGACTACTGGGGAC AGGGCACACTGGTCACCGTTA GCTCTGCATCCACCAAGGGCC CATCGGTCTTCCCCCTGGCAC CCTCCTCCAAGAGCACCTCTG GGGGCACAGCGGCCCTGGGC TGCCTGGTCAAGGACTACTTCC CCGAACCGGTGACGGTGTCGT GGAACTCAGGCGCCCTGACCA GCGGCGTGCACACCTTCCCGG CTGTCCTACAGTCCTCAGGACT CTACTCCCTCAGCAGCGTGGT GACCGTGCCCTCCAGCAGCTT GGGCACCCAGACCTACATCTG CAACGTGAATCACAAGCCCAG CAACACCAAGGTGGACAAGAA AGTTGAGCCCAAATCTTGTGAC AAAACTCACACATGCCCACCGT Petition 870260065905, dated 03 / 07 / 2026, p. 121 / 1400 118 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Amino acid sequence of full-length mAb Ig chain GCCCAGCACCTGAACTCCTGG GGGGACCGTCAGTCTTCCTCT TCCCCCCAAAACCCAAGGACA CTGAGGTCAAGTTCAACTGGTA CGTGGACGGCGTGGAGGTGCA TAATGCCAAGACAAAGCCG GGAGGAGCAGTACAACAGCCAC GTACCGTGTGGTCAGCGTCCT CACCGTCCTGCACCAGGACTG GCTGAATGGCAAGGAGTCAAA GTGCAAGGTCTCCAACCAACCAAGCAACCATCC AACCATCTCCAAAGCCAAAGG GCAGCCCCGAGAACCACAGGT GTACACCCTGCCCCCATCCCG GGATGAGCTGACCAAGAACCA GGTCAGCCTGACCTGCCTGGT CAAAGGCTTCTATCCCAGCGA CATCGCCGTGGAGTGGGAGAG CAATGGGCAGCCGGAGAACAA CTACACCAGTCCCAG Petition 870260065905, of 03 / 07 / 2026, p. 122 / 1400 119 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence GCTGGACTCCGACGGCTCCTT CTTCTTATATTCAAAGCTCACC GTGGACAAGAGCAGGTGGCAG CAGGGGAACGTCTTCTCATGC TCCGTGATGCATGAGGCTCTG CACAACCACTACACGCAGAAG AGCCTCTCCCTGTCTCCCCGGG AAATGA 122 zuJ591- H6 Human PSMA Human IgG1 GAAGTTCAACTTGTTCAGAGCG GAGCCGAAGTGAAGAAACCCG GCGCTACAGTGAAGATCAGCT GCAAGGTGTCCGGCTACACCT TCACCGAGTACACCATTCACTG GGTGCAGCAGGCCCCTGGCAA AGGACTGGAATGGATGGGCAA CATCAACCCCAACAACGGCGG CACCACCTACAACCAGAAATTC GAGGACAGAGTGACCATCACC GCCGACACCAGCACCAGCACA GCCTACATGGAACTGAGCAGC CTGAGAAGCGAGGACACCGCC GTGTATTATTGTGCCACCGGCT GGAACTTCGACTACTGGGGAC AGGGCACACTGGTCACCGTTA Petition 870260065905, dated 03 / 07 / 2026, p. 123 / 1400 120 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain GCTCTGCATCCACCAAGGGCC CATCGGTCTTCCCCCTGGCAC CCTCCTCCAAGAGCACCTCTG GGGGCACAGCGGCCCTGGGC TGCCTGGTCAAGGACTACTTCC CCGAACCGGTGACGGTGTCGT GGAACTCAGGCGCCCTGACCA GCGGCGTGCACACCTTCCCGG CTGTCCTACAGTCCTCAGGACT CTACTCCCTCAGCAGCGTGGT GACCGTGCCCTCCAGCAGCTT GGGCACCCAGACCTACATCTG CAACGTGAATCACAAGCCCAG CAACACCAAGGTGGACAAGAA AGTTGAGCCCAAATCTTGTGAC AAAACTCACACATGCCCACCGT GCCCAGCACCTGAACTCCTGG GGGGACCGTCAGTCTTCCTCT TCCCCCCAAAACCCAAGGACA CCCTCATGATCTCCCGGACCC CTGAGGTCACATGCGTGGTGG TGGACGTGAGCCACGAAGACC CTGAGGTCAAGTTCAACTGGTA CGTGGACGGCGTGGAGGTGCA Petition 870260065905, dated 03 / 07 / 2026, p. 124 / 1400 121 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain TAATGCCAAGACAAAGCCGCG GGAGGAGCAGTACAACAGCAC GTACCGTGTGGTCAGCGTCCT CACCGTCCTGCACCAGGACTG GCTGAATGGCAAGGAGTACAA GTGCAAGGTCTCCAACAAAGC CCTCCCAGCCCCCATCGAGAA AACCATCTCCAAAGCCAAAGG GCAGCCCCGAGAACCACAGGT GTACACCCTGCCCCCATCCCG GGATGAGCTGACCAAGAACCA GGTCAGCCTGACCTGCCTGGT CAAAGGCTTCTATCCCAGCGA CATCGCCGTGGAGTGGGAGAG CAATGGGCAGCCGGAGAACAA CTACAAGACCACCGCCTCCCGT GCTGGACTCCGACGGCTCCTT CTTCTTATATTCAAAGCTCACC GTGGACAAGAGCAGGTGGCAG CAGGGGAACGTCTTCTCATGC TCCGTGATGCATGAGGCTCTG CACAACCACTACACGCAGAAG AGCCTCTCCCTGTCTCCCGGG AAATGA Petition 870260065905, dated 03 / 07 / 2026, p. 125 / 1400 122 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain 123 zuJ591- H7 Human PSMA Human IgG1 GAAGTTCAACTTGTTCAGAGCG GAGCCGAAGTGAAGAAACCCG GCGCTACAGTGAAGATCAGCT GCAAGGTGTCCGGCTACACCT TCACCGAGTACACCATTCACTG GGTGCAGCAGGCCCCTGGCAA AGGACTGGAATGGATGGGCAA CATCAACCCCAACAACGGCGG CACCACCTACAACCAGAAATTC GAGGACAGAGTGACCATCACC GCCGACACCAGCACCGATACA GCCTACATGGAACTGAGCAGC CTGAGAAGCGAGGACACCGCC GTGTATTATTGTGCCGCCGGCT GGAACTTCGACTACTGGGGAC AGGGCACACTGGTCACCGTTA GCTCTGCATCCACCAAGGGCC CATCGGTCTTCCCCCTGGCAC CCTCCTCCAAGAGCACCTCTG GGGGCACAGCGGCCCTGGGC TGCCTGGTCAAGGACTACTTCC CCGAACCGGTGACGGTGTCGT GGAACTCAGGCGCCCTGACCA GCGGCGTGCACACCTTCCCGG Petition 870260065905, dated 03 / 07 / 2026, pp. 126 / 1400 123 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain CTGTCCTACAGTCCTCAGGACT CTACTCCCTCAGCAGCGTGGT GACCGTGCCCTCCAGCAGCTT GGGCACCCAGACCTACATCTG CAACGTGAATCACAAGCCCAG CAACACCAAGGTGGACAAGAA AGTTGAGCCCAAATCTTGTGAC AAAACTCACACATGCCCACCGT GCCCAGCACCTGAACTCCTGG GGGGACCGTCAGTCTTCCTCT TCCCCCCAAAACCCAAGGACA CCCTCATGATCTCCCGGACCC CTGAGGTCACATGCGTGGTGG TGGACGTGAGCCACGAAGACC CTGAGGTCAAGTTCAACTGGTA CGTGGACGGCGTGGAGGTGCA TAATGCCAAGACAAAGCCGCG GGAGGAGCAGTACAACAGCAC GTACCGTGTGGTCAGCGTCCT CACCGTCCTGCACCAGGACTG GCTGAATGGCAAGGAGTACAA GTGCAAGGTCTCCAACAAAGC CCTCCCAGCCCCCATCGAGAA AACCATCTCCAAAGCCAAAGG Petition 870260065905, dated 03 / 07 / 2026, p. 127 / 1400 124 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence GCAGCCCCGAGAACCACAGGT GTACACCCTGCCCCCATCCCG GGATGAGCTGACCAAGAACCA GGTCAGCCTGACCTGCCTGGT CAAAGGCTTCTATCCCAGCGA CATCGCCGTGGAGTGGGAGAG CAATGGGCAGCCGGAGAACAA CTACAAGACCACGCCTCCCGT GCTGGACTCCGACGGCTCCTT CTTCTTATATTCAAAGCTCACC GTGGACAAGAGCAGGTGGCAG CAGGGGAACGTCTTCTCATGC TCCGTGATGCATGAGGCTCTG CACAACCACTACACGCAGAAG AGCCTCTCCCTGTCTCCCCGGG AAATGA 124 zuJ591- H8 PSMA human IgG1 human GAAGTTCAACTTGTTCAGAGCG GAGCCGAAGTGAAGAAACCCG GCGCTACAGTGAAGATCAGCT GCAAGGTGTCCGGCTACACCT TCACCGAGTACACCATTCACTG GGTGCAGCAGGCCCCTGGCAA AGGACTGGAATGGATCGGCAA CATCAACCCCAACAACGGCGG Petition 870260065905, dated 03 / 07 / 2026, pp. 128 / 1400 125 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain CACCACCTACAACCAGAAATTC GAGGACAGAGTGACCATCACC GCCGACACCAGCACCGATACA GCCTACATGGAACTGAGCAGC CTGAGAAGCGAGGACACCGCC GTGTATTATTGTGCCGCCGGCT GGAACTTCGACTACTGGGGAC AGGGCACACTGGTCACCGTTA GCTCTGCATCCACCAAGGGCC CATCGGTCTTCCCCCTGGCAC CCTCCTCCAAGAGCACCTCTG GGGGCACAGCGGCCCTGGGC TGCCTGGTCAAGGACTACTTCC CCGAACCGGTGACGGTGTCGT GGAACTCAGGCGCCCTGACCA GCGGCGTGCACACCTTCCCGG CTGTCCTACAGTCCTCAGGACT CTACTCCCTCAGCAGCGTGGT GACCGTGCCCTCCAGCAGCTT GGGCACCCAGACCTACATCTG CAACGTGAATCACAAGCCCAG CAACACCAAGGTGGACAAGAA AGTTGAGCCCAAATCTTGTGAC AAAACTCACACATGCCCACCGT Petition 870260065905, dated 03 / 07 / 2026, pp. 129 / 1400 126 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Amino acid sequence of full-length mAb Ig chain GCCCAGCACCTGAACTCCTGG GGGGACCGTCAGTCTTCCTCT TCCCCCCAAAACCCAAGGACA CTGAGGTCAAGTTCAACTGGTA CGTGGACGGCGTGGAGGTGCA TAATGCCAAGACAAAGCCG GGAGGAGCAGTACAACAGCCAC GTACCGTGTGGTCAGCGTCCT CACCGTCCTGCACCAGGACTG GCTGAATGGCAAGGAGTCAAA GTGCAAGGTCTCCAACCAACCAAGCAACCATCC AACCATCTCCAAAGCCAAAGG GCAGCCCCGAGAACCACAGGT GTACACCCTGCCCCCATCCCG GGATGAGCTGACCAAGAACCA GGTCAGCCTGACCTGCCTGGT CAAAGGCTTCTATCCCAGCGA CATCGCCGTGGAGTGGGAGAG CAATGGGCAGCCGGAGAACAA CTACACCAGTCCCAG Petition 870260065905, of 03 / 07 / 2026, p. 130 / 1400 127 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence GCTGGACTCCGACGGCTCCTT CTTCTTATATTCAAAGCTCACC GTGGACAAGAGCAGGTGGCAG CAGGGGAACGTCTTCTCATGC TCCGTGATGCATGAGGCTCTG CACAACCACTACACGCAGAAG AGCCTCTCCCTGTCTCCCCGGG AAATGA 125 zuJ591- H9 Human PSMA Human IgG1 GAAGTTCAACTTGTTCAGAGCG GAGCCGAAGTGAAGAAACCCG GCGCTACAGTGAAGATCAGCT GCAAGACCTCCGGCTACACCT TCACCGAGTACACCATTCACTG GGTGCAGCAGGCCCCTGGCAA AGGACTGGAATGGATCGGCAA CATCAACCCCAACAACGGCGG CACCACCTACAACCAGAAATTC GAGGACAGAGTGACCATCACC GCCGACAAGAGCACCAGCACA GCCTACATGGAACTGAGCAGC CTGAGAAGCGAGGACACCGCC GTGTATTATTGTGCCGCCGGCT GGAACTTCGACTACTGGGGAC AGGGCACACTGGTCACCGTTA Petition 870260065905, dated 03 / 07 / 2026, pp. 131 / 1400 128 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain GCTCTGCATCCACCAAGGGCC CATCGGTCTTCCCCCTGGCAC CCTCCTCCAAGAGCACCTCTG GGGGCACAGCGGCCCTGGGC TGCCTGGTCAAGGACTACTTCC CCGAACCGGTGACGGTGTCGT GGAACTCAGGCGCCCTGACCA GCGGCGTGCACACCTTCCCGG CTGTCCTACAGTCCTCAGGACT CTACTCCCTCAGCAGCGTGGT GACCGTGCCCTCCAGCAGCTT GGGCACCCAGACCTACATCTG CAACGTGAATCACAAGCCCAG CAACACCAAGGTGGACAAGAA AGTTGAGCCCAAATCTTGTGAC AAAACTCACACATGCCCACCGT GCCCAGCACCTGAACTCCTGG GGGGACCGTCAGTCTTCCTCT TCCCCCCAAAACCCAAGGACA CCCTCATGATCTCCCGGACCC CTGAGGTCACATGCGTGGTGG TGGACGTGAGCCACGAAGACC CTGAGGTCAAGTTCAACTGGTA CGTGGACGGCGTGGAGGTGCA Petition 870260065905, dated 03 / 07 / 2026, p. 132 / 1400 129 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain TAATGCCAAGACAAAGCCGCG GGAGGAGCAGTACAACAGCAC GTACCGTGTGGTCAGCGTCCT CACCGTCCTGCACCAGGACTG GCTGAATGGCAAGGAGTACAA GTGCAAGGTCTCCAACAAAGC CCTCCCAGCCCCCATCGAGAA AACCATCTCCAAAGCCAAAGG GCAGCCCCGAGAACCACAGGT GTACACCCTGCCCCCATCCCG GGATGAGCTGACCAAGAACCA GGTCAGCCTGACCTGCCTGGT CAAAGGCTTCTATCCCAGCGA CATCGCCGTGGAGTGGGAGAG CAATGGGCAGCCGGAGAACAA CTACAAGACCACCGCCTCCCGT GCTGGACTCCGACGGCTCCTT CTTCTTATATTCAAAGCTCACC GTGGACAAGAGCAGGTGGCAG CAGGGGAACGTCTTCTCATGC TCCGTGATGCATGAGGCTCTG CACAACCACTACACGCAGAAG AGCCTCTCCCTGTCTCCCGGG AAATGA Petition 870260065905, dated 03 / 07 / 2026, pp. 133 / 1400 130 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain 126 zuJ591- H10 Human PSMA Human IgG1 GAAGTTCAACTTGTTCAGAGCG GAGCCGAAGTGAAGAAACCCG GCGCTACAGTGAAGATCAGCT GCAAGACCTCCGGCTACACCT TCACCGAGTACACCATTCACTG GGTGCAGCAGGCCCCTGGCAA AGGACTGGAATGGATCGGCAA CATCAACCCCAACAACGGCGG CACCACCTACAACCAGAAATTC GAGGACAGAGTGACCATCACC GCCGACACCAGCACCGATACA GCCTACATGGAACTGAGCAGC CTGAGAAGCGAGGACACCGCC GTGTATTATTGTGCCGCCGGCT GGAACTTCGACTACTGGGGAC AGGGCACACTGGTCACCGTTA GCTCTGCATCCACCAAGGGCC CATCGGTCTTCCCCCTGGCAC CCTCCTCCAAGAGCACCTCTG GGGGCACAGCGGCCCTGGGC TGCCTGGTCAAGGACTACTTCC CCGAACCGGTGACGGTGTCGT GGAACTCAGGCGCCCTGACCA GCGGCGTGCACACCTTCCCGG Petition 870260065905, dated 03 / 07 / 2026, pp. 134 / 1400 131 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain CTGTCCTACAGTCCTCAGGACT CTACTCCCTCAGCAGCGTGGT GACCGTGCCCTCCAGCAGCTT GGGCACCCAGACCTACATCTG CAACGTGAATCACAAGCCCAG CAACACCAAGGTGGACAAGAA AGTTGAGCCCAAATCTTGTGAC AAAACTCACACATGCCCACCGT GCCCAGCACCTGAACTCCTGG GGGGACCGTCAGTCTTCCTCT TCCCCCCAAAACCCAAGGACA CCCTCATGATCTCCCGGACCC CTGAGGTCACATGCGTGGTGG TGGACGTGAGCCACGAAGACC CTGAGGTCAAGTTCAACTGGTA CGTGGACGGCGTGGAGGTGCA TAATGCCAAGACAAAGCCGCG GGAGGAGCAGTACAACAGCAC GTACCGTGTGGTCAGCGTCCT CACCGTCCTGCACCAGGACTG GCTGAATGGCAAGGAGTACAA GTGCAAGGTCTCCAACAAAGC CCTCCCAGCCCCCATCGAGAA AACCATCTCCAAAGCCAAAGG Petition 870260065905, dated 03 / 07 / 2026, pp. 135 / 1400 132 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence GCAGCCCCGAGAACCACAGGT GTACACCCTGCCCCCATCCCG GGATGAGCTGACCAAGAACCA GGTCAGCCTGACCTGCCTGGT CAAAGGCTTCTATCCCAGCGA CATCGCCGTGGAGTGGGAGAG CAATGGGCAGCCGGAGAACAA CTACAAGACCACGCCTCCCGT GCTGGACTCCGACGGCTCCTT CTTCTTATATTCAAAGCTCACC GTGGACAAGAGCAGGTGGCAG CAGGGGAACGTCTTCTCATGC TCCGTGATGCATGAGGCTCTG CACAACCACTACACGCAGAAG AGCCTCTCCCTGTCTCCCCGGG AAATGA 127 zuJ591- H11 PSMA human IgG1 human GAAGTTCAACTTGTTCAGAGCG GAGCCGAAGTGAAGAAACCCG GCGCTACAGTGAAGATCAGCT GCAAGGTGTCCGGCTACACCT TCACCGAGTACACCATTCACTG GGTGCAGCAGGCCCCTGGCAA AGGACTGGAATGGATGGGCAA CATCAACCCCAACAACGGCGG Petition 870260065905, dated 03 / 07 / 2026, pp. 136 / 1400 133 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence CACCACCTACAACCAGAAATTC GAGGGCAGAGTGACCATCACC GCCGACACCAGCACCGATACA GCCTACATGGAACTGAGCAGC CTGAGAAGCGAGGACACCGCC GTGTATTATTGTGCCACCGGCT GGAACTTCGACTACTGGGGAC AGGGCACACTGGTCACCGTTA GCTCTGCATCCACCAAGGGCC CATCGGTCTTCCCCCTGGCAC CCTCCTCCAAGAGCACCTCTG GGGGCACAGCGGCCCTGGGC TGCCTGGTCAAGGACTACTTCC CCGAACCGGTGACGGTGTCGT GGAACTCAGGCGCCCTGACCA GCGGCGTGCACACCTTCCCGG CTGTCCTACAGTCCTCAGGACT CTACTCCCTCAGCAGCGTGGT GACCGTGCCCTCCAGCAGCTT GGGCACCCAGACCTACATCTG CAACGTGAATCACAAGCCCAG CAACACCAAGGTGGACAAGAA AGTTGAGCCCAAATCTTGTGAC AAAACTCACACATGCCCACCGT Petition 870260065905, dated 03 / 07 / 2026, pp. 137 / 1400 134 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Amino acid sequence of full-length mAb Ig chain GCCCAGCACCTGAACTCCTGG GGGGACCGTCAGTCTTCCTCT TCCCCCCAAAACCCAAGGACA CTGAGGTCAAGTTCAACTGGTA CGTGGACGGCGTGGAGGTGCA TAATGCCAAGACAAAGCCG GGAGGAGCAGTACAACAGCCAC GTACCGTGTGGTCAGCGTCCT CACCGTCCTGCACCAGGACTG GCTGAATGGCAAGGAGTCAAA GTGCAAGGTCTCCAACCAACCAAGCAACCATCC AACCATCTCCAAAGCCAAAGG GCAGCCCCGAGAACCACAGGT GTACACCCTGCCCCCATCCCG GGATGAGCTGACCAAGAACCA GGTCAGCCTGACCTGCCTGGT CAAAGGCTTCTATCCCAGCGA CATCGCCGTGGAGTGGGAGAG CAATGGGCAGCCGGAGAACAA CTACACCAGTCCCAG Petition 870260065905, of 03 / 07 / 2026, p. 138 / 1400 135 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence GCTGGACTCCGACGGCTCCTT CTTCTTATATTCAAAGCTCACC GTGGACAAGAGCAGGTGGCAG CAGGGGAACGTCTTCTCATGC TCCGTGATGCATGAGGCTCTG CACAACCACTACACGCAGAAG AGCCTCTCCCTGTCTCCCCGGG AAATGA 128 zuJ591- H12 Human PSMA Human IgG1 GAAGTTCAACTTGTTCAGAGCG GAGCCGAAGTGAAGAAACCCG GCGCTACAGTGAAGATCAGCT GCAAGGTGTCCGGCTACACCT TCACCGAGTACACCATTCACTG GGTGCAGCAGGCCCCTGGCAA AGGACTGGAATGGATGGGCAA CATCAACCCCAACAACGGCGG CACCACCTACAACCAGAAATTC CAGGGCAGAGTGACCATCACC GCCGACACCAGCACCGATACA GCCTACATGGAACTGAGCAGC CTGAGAAGCGAGGACACCGCC GTGTATTATTGTGCCACCGGCT GGAACTTCGACTACTGGGGAC AGGGCACACTGGTCACCGTTA Petition 870260065905, dated 03 / 07 / 2026, pp. 139 / 1400 136 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain GCTCTGCATCCACCAAGGGCC CATCGGTCTTCCCCCTGGCAC CCTCCTCCAAGAGCACCTCTG GGGGCACAGCGGCCCTGGGC TGCCTGGTCAAGGACTACTTCC CCGAACCGGTGACGGTGTCGT GGAACTCAGGCGCCCTGACCA GCGGCGTGCACACCTTCCCGG CTGTCCTACAGTCCTCAGGACT CTACTCCCTCAGCAGCGTGGT GACCGTGCCCTCCAGCAGCTT GGGCACCCAGACCTACATCTG CAACGTGAATCACAAGCCCAG CAACACCAAGGTGGACAAGAA AGTTGAGCCCAAATCTTGTGAC AAAACTCACACATGCCCACCGT GCCCAGCACCTGAACTCCTGG GGGGACCGTCAGTCTTCCTCT TCCCCCCAAAACCCAAGGACA CCCTCATGATCTCCCGGACCC CTGAGGTCACATGCGTGGTGG TGGACGTGAGCCACGAAGACC CTGAGGTCAAGTTCAACTGGTA CGTGGACGGCGTGGAGGTGCA Petition 870260065905, dated 03 / 07 / 2026, p. 140 / 1400 137 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain TAATGCCAAGACAAAGCCGCG GGAGGAGCAGTACAACAGCAC GTACCGTGTGGTCAGCGTCCT CACCGTCCTGCACCAGGACTG GCTGAATGGCAAGGAGTACAA GTGCAAGGTCTCCAACAAAGC CCTCCCAGCCCCCATCGAGAA AACCATCTCCAAAGCCAAAGG GCAGCCCCGAGAACCACAGGT GTACACCCTGCCCCCATCCCG GGATGAGCTGACCAAGAACCA GGTCAGCCTGACCTGCCTGGT CAAAGGCTTCTATCCCAGCGA CATCGCCGTGGAGTGGGAGAG CAATGGGCAGCCGGAGAACAA CTACAAGACCACCGCCTCCCGT GCTGGACTCCGACGGCTCCTT CTTCTTATATTCAAAGCTCACC GTGGACAAGAGCAGGTGGCAG CAGGGGAACGTCTTCTCATGC TCCGTGATGCATGAGGCTCTG CACAACCACTACACGCAGAAG AGCCTCTCCCTGTCTCCCGGG AAATGA Petition 870260065905, dated 03 / 07 / 2026, pp. 141 / 1400 138 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Amino acid sequence of full-length mAb Ig chain 129 zuJ591- H13 Human PSMA Human IgG1 GAAGTTCAACTTGTTCAGAGCG GAGCCGAAGTGAAGAAACCCG GCGCTACAGTGAAGATCAGCT GCAAGGTGTCCGGCTACACCT TCACCGAGTACACCATTCACTG GGTGCAGCAGGCCCCTGGCAA AGGACTGGAATGGATGGGCAA CATCAACCCCAACAACGGCGG CACCACCTACAACGAAAAATTC CAGGGCAGAGTGACCATCACC GCCGACACCAGCACCGATACA GCCTACATGGAACTGAGCAGC CTGAGAAGCGAGGACACCGCC GTGTATTATTGTGCCACCGGCT GGAACTTCGACTACTGGGGAC AGGGCACACTGGTCACCGTTA GCTCTGCATCCACCAAGGGCC CATCGGTCTTCCCCCTGGCAC CCTCCTCCAAGAGCACCTCTG GGGGCACAGCGGCCCTGGGC TGCCTGGTCAAGGACTACTTCC CCGAACCGGTGACGGTGTCGT GGAACTCAGGCGCCCTGACCA GCGGCGTGCACACCTTCCCGG Petition 870260065905, dated 03 / 07 / 2026, p. 142 / 1400 139 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain CTGTCCTACAGTCCTCAGGACT CTACTCCCTCAGCAGCGTGGT GACCGTGCCCTCCAGCAGCTT GGGCACCCAGACCTACATCTG CAACGTGAATCACAAGCCCAG CAACACCAAGGTGGACAAGAA AGTTGAGCCCAAATCTTGTGAC AAAACTCACACATGCCCACCGT GCCCAGCACCTGAACTCCTGG GGGGACCGTCAGTCTTCCTCT TCCCCCCAAAACCCAAGGACA CCCTCATGATCTCCCGGACCC CTGAGGTCACATGCGTGGTGG TGGACGTGAGCCACGAAGACC CTGAGGTCAAGTTCAACTGGTA CGTGGACGGCGTGGAGGTGCA TAATGCCAAGACAAAGCCGCG GGAGGAGCAGTACAACAGCAC GTACCGTGTGGTCAGCGTCCT CACCGTCCTGCACCAGGACTG GCTGAATGGCAAGGAGTACAA GTGCAAGGTCTCCAACAAAGC CCTCCCAGCCCCCATCGAGAA AACCATCTCCAAAGCCAAAGG Petition 870260065905, dated 03 / 07 / 2026, pp. 143 / 1400 140 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence GCAGCCCCGAGAACCACAGGT GTACACCCTGCCCCCATCCCG GGATGAGCTGACCAAGAACCA GGTCAGCCTGACCTGCCTGGT CAAAGGCTTCTATCCCAGCGA CATCGCCGTGGAGTGGGAGAG CAATGGGCAGCCGGAGAACAA CTACAAGACCACGCCTCCCGT GCTGGACTCCGACGGCTCCTT CTTCTTATATTCAAAGCTCACC GTGGACAAGAGCAGGTGGCAG CAGGGGAACGTCTTCTCATGC TCCGTGATGCATGAGGCTCTG CACAACCACTACACGCAGAAG AGCCTCTCCCTGTCTCCCCGGG AAATGA 130 zuJ591- H14 PSMA human IgG1 human GAAGTTCAACTTGTTCAGAGCG GAGCCGAAGTGAAGAAACCCG GCGCTACAGTGAAGATCAGCT GCAAGGTGTCCGGCTACACCT TCACCGAGTACACCATTCACTG GGTGCAGCAGGCCCCTGGCAA AGGACTGGAATGGATGGGCAA CATCAACCCCAACAACGGCGG Petition 870260065905, dated 03 / 07 / 2026, p. 144 / 1400 141 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain CACCACCTACGCCGAAAAATTC CAGGGCAGAGTGACCATCACC GCCGACACCAGCACCGATACA GCCTACATGGAACTGAGCAGC CTGAGAAGCGAGGACACCGCC GTGTATTATTGTGCCACCGGCT GGAACTTCGACTACTGGGGAC AGGGCACACTGGTCACCGTTA GCTCTGCATCCACCAAGGGCC CATCGGTCTTCCCCCTGGCAC CCTCCTCCAAGAGCACCTCTG GGGGCACAGCGGCCCTGGGC TGCCTGGTCAAGGACTACTTCC CCGAACCGGTGACGGTGTCGT GGAACTCAGGCGCCCTGACCA GCGGCGTGCACACCTTCCCGG CTGTCCTACAGTCCTCAGGACT CTACTCCCTCAGCAGCGTGGT GACCGTGCCCTCCAGCAGCTT GGGCACCCAGACCTACATCTG CAACGTGAATCACAAGCCCAG CAACACCAAGGTGGACAAGAA AGTTGAGCCCAAATCTTGTGAC AAAACTCACACATGCCCACCGT Petition 870260065905, dated 03 / 07 / 2026, pp. 145 / 1400 142 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Amino acid sequence of full-length mAb Ig chain GCCCAGCACCTGAACTCCTGG GGGGACCGTCAGTCTTCCTCT TCCCCCCAAAACCCAAGGACA CTGAGGTCAAGTTCAACTGGTA CGTGGACGGCGTGGAGGTGCA TAATGCCAAGACAAAGCCG GGAGGAGCAGTACAACAGCCAC GTACCGTGTGGTCAGCGTCCT CACCGTCCTGCACCAGGACTG GCTGAATGGCAAGGAGTCAAA GTGCAAGGTCTCCAACCAACCAAGCAACCATCC AACCATCTCCAAAGCCAAAGG GCAGCCCCGAGAACCACAGGT GTACACCCTGCCCCCATCCCG GGATGAGCTGACCAAGAACCA GGTCAGCCTGACCTGCCTGGT CAAAGGCTTCTATCCCAGCGA CATCGCCGTGGAGTGGGAGAG CAATGGGCAGCCGGAGAACAA CTACACCAGTCCCAG Petition 870260065905, of 03 / 07 / 2026, p. 146 / 1400 143 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence GCTGGACTCCGACGGCTCCTT CTTCTTATATTCAAAGCTCACC GTGGACAAGAGCAGGTGGCAG CAGGGGAACGTCTTCTCATGC TCCGTGATGCATGAGGCTCTG CACAACCACTACACGCAGAAG AGCCTCTCCCTGTCTCCCCGGG AAATGA 131 zuJ591- L1 Human PSMA Human IgK GATATTCAGATGACACAGAGCC CTAGCAGCCTGAGCGCCTCTG TGGGCGATAGAGTGACAATCA CATGCAAGGCCAGCCAGGATG TGGGCACCGCTGTTGACTGGT ATCAGCAGAAGCCTGGCAAGG CCCCTAAGCTGCTGATCTACTG GGCCAGCACAAGACACACAGG CGTGCCAAGCAGAIIIICTGG CAGCGGCTCTGGCACCGACTT CACCCTGACCA m CTAGCCTC CAGCCTGAGGACTTCGCCACC TACTACTGTCAGCAGTACAACA GCTACCCTCTGACC mGGCCA GGGCACCAAGCTGGAAATCAA ACGAACTGTGGCTGCACCATC Petition 870260065905, dated 03 / 07 / 2026, p. 147 / 1400 144 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence TGTCTTCATCTTCCCGCCATCT GATGAGCAGTTGAAATCTGGAA CTGCCTCTGTTGTGTGCCTGCT GAATAACTTCTATCCCAGAGAG GCCAAAGTACAGTGGAAGGTG GATAACGCCCTCCAATCGGGT AACTCCCAGGAGAGTGTCACA GAGCAGGACAGCAAGGACAGC ACCTACAGCCTCAGCAGCACC CTGACGCTGAGCAAAGCAGAC TACGAGAAACACAAAGTCTACG CCTGCGAAGTCACCCATCAGG GCCTGAGCTCGCCCGTCACAA AGAGCTTCAACAGGGGAGAGT GTTGA 132 zuJ591- L2 PSMA human igK human GATATTCAGATGACACAGAGCC CTAGCAGCCTGAGCGCCTCTG TGGGCGATAGAGTGACAATCA CATGCAGAGCCAGCCAGGATG TGGGCACCGCTGTTGACTGGT ATCAGCAGAAGCCTGGCAAGG CCCCTAAGCTGCTGATCTACTG GGCCAGCACAAGACACACAGG CGTGCCAAGCAGAIIIICTGG Petition 870260065905, dated 03 / 07 / 2026, pp. 148 / 1400 145 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain CAGCGGCTCTGGCACCGACTT CACCCTGACCA III CTAGCCTC CAGCCTGAGGACTTCGCCACC TACTACTGTCAGCAGTACAACA GCTACCCTCTGACC mGGCCA GGGCACCAAGCTGGAAATCAA ACGAACTGTGGCTGCACCATC TGTCTTCATCTTCCCGCCATCT GATGAGCAGTTGAAATCTGGAA CTGCCTCTGTTGTGTGCCTGCT GAATAACTTCTATCCCAGAGAG GCCAAAGTACAGTGGAAGGTG GATAACGCCCTCCAATCGGGT AACTCCCAGGAGAGTGTCACA GAGCAGGACAGCAAGGACAGC ACCTACAGCCTCAGCAGCACC CTGACGCTGAGCAAAGCAGAC TACGAGAAACACAAAGTCTACG CCTGCGAAGTCACCCATCAGG GCCTGAGCTCGCCCGTCACAA AGAGCTTCAACAGGGGAGAGT GTTGA 133 zuJ591- L3 human PSMA human igK GATATTCAGATGACACAGAGCC CTAGCAGCCTGAGCGCCTCTG Petition 870260065905, dated 03 / 07 / 2026, pp. 149 / 1400 146 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence TGGGCGATAGAGTGACAATCA CATGCAGAGCCAGCCAGGATG TGGGCACCGCTCTGAACTGGT ATCAGCAGAAGCCTGGCAAGG CCCCTAAGCTGCTGATCTACTG GGCCAGCACAAGACACACAGG CGTGCCAAGCAGAIIIICTGG CAGCGGCTCTGGCACCGACTT CACCCTGACCA m CTAGCCTC CAGCCTGAGGACTTCGCCACC TACTACTGTCAGCAGTACAACA GCTACCCTCTGACC mGGCCA GGGCACCAAGCTGGAAATCAA ACGAACTGTGGCTGCACCATC TGTCTTCATCTTCCCGCCATCT GATGAGCAGTTGAAATCTGGAA CTGCCTCTGTTGTGTGCCTGCT GAATAACTTCTATCCCAGAGAG GCCAAAGTACAGTGGAAGGTG GATAACGCCCTCCAATCGGGT AACTCCCAGGAGAGTGTCACA GAGCAGGACAGCAAGGACAGC ACCTACAGCCTCAGCAGCACC CTGACGCTGAGCAAAGCAGAC Petition 870260065905, dated 03 / 07 / 2026, pp. 150 / 1400 147 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence TACGAGAAACACAAAGTCTACG CCTGCGAAGTCACCCATCAGG GCCTGAGCTCGCCCGTCACAA AGAGCTTCAACAGGGGAGAGT GTTGA 134 zuJ591- L4 Human PSMA Human IgK GATATTCAGATGACACAGCC CTAGCAGCCTGAGCGCCTCTG TGGGCGATAGAGTGACAATCA CATGCAAGGCCAGCCAGGATG TGGGCACCGCTGTTGACTGGT ATCAGCAGAAGCCTGGCAAGG CCCCTAAGCTGCTGATCTACTG GGCCAGCACAAGACACAGCGG CGTGCCAAGCAGAIIIICTGG CAGCGGCTCTGGCACCGACTT CACCCTGACCA m CTAGCCTC CAGCCTGAGGACTTCGCCACC TACTACTGTCAGCAGTACAACA GCTACCCTCTGACC mGGCCA GGGCACCAAGCTGGAAATCAA ACGAACTGTGGCTGCACCATC TGTCTTCATCTTCCCGCCATCT GATGAGCAGTTGAAATCTGGAA CTGCCTCTGTTGTGTGCCTGCT Petition 870260065905, dated 03 / 07 / 2026, pp. 151 / 1400 148 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence GAATAACTTCTATCCCAGAGAG GCCAAAGTACAGTGGAAGGTG GATAACGCCCTCCAATCGGGT AACTCCCAGGAGAGTGTCACA GAGCAGGACAGCAAGGACAGC ACCTACAGCCTCAGCAGCACC CTGACGCTGAGCAAAGCAGAC TACGAGAAACACAAAGTCTACG CCTGCGAAGTCACCCATCAGG GCCTGAGCTCGCCCGTCACAA AGAGCTTCAACAGGGGAGAGT GTTGA 135 zuJ591- L5 PSMA human igK human GATATTCAGATGACACAGAGCC CTAGCAGCCTGAGCGCCTCTG TGGGCGATAGAGTGACAATCA CATGCAGAGCCAGCCAGGATG TGGGCACCGCTGTTGACTGGT ATCAGCAGAAGCCTGGCAAGG CCCCTAAGCTGCTGATCTACTG GGCCAGCACAAGACACAGCGG CGTGCCAAGCAGAIIIICTGG CAGCGGCTCTGGCACCGACTT CACCCTGACCA m CTAGCCTC CAGCCTGAGGACTTCGCCACC Petition 870260065905, dated 03 / 07 / 2026, p. 152 / 1400 149 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain TACTACTGTCAGCAGTACAACA GCTACCCTCTGACCIIIGGCCA GGGCACCAAGCTGGAAATCAA ACGAACTGTGGCTGCACCATC TGTCTTCATCTTCCCGCCATCT GATGAGCAGTTGAAATCTGGAA CTGCCTCTGTTGTGTGCCTGCT GAATAACTTCTATCCCAGAGAG GCCAAAGTACAGTGGAAGGTG GATAACGCCCTCCAATCGGGT AACTCCCAGGAGAGTGTCACA GAGCAGGACAGCAAGGACAGC ACCTACAGCCTCAGCAGCACC CTGACGCTGAGCAAAGCAGAC TACGAGAAACACAAAGTCTACG CCTGCGAAGTCACCCATCAGG GCCTGAGCTCGCCCGTCACAA AGAGCTTCAACAGGGGAGAGT GTTGA 136 zuJ591- L6 human PSMA human igK GATATTCAGATGACACAGAGCC CTAGCAGCCTGAGCGCCTCTG TGGGCGATAGAGTGACAATCA CATGCAGAGCCAGCCAGGATG TGGGCACCGCTCTGAACTGGT Petition 870260065905, dated 03 / 07 / 2026, p. 153 / 1400 150 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence ATCAGCAGAAGCCTGGCAAGG CCCCTAAGCTGCTGATCTACTG GGCCAGCACAAGACACAGCGG CGTGCCAAGCAGAIIIICTGG CAGCGGCTCTGGCACCGACTT CACCCTGACCA m CTAGCCTC CAGCCTGAGGACTTCGCCACC TACTACTGTCAGCAGTACAACA GCTACCCTCTGACC mGGCCA GGGCACCAAGCTGGAAATCAA ACGAACTGTGGCTGCACCATC TGTCTTCATCTTCCCGCCATCT GATGAGCAGTTGAAATCTGGAA CTGCCTCTGTTGTGTGCCTGCT GAATAACTTCTATCCCAGAGAGAG GCCAAAGTACAGTGGAAGGTG GATAACGCCCTCCAATCGGGT AACTCCCAGGAGAGTGTCACA GAGCAGGACAGCAAGGACAGC ACCTACAGCCTCAGCAGCACC CTGACGCTGAGCAAAGCAGAC TACGAGAAACACAAAGTCTACG CCTGCGAAGTCACCCATCAGG GCCTGAGCTCGCCCGTCACAA Petition 870260065905, dated 03 / 07 / 2026, p. 154 / 1400 151 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence AGAGCTTCAACAGGGGAGAGT GTTGA 137 deJ591- HC Human PSMA Human IgG1 GAAGTTCAACTTGTGCAGAGC GGCCCTGAAGTGAAGAAACCT GGCGCTACCGTGAAGATCAGC TGCAAGACCAGCGGCTACACC TTCACCGAGTACACCATCCACT GGGTTAAGCAGGCCCCTGGCA AAGGCCTGGAATGGATCGGCA ACATCAACCCCAACAACGGCG GCACCACCTACAACCAGAAGTT CGAGGATAAGGGCCACACTGAC CGTGGACAAGAGCACCGACAC AGCCTACATGGAACTGAGCAG CCTGAGAAGCGAGGACACCGC CGTGTATTATTGTGCCGCCGG ATGGAACTTCGACTACTGGGG ACAGGGCACCCTGCTGACAGT CTCTTCTGCATCCACCAAGGG CCCATCGGTCTTCCCCCTGGC ACCCTCCTCCAAGAGCACCTCT GGGGGCACAGCGGCCCTGGG CTGCCTGGTCAAGGACTACTTC CCCGAACCGGTGACGGTGTCG Petition 870260065905, dated 03 / 07 / 2026, pp. 155 / 1400 152 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Name Target Ig Chain Amino acid sequence of full-length mAb Ig chain TGGAACTCAGGCGCCCTGACC AGCGGCGTGCACACCTTCCCG GCTGTCCTACAGTCCTCAGGA CTCTACTCCCTCAGCAGCGTG GTGACCGTGCCCTCCAGCAGC TTGGGCACCCAGACCTACATCT GCAACGTGAATCACAAGCCCA GCAACACCAAGGTGGACAAGA AAGTTGAGCCCAAATCTTGTGA CAAAACTCACACATGCCCACC GTGCCCAGCACCTGAACTCCT GGGGGGACCGTCAGTCTTCCT CTTCCCCCCAAAACCCAAGGA CACCCTCATGATCTCCCGGAC CCCTGAGGTCACATGCGTGGT GGTGGACGTGAGCCACGAAGA CCCTGAGGTCAAGTTCAACTG GTACGTGGACGGCGTGGAGGT GCATAATGCCAAGACAAAGCC GCGGGAGGAGCAGTACAACAG CACGTACCGTGTGGTCACGGT CCTCACCGTCCTGCACCAGGGA CTGGCTGAATGGCAAGGAGTA CAAGTGCAAGGTCTCCAACAAA Petition 870260065905, dated 03 / 07 / 2026, p. 156 / 1400 153 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence GCCCTCCCAGCCCCCATCGAG AAAACCATCTCCAAAGCCAAAG GGCAGCCCCGAGAACCACAGG TGTACACCCTGCCCCCATCCC GGGATGAGCTGACCAAGAACC AGGTCAGCCTGACCTGCCTGG TCAAAGGCTTCTATCCCAGCGA CATCGCCGTGGAGTGGGAGAG CAATGGGCAGCCGGAGAACAA CTACAAGACCACGCCTCCCGT GCTGGACTCCGACGGCTCCTT CTTCTTATATTCAAAGCTCACC GTGGACAAGAGCAGGTGGCAG CAGGGGAACGTCTTCTCATGC TCCGTGATGCATGAGGCTCTG CACAACCACTACACGCAGAAG AGCCTCTCCCTGTCTCCCCGGG AAATGA 138 deJ591- LC PSMA human igK human GATATTCAGATGACACAGAGCC CCAGCAGCCTGAGCACATCTG TGGGAGATAGAGTGACCCTGA CCTGCAAGGCCTCTCAGGATG TGGGAACCGCCGTGGACTGGT ATCAGCAGAAACCCGGACCTT Petition 870260065905, dated 03 / 07 / 2026, p. 157 / 1400 154 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig Chain Amino Acid Sequence CTCCAAAGCTGCTGATCTACTG GGCCAGCACCAGACACACAGG CATCCCTAGCAGA Illi CTGGC AGCGGCTCTGGCACCGACTTC ACCCTGACCA mCTAGCCTCCC AGCCTGAGGACTTCGCCGACT ACTACTGCCAGCAGTACAACA GCTACCCTCTGACATTCGGCC CTGGCACCAAGGTGGACATCA AACGAACTGTGGCTGCACCAT CTGTCTTCATCTTCCCGCCATC TGATGAGCAGTTGAAATCTGGA ACTGCCTCTGTTGTGTGCCTGC TGAATAACTTCTATCCCAGAGA GGCCAAAGTACAGTGGAAGGT GGATAACGCCCTCCAATCGGG TAACTCCCAGGAGAGTGTCAC AGAGCAGGACAGCAAGGACAG CACCTACAGCCTCAGCAGCAC CCTGACGCTGAGCAAAGCAGA CTACGAGAAACACAAAGTCTAC GCCTGCGAAGTCACCCATCAG GGCCTGAGCTCGCCCGTCACA AAGAGCTTCAACAGGGGAGAG Petition 870260065905, dated 03 / 07 / 2026, p. 158 / 1400 155 / 650 Table 12. Nucleic acid sequences of full-length mAb Ig chains (continued) SEQ ID NO Target Name Ig Chain Full-length mAb Ig chain amino acid sequence TGTTGA

[0232] The anti-PSMA antibodies or antigen-binding fragments provided by SEQ IDs 1-39 and 42-46 may provide improved properties compared to other anti-PSMA antibodies, for example, J591 and / or deJ591. In some embodiments, the anti-PSMA antibodies or antigen-binding fragments disclosed herein have superior stability compared to other anti-PSMA antibodies, for example, J591 and / or deJ591. In some embodiments, the anti-PSMA antibodies or antigen-binding fragments disclosed herein are less immunogenic compared to other anti-PSMA antibodies, for example, J591 and / or deJ591.

[0233] In some embodiments, the sequences of the variable heavy chain domains, variable light chain domains, full-length heavy chains, and full-length light chains can be “mixed and matched” to create variants of the anti-PSMA antibodies. Such “mixed and matched” anti-PSMA antibodies can be tested using known binding assays in the art (e.g., ELISAs and other assays described in the Examples). In several embodiments, the antibodies disclosed herein may comprise any set of variable heavy and light chain domains mentioned in the tables above, or the set of six CDR sequences from the heavy and light chain set. In Petition 870260065905, dated 03 / 07 / 2026, page 159 / 1400 156 / 650 In some embodiments, the antibodies additionally comprise human heavy and light chain constant domains or fragments thereof. In several embodiments, the antibodies may comprise any set of full-length heavy chain or full-length light chain sequences listed in the tables above. In some embodiments, the antibodies may comprise a human IgG heavy chain constant domain and a human kappa light chain constant domain. In some embodiments, the antibodies may comprise a human IgG1, IgG2, IgG3, or IgG4 heavy chain constant domain. In several embodiments, an antibody of the present invention comprises a human immunoglobulin G (IgG1) subtype 1 heavy chain constant domain with a human Ig kappa light chain constant domain.In some embodiments, the constant domain is a modified version of a human constant domain, for example, comprising one or more L234A, L235A, P238S, H268Q and / or K274Q modifications of a human IgG1 heavy chain constant domain.

[0234] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 44, wherein SEQ ID NO: 44 comprises NINPNNGGTTYX1X2KFX3X4, as defined by the Kabat numbering system. In some modalities, in SEQ ID NO: 44, X1 is A or N, X2 is E or Q, X3 is Q or E, and X4 is G or D. In some modalities, in SEQ ID NO: 44, X1 is A, X2 is E, X3 is Q and / or X4 is G. In some modalities, in SEQ ID NO: 44, X1 is N, X2 is E, X3 is Q and / or X4 is G. In some modalities, in SEQ ID NO: 44, X1 is N, X2 is Q, X3 is Q and / or X4 is G. In some modalities, in SEQ ID NO: 44, X1 is N, X2 is Q, X3 is E and / or X4 is G. In some modalities, in SEQ ID NO: 44, X1 is N, X2 is Q, X3 is E and / or X4 is D.

[0235] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof is provided in this document. Petition 870260065905, dated 03 / 07 / 2026, pp. 160 / 1400 157 / 650 comprises a lightweight chain CDR1 (LCDR1) comprising SEQ ID NO: 45, where SEQ ID NO: 45 comprises X5ASQDVGTAX6X7 as defined by the Kabat numbering system. In some embodiments, in SEQ ID NO: 45, X5 is R or K, X6 is V or L, X7 is D or N. In some embodiments, in SEQ ID NO: 45, X5 is R, X6 is V and / or X7 is D. In some embodiments, in SEQ ID NO: 45, X5 is K, X6 is V and / or X7 is D. In some embodiments, in SEQ ID NO: 45, X5 is R, X6 is L and / or X7 is N.

[0236] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a light chain CDR2 (LCDR2) comprising SEQ ID NO: 46, wherein SEQ ID NO: 46 comprises WASTRHX8, as defined by the Kabat numbering system. In some embodiments, in SEQ ID NO: 46, X8 is either S or T. In some embodiments, in SEQ ID NO: 46, X8 is S. In some embodiments, in SEQ ID NO: 46, X8 is T.

[0237] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: Heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, Heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 44, Heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; Light chain CDR1 (LCDR1) comprising SEQ ID NO: 45, Light chain CDR2 (LCDR2) comprising SEQ ID NO: 46 and Light chain CDR3 (LCDR3) comprising SEQ ID NO: 37 as defined by the Kabat numbering system. In some modalities, in SEQ ID NO: 44, X1 is A, X2 is E, X3 is Q and / or X4 is G. In some modalities, in SEQ ID NO: 44, X1 is N, X2 is E, X3 is Q and / or X4 is G. In some modalities, in SEQ ID NO: 44, X1 is N, X2 is Q, X3 is Q and / or X4 is G. In some modalities, in SEQ ID NO: 44, X1 is N, X2 is Q, X3 is E and / or X4 is G. In some modalities, in SEQ ID NO: 44, X1 is N, X2 is Q, X3 is E and / or X4 is D. In some modalities, in SEQ ID NO: 45, X5 is R, X6 is V and / or X7 is D. In some modalities, in SEQ ID NO: 45, X5 is K, X6 is V and / or Petition 870260065905, dated 03 / 07 / 2026, p. 161 / 1400 158 / 650 X7 is D. In some modalities, in SEQ ID NO: 45, X5 is R, X6 is L and / or X7 is N. In some modalities, in SEQ ID NO: 46, X8 is S. In some modalities, in SEQ ID NO: 46, X8 is T.

[0238] In some modes, in SEQ ID NO: 44, X1 is A, X2 is E, X3 is Q and X4 is G; in SEQ ID NO: 45, X5 is R, X6 is V and X7 is D; and in SEQ ID NO: 46, X8 is S. In some modes, in SEQ ID NO: 44, X1 is A, X2 is E, X3 is Q and X4 is G; in SEQ ID NO: 45, X5 is R, X6 is V and X7 is D; and in SEQ ID NO: 46, X8 is T. In some modes, in SEQ ID NO: 44, X1 is A, X2 is E, X3 is Q and X4 is G; in SEQ ID NO: 45, X5 is K, X6 is V, and X7 is D; and in SEQ ID NO: 46, X8 is S. In some modalities, in SEQ ID NO: 44, X1 is A, X2 is E, X3 is Q and X4 is G; in SEQ ID NO: 45, X5 is K, X6 is V, and X7 is D; and in SEQ ID NO: 46, X8 is T. In some modalities, in SEQ ID NO: 44, X1 is A, X2 is E, X3 is Q and X4 is G; in SEQ ID NO: 45, X5 is R, X6 is L and X7 is N; and in SEQ ID NO: 46, X8 is S. In some modalities, in SEQ ID NO: 44, X1 is A, X2 is E, X3 is Q and X4 is G; in SEQ ID NO: 45, X5 is R, X6 is L and X7 is N; and in SEQ ID NO: 46, X8 is T. In some modalities, in SEQ ID NO: 44, X1 is N, X2 is E, X3 is Q and X4 is G; in SEQ ID In sequence ID No. 45, X5 is R, X6 is V, and X7 is D; and in sequence ID No. 46, X8 is S. In some modalities, in sequence ID No. 44, X1 is N, X2 is E, X3 is Q, and X4 is G; in sequence ID In sequence ID No. 45, X5 is R, X6 is V, and X7 is D; and in sequence ID No. 46, X8 is T. In some modalities, in sequence ID No. 44, X1 is N, X2 is E, X3 is Q, and X4 is G; in sequence ID In sequence ID No. 45, X5 is K, X6 is V, and X7 is D; and in sequence ID No. 46, X8 is S. In some modalities, in sequence ID No. 44, X1 is N, X2 is E, X3 is Q, and X4 is G; in sequence ID In sequence ID No. 45, X5 is K, X6 is V, and X7 is D; and in sequence ID No. 46, X8 is T. In some modalities, in sequence ID No. 44, X1 is N, X2 is E, X3 is Q, and X4 is G; in sequence ID In sequence ID No. 45, X5 is R, X6 is L, and X7 is N; and in sequence ID No. 46, X8 is S. In some modalities, in sequence ID No. 44, X1 is N, X2 is E, X3 is Q, and X4 is G; in sequence ID In sequence ID No. 45, X5 is R, X6 is L, and X7 is N; and in sequence ID No. 46, X8 is T. In some modalities, in sequence ID No. 44, X1 is N, X2 is Q, X3 is Q, and X4 is G; in sequence ID In sequence ID No. 45, X5 is R, X6 is V, and X7 is D; and in sequence ID No. 46, X8 is S. In some modalities, in sequence ID No. 44, X1 is N, X2 is Q, X3 is Q, and X4 is G; in sequence ID Petition 870260065905, dated 03 / 07 / 2026, page 162 / 1400 159 / 650 In sequence ID No. 45, X5 is R, X6 is V, and X7 is D; and in sequence ID No. 46, X8 is T. In some modalities, in sequence ID No. 44, X1 is N, X2 is Q, X3 is Q, and X4 is G; in sequence ID In sequence ID No. 45, X5 is K, X6 is V, and X7 is D; and in sequence ID No. 46, X8 is S. In some modalities, in sequence ID No. 44, X1 is N, X2 is Q, X3 is Q, and X4 is G; in sequence ID In sequence ID No. 45, X5 is K, X6 is V, and X7 is D; and in sequence ID No. 46, X8 is T. In some modalities, in sequence ID No. 44, X1 is N, X2 is Q, X3 is Q, and X4 is G; in sequence ID In sequence ID No. 45, X5 is R, X6 is L, and X7 is N; and in sequence ID No. 46, X8 is S. In some modalities, in sequence ID No. 44, X1 is N, X2 is Q, X3 is Q, and X4 is G; in sequence ID In sequence ID No. 45, X5 is R, X6 is L, and X7 is N; and in sequence ID No. 46, X8 is T. In some modalities, in sequence ID No. 44, X1 is N, X2 is Q, X3 is E, and X4 is G; in sequence ID In sequence ID No. 45, X5 is R, X6 is V, and X7 is D; and in sequence ID No. 46, X8 is S. In some modalities, in sequence ID No. 44, X1 is N, X2 is Q, X3 is E, and X4 is G; in sequence ID In sequence ID No. 45, X5 is R, X6 is V, and X7 is D; and in sequence ID No. 46, X8 is T. In some modalities, in sequence ID No. 44, X1 is N, X2 is Q, X3 is E, and X4 is G; in sequence ID In sequence ID No. 45, X5 is K, X6 is V, and X7 is D; and in sequence ID No. 46, X8 is S. In some modalities, in sequence ID No. 44, X1 is N, X2 is Q, X3 is E, and X4 is G; in sequence ID In sequence ID No. 45, X5 is K, X6 is V, and X7 is D; and in sequence ID No. 46, X8 is T. In some modalities, in sequence ID No. 44, X1 is N, X2 is Q, X3 is E, and X4 is G; in sequence ID In sequence ID No. 45, X5 is R, X6 is L, and X7 is N; and in sequence ID No. 46, X8 is S. In some modalities, in sequence ID No. 44, X1 is N, X2 is Q, X3 is E, and X4 is G; in sequence ID In sequence ID No. 45, X5 is R, X6 is L, and X7 is N; and in sequence ID No. 46, X8 is T. In some modalities, in sequence ID No. 44, X1 is N, X2 is Q, X3 is E, and X4 is D; in sequence ID No. 45, X5 is R, X6 is V, and X7 is D; and in SEQ ID NO: 46, X8 is S. In some modalities, in SEQ ID NO: 44, X1 is N, X2 is Q, X3 is E, and X4 is D; in SEQ ID NO: 45, X5 is R, X6 is V, and X7 is D; and in SEQ ID NO: 46, X8 is T. In some modalities, in SEQ ID NO: 44, X1 is N, X2 is Q, X3 is E, and X4 is D; in SEQ ID NO: In some modes, in SEQ ID NO: 44, X1 is N, X2 is Q, X3 is E, and X4 is D; in SEQ ID NO: 45, X5 is R, X6 is L, and X7 is N; and in SEQ ID NO: 46, X8 is S. In some modes, in SEQ ID NO: 44, X1 is N, X2 is Q, X3 is E, and X4 is D; in SEQ ID NO: 45, X5 is R, X6 is L, and X7 is N; and in SEQ ID NO: 46, X8 is S. Petition 870260065905, dated 03 / 07 / 2026, page 163 / 1400 160 / 650 45, X5 is R, X6 is L and X7 is N; and in SEQ ID NO: 46, X8 is T.

[0239] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 22, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 34, light chain CDR2 (LCDR2) comprising SEQ ID NO: 35 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the Kabat numbering system.

[0240] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 23, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 34, light chain CDR2 (LCDR2) comprising SEQ ID NO: 35 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the Kabat numbering system.

[0241] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 24, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 34, light chain CDR2 (LCDR2) comprising SEQ ID NO: 35 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the numbering system Petition 870260065905, dated 03 / 07 / 2026, page 164 / 1400 161 / 650 Kabat.

[0242] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 25, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 34, light chain CDR2 (LCDR2) comprising SEQ ID NO: 35 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the Kabat numbering system.

[0243] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 26, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 34, light chain CDR2 (LCDR2) comprising SEQ ID NO: 35 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the Kabat numbering system.

[0244] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 22, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 32, light chain CDR2 (LCDR2) comprising SEQ ID NO: 35 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the numbering system Petition 870260065905, dated 03 / 07 / 2026, page 165 / 1400 162 / 650 Kabat.

[0245] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 23, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 32, light chain CDR2 (LCDR2) comprising SEQ ID NO: 35 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the Kabat numbering system.

[0246] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 24, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 32, light chain CDR2 (LCDR2) comprising SEQ ID NO: 35 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the Kabat numbering system.

[0247] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 25, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 32, light chain CDR2 (LCDR2) comprising SEQ ID NO: 35 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the numbering system Petition 870260065905, dated 03 / 07 / 2026, page 166 / 1400 163 / 650 Kabat.

[0248] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 26, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 32, light chain CDR2 (LCDR2) comprising SEQ ID NO: 35 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the Kabat numbering system.

[0249] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 22, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 33, light chain CDR2 (LCDR2) comprising SEQ ID NO: 35 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the Kabat numbering system.

[0250] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 23, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 33, light chain CDR2 (LCDR2) comprising SEQ ID NO: 35 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the numbering system Petition 870260065905, dated 03 / 07 / 2026, page 167 / 1400 164 / 650 Kabat.

[0251] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 24, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 33, light chain CDR2 (LCDR2) comprising SEQ ID NO: 35 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the Kabat numbering system.

[0252] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 25, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 33, light chain CDR2 (LCDR2) comprising SEQ ID NO: 35 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the Kabat numbering system.

[0253] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 26, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 33, light chain CDR2 (LCDR2) comprising SEQ ID NO: 35 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the numbering system Petition 870260065905, dated 03 / 07 / 2026, page 168 / 1400 165 / 650 Kabat.

[0254] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 22, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 34, light chain CDR2 (LCDR2) comprising SEQ ID NO: 36 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the Kabat numbering system.

[0255] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 23, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 34, light chain CDR2 (LCDR2) comprising SEQ ID NO: 36 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the Kabat numbering system.

[0256] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 24, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 34, light chain CDR2 (LCDR2) comprising SEQ ID NO: 36 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the numbering system Petition 870260065905, dated 03 / 07 / 2026, page 169 / 1400 166 / 650 Kabat.

[0257] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 25, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 34, light chain CDR2 (LCDR2) comprising SEQ ID NO: 36 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the Kabat numbering system.

[0258] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 26, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 34, light chain CDR2 (LCDR2) comprising SEQ ID NO: 36 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the Kabat numbering system.

[0259] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 22, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 32, light chain CDR2 (LCDR2) comprising SEQ ID NO: 36 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the numbering system Petition 870260065905, dated 03 / 07 / 2026, pages 170 / 1400 167 / 650 Kabat.

[0260] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 23, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 32, light chain CDR2 (LCDR2) comprising SEQ ID NO: 36 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the Kabat numbering system.

[0261] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 24, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 32, light chain CDR2 (LCDR2) comprising SEQ ID NO: 36 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the Kabat numbering system.

[0262] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 25, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 32, light chain CDR2 (LCDR2) comprising SEQ ID NO: 36 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the numbering system Petition 870260065905, dated 03 / 07 / 2026, page 171 / 1400 168 / 650 Kabat.

[0263] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 26, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 32, light chain CDR2 (LCDR2) comprising SEQ ID NO: 36 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the Kabat numbering system.

[0264] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 22, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 33, light chain CDR2 (LCDR2) comprising SEQ ID NO: 36 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the Kabat numbering system.

[0265] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 23, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 33, light chain CDR2 (LCDR2) comprising SEQ ID NO: 36 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the numbering system Petition 870260065905, dated 03 / 07 / 2026, page 172 / 1400 169 / 650 Kabat.

[0266] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 24, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 33, light chain CDR2 (LCDR2) comprising SEQ ID NO: 36 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the Kabat numbering system.

[0267] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 21, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 25, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 27; light chain CDR1 (LCDR1) comprising SEQ ID NO: 33, light chain CDR2 (LCDR2) comprising SEQ ID NO: 36 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the Kabat numbering system.

[0268] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 28, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 29, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 30; light chain CDR1 (LCDR1) comprising SEQ ID NO: 38, light chain CDR2 (LCDR2) comprising SEQ ID NO: 39 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the numbering system Petition 870260065905, dated 03 / 07 / 2026, page 173 / 1400 170 / 650 IMGT (International ImMunoGeneTics Information System (IMGT®)).

[0269] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises three heavy chain CDRs and three light chain CDRs as follows: heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 28, heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 29, heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 31; light chain CDR1 (LCDR1) comprising SEQ ID NO: 38, light chain CDR2 (LCDR2) comprising SEQ ID NO: 39 and light chain CDR3 (LCDR3) comprising SEQ ID NO: 37, as defined by the IMGT numbering system.

[0270] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region of SEQ ID NO: 42, wherein SEQ ID NO: 42 comprises the amino acid sequence: EVQLVQSGAEVKKPGATVKISCKX9SGYTFTEYTIHWVQQAPGK GLEWX10GNINPNNGGTTYX11X12KFX13X14RVTITX15DX16STX17TAYMELSSLR SEDTAVYYCAX18GWNFDYWGQGTLLTVSS where X9 is V or T, X10 is M or I, X11 is A or N, X12 is E or Q, X13 is Q or E, X14 is G or D, X15 is A or V, X16 is T or K, X17 is D or S, and X18 is T or A. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable light chain region of SEQ ID NO: 43, wherein SEQ ID NO: 43 comprises the amino acid sequence: DIQMTQSPSSLSASVGDRVTITCX19ASQDVGTAX20X21WYQQKP GKAPKLLIYWASTRHX22GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYN SYPLTFGQGTKLEIK where X19 is R or K, X20 is L or V, X21 is N or D, and X22 is S or T. In some embodiments, the antibody or antigen-binding fragment comprises a variable heavy chain region with SEQ ID NO: 42 and a Petition 870260065905, dated 03 / 07 / 2026, p. 174 / 1400 171 / 650 variable light chain region of SEQ ID NO: 43, where X9 is V or T, X10 is M or I, X11 is A or N, X12 is E or Q, X13 is Q or E, X14 is G or D, X15 is A or V, X16 is T or K, X17 is D or S, X18 is T or A, X19 is R or K, X20 is L or V, X21 is N or D and X22 is S or T.

[0271] In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is A, X12 is E, X13 is Q, X14 is G, X15 is A, X16 is T, X17 is D and / or X18 is T. In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is E, X13 is Q, X14 is G, X15 is A, X16 is T, X17 is D and / or X18 is T. In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is Q, X14 is G, X15 is A, X16 is T, X17 is D and / or X18 is T. In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is G, X15 is A, X16 is T, X17 is D and / or X18 is T. In some modalities, in SEQ ID NO: 42, X9 is T, X10 is I, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is D and / or X18 is A. In some modalities, in SEQ ID NO: 42, X9 is T, X10 is I, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is K, X17 is S and / or X18 is A. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is I, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is K, X17 is D and / or X18 is A. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is K, X17 is D and / or X18 is A. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is S and / or X18 is T. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is K, X17 is D and / or X18 is T. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is V, X16 is T, X17 is D and / or X18 is T. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is I, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is D and / or X18 is T. In some modalities, in SEQ ID NO: 42, X9 is T, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is D and / or X18 is T. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is D and / or X18 is T. In some modalities, in SEQ ID NO: 43, X19 is K, X20 is V, X21 is D and / or X22 is T. In some modalities, in SEQ ID NO: 43, X19 is R, X20 is V, X21 is D Petition 870260065905, dated 03 / 07 / 2026, p. 175 / 1400 172 / 650 and / or X22 is T. In some modalities, in SEQ ID NO: 43, X19 is R, X20 is L, X21 is N and / or X22 is T. In some modalities, in SEQ ID NO: 43, X19 is K, X20 is V, X21 is D and / or X22 is S. In some modalities, in SEQ ID NO: 43, X19 is R, X20 is V, X21 is D and / or X22 is S. In some modalities, in SEQ ID NO: 43, X19 is R, X20 is L, X21 is N and / or X22 is S.

[0272] In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is A, X12 is E, X13 is Q, X14 is G, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is K, X20 is V, X21 is D and X22 is T. In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is A, X12 is E, X13 is Q, X14 is G, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is V, X21 is D and X22 is T. In some modes, in SEQ ID NO: 42, X9 is V, In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is A, X12 is E, X13 is Q, X14 is G, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is L, X21 is N and X22 is T. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is A, X12 is E, X13 is Q, X14 is G, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is K, X20 is V, X21 is D and X22 is S. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is A, X12 is E, X13 is Q, X14 is G, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43,In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is A, X12 is E, X13 is Q, X14 is G, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is L, X21 is N and X22 is S. In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is E, X13 is Q, X14 is G, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is K, X20 is V, X21 is D and X22 is T. In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is E, X13 is Q, X14 is G, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is V, X21 is D and X22 is T. A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is K, X20 is V, Petition 870260065905, dated 03 / 07 / 2026, page 176 / 1400 173 / 650 In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is E, X13 is Q, X14 is G, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is V, X21 is D and X22 is S. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is E, X13 is Q, X14 is G, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is L, X21 is N and X22 is S. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is Q, X14 is G, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X16é T, X17é D and X18é In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is Q, X14 is G, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is L, X21 is N and X22 is T. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is Q, X14 is G, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is K, X20 is V, X21 is D and X22 is S. In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is G, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is K, X20 is V, X21 is D and X22 is T. In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is G, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is V, X21 is D and X22 is T. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is G, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is L, X21 is N and X22 is T.In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is G, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is K, X20 is V, X21 is D and X22 is S. In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is G, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is V,. Petition 870260065905, dated 03 / 07 / 2026, page 177 / 1400 174 / 650 X21 is D and X22 is S. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is G, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is L, X21 is N and X22 is S. In some modalities, in SEQ ID NO: 42, X9 is T, X10 is I, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is D and X18 is A, and in SEQ ID NO: 43, X19 is K, X20 is V, X21 is D and X22 is T. In some modalities, in SEQ ID NO: 42, In some modalities, in SEQ ID NO: 42, X9é T, X10é I, X11é N, X12é Q, X13é E, X14é D, X15é A, X16é T, X17é D and X18é A, and in SEQ ID NO: 43, X19é R, X20é V, X21é D and X22é T. E, X14 is D, X15 is A, X16 is T, X17 is D and X18 is A, and in SEQ ID NO: 43,In some modes, in SEQ ID NO: 42, X9 is T, X10 is I, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is D and X18 is A, and in SEQ ID NO: 43, X19 is... In some modes, in SEQ ID NO: 42, X9 is T, X10 is I, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is D, and X18 is A, and in SEQ ID NO: 43, X19 is R, X20 is L, X21 is N, and X22 is S. In some modes, in SEQ ID NO: 42, X9 is T, X10 is I, X11 is N, X12 is Q, X13 is E, X14 is In some modalities, in the SEQ ID NO: 42, X9 is T, X10 is I, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is K, X17 is S and X18 is A, and in the SEQ ID NO: 43, X19 is R, X20 is V, X21 is D and X22 is T. In some modalities, in the SEQ ID NO: 42, X9 is T, X10 is I, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is K, X17 is S and X18 is A, and in the SEQ ID NO: 43, X19 is R, X20 is L, X21 is N, and X22 is T. In some modalities, in SEQ ID NO: 42, X9 is T, X10 is I, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is K, X17 is S, and X18 is A, and in SEQ ID NO: 43, X19 is K, X20 is V, X21 is D, and X22 is S. In some modalities, in SEQ ID NO: 42, X9 is T, X10 is I, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is K, X17 is S, and X18 is A, and in SEQ ID NO: 43, X19 is R, X20 is V, X21 is D, and X22 is S. In some modalities, in SEQ ID NO: 42, X9 is T, X10 is I, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 Petition 870260065905, dated 03 / 07 / 2026, page 178 / 1400 175 / 650 is K, X17 is S and X18 is A, and in SEQ ID NO: 43, X19 is R, X20 is L, X21 is N and X22 is S. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is I, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is K, X17 is D and X18 is A, and in SEQ ID NO: 43, X19 is In some modalities, in SEQ ID NO: 42, X9 is V, X10 is I, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is K, X17 is D, and X18 is A, and in SEQ ID NO: 43, X19 is R, X20 is V, X21 is D, and X22 is T. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is I, X11 is N, X12 is Q, X13 is E, X14 is In some modalities, in the SEQ ID NO: 42, X9é V, X10é I, X11é N, X12é Q, X13é E, X14é D, X15é A, X16é K, X17é D and X18é A, and in the SEQ ID NO: 43, X19é K, X20é V, X21é D and X22é S. In some modalities, in the SEQ ID NO: 42, X9é V, X10é I, X11é N, X12é Q, X13é E, X14é D, X15é A, X16é K, X17é D and X18é A, and in the SEQ ID NO: 43, X19 is R, X20 is V, X21 is D, and X22 is S. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is I, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is K, X17 is D, and X18 is A, and in SEQ ID NO: 43, X19 is R, X20 is L, X21 is N, and X22 is S. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is K, X17 is D, and X18 is A, and in SEQ ID NO: 43, X19 is K, X20 is V, X21 is D, and X22 is T. In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is K, X17 is D and X18 is A, and in SEQ ID NO: 43, X19 is R, X20 is V, X21 is D and X22 is T.In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is K, X17 is D and X18 is A, and in SEQ ID NO: 43, X19 is R, X20 is L, X21 is N and X22 is T. In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is K, X17 is D and X18 is A, and in SEQ ID NO: 43, X19 is K, X20 is V, X21 is D and X22 is S. In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, In some modalities, in the SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is K, X17 is D and X18 is A, and in the SEQ ID NO: 43, X19 is R, X20 is V, X21 is D and X22 is S. Petition 870260065905, dated 03 / 07 / 2026, page 179 / 1400 176 / 650 in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is S and X18 is T, and in SEQ ID NO: 43, X19 is K, X20 is V, X21 is D and X22 is T. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is S and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is V, X21 is D and X22 is T. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is S and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is L, X21 is N and X22 is T. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is S and X18 is T, and in SEQ ID NO: 43, X19 is K, X20 is V, X21 is D and X22 is S. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is S and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is V, X21 is D andIn some modes, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is S and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is L, X21 is N and X22 is S. In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is K, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is K, X20 is V, X21 is D and X22 is T. In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is K, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is V, X21 is D and X22 is T. A, X16 is K, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is K, X20 is V, X21 is D andIn some modes, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is K, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is V, X21 is D and X22 is S. In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is K, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is L, X21 is N and X22 is S. In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is V, X16 is T, X17 is D and Petition 870260065905, dated 03 / 07 / 2026, pages 180 / 1400 177 / 650 in SEQ ID NO: 43, X19 is K, X20 is V, X21 is D and X22 is T. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is V, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is V, X21 is D and X22 is T. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is V, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is L, X21 is N and X22 is T. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is V, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is K, X20 is V, X21 is D and X22 is S. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is V, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is V, X21 is D and X22 is S. In some modalities, in SEQ ID NO: 42, X9é V, X10é M, X11é N, X12é Q, X13é E, X14é D, X15é V,In some modes, in SEQ ID NO: 42, X9 is V, X10 is I, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is K, X20 is V, X21 is D and X22 is T. In some modes, in SEQ ID NO: 42, X9 is V, X10 is I, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is V, X21 is D and X22 is T. In some modes, in SEQ ID NO: 42, X9 is V, X10 is I, In some modes, in SEQ ID NO: 42, X9 is V, X10 is I, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is L, X21 is N and X22 is T. In some modes, in SEQ ID NO: 42, X9 is V, X10 is I, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is K, X20 is V, X21 is D and X22 is S. In some modes, in SEQ ID NO: 42, X9 is V, X10 is I, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16é T, X17é D and X18é T, and in SEQ ID NO: 43, X19é R, X20é V,In some modes, in SEQ ID NO: 42, X9 is V, X10 is I, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is L, X21 is N and X22 is S. In some modes, in SEQ ID NO: 42, X9 is T, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is K, X20 is V, X21 is D and X22 is T. In some modes, in SEQ ID NO: 42, X9 is T, X10 is M,. Petition 870260065905, dated 03 / 07 / 2026, pp. 181 / 1400 178 / 650 In some modalities, in SEQ ID NO: 42, X9 is T, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is V, X21 is D and X22 is T. In some modes, in SEQ ID NO: 42, X9 is T, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is V, X21 is D and X22 is S. In some modes, in SEQ ID NO: 42, X9 is T, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is L, X21 is N and X22 is S. In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is K, X20 is V, X21 is D and X22 is T.In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is V, X21 is D and X22 is T. In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is L, X21 is N and X22 is T. In some modes, in SEQ ID NO: 42, X9 is V, X10 is M, In some modalities, in SEQ ID NO: 42, X9 is V, X10 is M, X11 is N, X12 is Q, X13 is E, X14 is D, X15 is A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is K, X20 is V, X21 is D and X22 is S. A, X16 is T, X17 is D and X18 is T, and in SEQ ID NO: 43, X19 is R, X20 is L,

[0273] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 1 and a variable chain region. Petition 870260065905, dated 03 / 07 / 2026, page 182 / 1400 179 / 650 light comprising the amino acid sequence of SEQ ID NO: 15. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 1 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 16. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 1 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 17.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 1 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 1 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 19. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 1 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 20.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 2 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 15. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a region. Petition 870260065905, dated 03 / 07 / 2026, page 183 / 1400 180 / 650 variable heavy chain comprising the amino acid sequence of SEQ ID NO: 2 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 16. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 2 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 17. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 2 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 18.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 2 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 19. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 2 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 20. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 3 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 15.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence SEQ ID NO: 3 and a variable light chain region comprising the amino acid sequence SEQ ID NO: 16. In some embodiments, an anti-PSMA antibody... Petition 870260065905, dated 03 / 07 / 2026, p. 184 / 1400 181 / 650 PSMA or an antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 3 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 17. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 3 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 3 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 19.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 3 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 20. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 4 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 15. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 4 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 16.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 4 and a variable chain region. Petition 870260065905, dated 03 / 07 / 2026, page 185 / 1400 182 / 650 light comprising the amino acid sequence of SEQ ID NO: 17. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 4 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 4 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 19.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 4 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 20. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 5 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 15. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 5 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 16.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 5 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 17. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a region. Petition 870260065905, dated 03 / 07 / 2026, page 186 / 1400 183 / 650 variable heavy chain comprising the amino acid sequence of SEQ ID NO: 5 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 5 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 19. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 5 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 20.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 6 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 15. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 6 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 16. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 6 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 17.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence SEQ ID NO: 6 and a variable light chain region comprising the amino acid sequence SEQ ID NO: 18. In some embodiments, an anti-PSMA antibody... Petition 870260065905, dated 03 / 07 / 2026, p. 187 / 1400 184 / 650 PSMA or an antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 6 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 19. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 6 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 20. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 7 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 15.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 7 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 16. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 7 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 17. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 7 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 18.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 7 and a variable chain region. Petition 870260065905, dated 03 / 07 / 2026, page 188 / 1400 185 / 650 light comprising the amino acid sequence of SEQ ID NO: 19. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 7 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 20. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 8 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 15.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 8 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 16. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 8 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 17. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 8 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 18.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 8 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 19. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a region. Petition 870260065905, dated 03 / 07 / 2026, page 189 / 1400 186 / 650 heavy chain variable comprising the amino acid sequence of SEQ ID NO: 8 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 20. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 9 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 15. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 9 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 16.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 9 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 17. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 9 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 9 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 19.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence SEQ ID NO: 9 and a variable light chain region comprising the amino acid sequence SEQ ID NO: 20. In some embodiments, an anti-PSMA antibody... Petition 870260065905, dated 03 / 07 / 2026, pp. 190 / 1400 187 / 650 PSMA or an antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 10 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 15. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 10 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 16. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 10 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 17.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 10 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 10 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 19. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 10 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 20.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 11 and a variable chain region. Petition 870260065905, dated 03 / 07 / 2026, page 191 / 1400 188 / 650 light chain comprising the amino acid sequence of SEQ ID NO: 15. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 11 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 16. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 11 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 17.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 11 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 11 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 19. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 11 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 20.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 12 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 15. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a region. Petition 870260065905, dated 03 / 07 / 2026, page 192 / 1400 189 / 650 heavy chain variable comprising the amino acid sequence of SEQ ID NO: 12 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 16. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 12 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 17. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 12 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 18.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 12 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 19. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 12 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 20. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 13 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 15.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence SEQ ID NO: 13 and a variable light chain region comprising the amino acid sequence SEQ ID NO: 16. In some embodiments, an anti-PSMA antibody... Petition 870260065905, dated 03 / 07 / 2026, p. 193 / 1400 190 / 650 PSMA or an antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 13 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 17. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 13 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 13 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 19.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 13 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 20. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 14 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 15. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 14 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 16.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 14 and a variable chain region. Petition 870260065905, dated 03 / 07 / 2026, page 194 / 1400 191 / 650 light chain comprising the amino acid sequence of SEQ ID NO: 17. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 14 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 14 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 19.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 14 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 20.

[0274] In some embodiments, the anti-PSMA antibody or antigen-binding fragment thereof comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 7 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-PSMA antibody or antigen-binding fragment thereof comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 8 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-PSMA antibody or antigen-binding fragment thereof comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 9 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 15.In some embodiments, the anti-PSMA antibody or antigen-binding fragment thereof comprises a variable heavy chain region comprising the amino acid sequence of the SEQ. Petition 870260065905, dated 03 / 07 / 2026, page 195 / 1400 192 / 650 ID NO: 10 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 15.

[0275] In some embodiments, the anti-PSMA antibody or antigen-binding fragment thereof comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 1 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-PSMA antibody or antigen-binding fragment thereof comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 2 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-PSMA antibody or antigen-binding fragment thereof comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 3 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 15.In some embodiments, the anti-PSMA antibody or antigen-binding fragment thereof comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 14 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 15.

[0276] In some embodiments, the anti-PSMA antibody or antigen-binding fragment thereof comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 14 and a variable light chain region comprising the amino acid sequence of SEQ ID NO: 19.

[0277] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region with at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or Petition 870260065905, dated 03 / 07 / 2026, page 196 / 1400 193 / 650 at least 99% identity with SEQ ID NO: 1. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region with at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with SEQ ID NO: 2. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region with at least 85%, at least 86%, at least 87 %, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% matching SEQ ID NO: 3.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region with at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with SEQ ID NO: 14. In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable light chain region with at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, or at least 99% identity with SEQ ID NO: 14. less than 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% match with SEQ ID NO: 15.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable light chain region with at least 85%, at least 86%, at least 87%, at least 88%, at least 89%,. Petition 870260065905, dated 03 / 07 / 2026, page 197 / 1400 194 / 650 at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% match with SEQ ID NO: 19.

[0278] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region with at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with SEQ ID NO: 40 (i.e., does not share 100% identity with SEQ ID NO: 40), wherein the anti-PSMA antibody or antigen-binding fragment provides enhanced properties over other anti-PSMA antibodies, for example, J591 and / or J591.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable light chain region with at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with SEQ ID NO: 41 (i.e., does not share 100% identity with SEQ ID NO: 41), wherein the anti-PSMA antibody or antigen-binding fragment provides enhanced properties over other anti-PSMA antibodies, for example, J591 and / or J591.In some embodiments, the anti-PSMA antibody or antigen-binding fragment comprises a variable heavy chain region with at least 86% identity to SEQ ID NO: 40 and a variable light chain region with at least 87% identity to SEQ ID NO: 41 (but not 100% identity to either variable region), wherein the anti-PSMA antibody or antigen-binding fragment provides enhanced properties over other anti-PSMA antibodies, for example, J591 and / or J591. The enhanced properties may include... Petition 870260065905, dated 03 / 07 / 2026, page 198 / 1400 195 / 650 superior stability and / or less immunogenicity.

[0279] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region with at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to SEQ ID NO: 40, wherein the anti-PSMA antibody or antigen-binding fragment comprises at least the following amino acids that differ from SEQ ID NO: 40: Table 13 Position relative to SEQ ID NO: 40 Amino acid 9 A 38 Q 67 R 68 V 70 I 111 V where the anti-PSMA antibody or antigen-binding fragment provides improved properties over other anti-PSMA antibodies, for example, J591 and / or J591. The improved properties may include superior stability and / or less immunogenicity. The position relative to SEQ ID NO: 40 is determined by aligning the variable heavy chain region of the anti-PSMA antibody or antigen-binding fragment with SEQ ID NO: 40, optionally using the BLAST algorithm, then counting the amino acid position starting from the N-terminus of the aligned sequences.

[0280] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises the variable light chain region with at least 85%, Petition 870260065905, dated 03 / 07 / 2026, page 199 / 1400 196 / 650 at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with SEQ ID NO: 41, wherein the anti-PSMA antibody or antigen-binding fragment comprises at least the following amino acids that differ from SEQ ID NO: 41: Table 14 Position in relation to SEQ ID NO: 41 Amino acid 13 A 21 I 42 K 43 A 58 V 85 T 100 Q 104 L 105 E where the anti-PSMA antibody or antigen-binding fragment provides improved properties over other anti-PSMA antibodies, for example, J591 and / or J591. The improved properties may include superior stability and / or less immunogenicity. The position relative to SEQ ID NO: 41 is determined by aligning the variable heavy chain region of the anti-PSMA antibody or antigen-binding fragment with SEQ ID NO: 41, optionally using the BLAST algorithm, then counting the amino acid position starting from the N-terminus of the aligned sequences.

[0281] In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable heavy chain region with at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least Petition 870260065905, dated 03 / 07 / 2026, page 200 / 1400 197 / 650%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with SEQ ID NO: 42, wherein the anti-PSMA antibody or antigen-binding fragment provides enhanced properties over other anti-PSMA antibodies, for example, J591 and / or J591.In some embodiments, an anti-PSMA antibody or antigen-binding fragment thereof provided herein comprises a variable light chain region with at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with SEQ ID NO: 43, wherein the anti-PSMA antibody or antigen-binding fragment provides enhanced properties over other anti-PSMA antibodies, for example, J591 and / or J591. The anti-PSMA antibody or antigen-binding fragment does not comprise a variable heavy chain region with 100% identity to SEQ ID NO: 40 and a variable light chain region with 100% identity to SEQ ID NO: 41. Improved properties may include superior stability and / or less immunogenicity.

[0282] In several embodiments, any of the anti-PSMA antibodies disclosed in this document may comprise a human IgG1 Fc domain. In some embodiments, an anti-PSMA antibody comprises a human IgG1 Fc domain that is modified to reduce binding to an FcyR compared to an antibody containing an IgG1 Fc domain with a wild-type IgG1 Fc domain. In some embodiments, the anti-PSMA antibodies comprise a mutated human IgG1 Fc domain comprising one or more (e.g., all) modifications of L234A, L235A, P238S, H268Q, and K274Q to a human IgG1 heavy chain constant domain.

[0283] In various forms, anti-PSMA antibodies Petition 870260065905, dated 03 / 07 / 2026, p. 201 / 1400 198 / 650 comprise a constant region of human Ig kappa light chain. In several embodiments, anti-PSMA antibodies comprise a constant region of human Ig lambda light chain.

[0284] In some embodiments, an anti-PSMA antibody provided herein comprises a heavy chain comprising an amino acid sequence selected from SEQ ID NOs: 47-60, and a light chain comprising an amino acid sequence selected from SEQ ID NOs: 61-66.

[0285] In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 47 and the light chain amino acid sequence of SEQ ID NO: 61. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 47 and the light chain amino acid sequence of SEQ ID NO: 62. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 47 and the light chain amino acid sequence of SEQ ID NO: 63. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 47 and the light chain amino acid sequence of SEQ ID NO: 64. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 47 and the light chain amino acid sequence of SEQ ID NO: 65.In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 47 and the light chain amino acid sequence of SEQ ID NO: 66. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 48 and the light chain amino acid sequence of SEQ ID NO: 61. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 48 and the light chain amino acid sequence of SEQ ID NO: 62. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 48. Petition 870260065905, dated 03 / 07 / 2026, p. 202 / 1400 199 / 650 and the light chain amino acid sequence of SEQ ID NO: 63. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 48 and the light chain amino acid sequence of SEQ ID NO: 64. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 48 and the light chain amino acid sequence of SEQ ID NO: 65. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 48 and the light chain amino acid sequence of SEQ ID NO: 66. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 49 and the light chain amino acid sequence of SEQ ID NO: 61. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 49 and the amino acid sequence of SEQ ID NO: 61. light chain amino acids with SEQ ID NO: 62.In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 49 and the light chain amino acid sequence of SEQ ID NO: 63. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 49 and the light chain amino acid sequence of SEQ ID NO: 64. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 49 and the light chain amino acid sequence of SEQ ID NO: 65. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 49 and the light chain amino acid sequence of SEQ ID NO: 66. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 50 and the light chain amino acid sequence of SEQ ID NO: 61.In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 50 and the light chain amino acid sequence of SEQ ID NO: 62. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 50. Petition 870260065905, dated 03 / 07 / 2026, p. 203 / 1400 200 / 650 and the light chain amino acid sequence of SEQ ID NO: 63. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 50 and the light chain amino acid sequence of SEQ ID NO: 64. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 50 and the light chain amino acid sequence of SEQ ID NO: 65. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 50 and the light chain amino acid sequence of SEQ ID NO: 66. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 51 and the light chain amino acid sequence of SEQ ID NO: 61. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 51 and the amino acid sequence of SEQ ID NO: 61. light chain amino acids with SEQ ID NO: 62.In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 51 and the light chain amino acid sequence of SEQ ID NO: 63. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 51 and the light chain amino acid sequence of SEQ ID NO: 64. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 51 and the light chain amino acid sequence of SEQ ID NO: 65. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 51 and the light chain amino acid sequence of SEQ ID NO: 66. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 52 and the light chain amino acid sequence of SEQ ID NO: 61.In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 52 and the light chain amino acid sequence of SEQ ID NO: 62. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 52. Petition 870260065905, dated 03 / 07 / 2026, p. 204 / 1400 201 / 650 and the light chain amino acid sequence of SEQ ID NO: 63. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 52 and the light chain amino acid sequence of SEQ ID NO: 64. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 52 and the light chain amino acid sequence of SEQ ID NO: 65. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 52 and the light chain amino acid sequence of SEQ ID NO: 66. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 53 and the light chain amino acid sequence of SEQ ID NO: 61. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 53 and the amino acid sequence of SEQ ID NO: 61. light chain amino acids with SEQ ID NO: 62.In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 53 and the light chain amino acid sequence of SEQ ID NO: 63. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 53 and the light chain amino acid sequence of SEQ ID NO: 64. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 53 and the light chain amino acid sequence of SEQ ID NO: 65. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 53 and the light chain amino acid sequence of SEQ ID NO: 66. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 54 and the light chain amino acid sequence of SEQ ID NO: 61.In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 54 and the light chain amino acid sequence of SEQ ID NO: 62. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 54. Petition 870260065905, dated 03 / 07 / 2026, p. 205 / 1400 202 / 650 and the light chain amino acid sequence of SEQ ID NO: 63. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 54 and the light chain amino acid sequence of SEQ ID NO: 64. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 54 and the light chain amino acid sequence of SEQ ID NO: 65. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 54 and the light chain amino acid sequence of SEQ ID NO: 66. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 55 and the light chain amino acid sequence of SEQ ID NO: 61. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 55 and the amino acid sequence of SEQ ID NO: 61. light chain amino acids with SEQ ID NO: 62.In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 55 and the light chain amino acid sequence of SEQ ID NO: 63. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 55 and the light chain amino acid sequence of SEQ ID NO: 64. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 55 and the light chain amino acid sequence of SEQ ID NO: 65. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 55 and the light chain amino acid sequence of SEQ ID NO: 66. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 56 and the light chain amino acid sequence of SEQ ID NO: 61.In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 56 and the light chain amino acid sequence of SEQ ID NO: 62. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 56. Petition 870260065905, dated 03 / 07 / 2026, p. 206 / 1400 203 / 650 and the light chain amino acid sequence of SEQ ID NO: 63. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 56 and the light chain amino acid sequence of SEQ ID NO: 64. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 56 and the light chain amino acid sequence of SEQ ID NO: 65. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 56 and the light chain amino acid sequence of SEQ ID NO: 66. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 57 and the light chain amino acid sequence of SEQ ID NO: 61. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 57 and the amino acid sequence of SEQ ID NO: 61. light chain amino acids with SEQ ID NO: 62.In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 57 and the light chain amino acid sequence of SEQ ID NO: 63. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 57 and the light chain amino acid sequence of SEQ ID NO: 64. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 57 and the light chain amino acid sequence of SEQ ID NO: 65. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 57 and the light chain amino acid sequence of SEQ ID NO: 66. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 58 and the light chain amino acid sequence of SEQ ID NO: 61.In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 58 and the light chain amino acid sequence of SEQ ID NO: 62. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 58. Petition 870260065905, dated 03 / 07 / 2026, p. 207 / 1400 204 / 650 and the light chain amino acid sequence of SEQ ID NO: 63. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 58 and the light chain amino acid sequence of SEQ ID NO: 64. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 58 and the light chain amino acid sequence of SEQ ID NO: 65. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 58 and the light chain amino acid sequence of SEQ ID NO: 66. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 59 and the light chain amino acid sequence of SEQ ID NO: 61. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 59 and the light chain amino acid sequence of SEQ ID NO: 61. light chain amino acids with SEQ ID NO: 62.In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 59 and the light chain amino acid sequence of SEQ ID NO: 63. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 59 and the light chain amino acid sequence of SEQ ID NO: 64. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 59 and the light chain amino acid sequence of SEQ ID NO: 65. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 59 and the light chain amino acid sequence of SEQ ID NO: 66. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 60 and the light chain amino acid sequence of SEQ ID NO: 61.In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 60 and the light chain amino acid sequence of SEQ ID NO: 62. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 60. Petition 870260065905, dated 03 / 07 / 2026, p. 208 / 1400 205 / 650 and the light chain amino acid sequence of SEQ ID NO: 63. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 60 and the light chain amino acid sequence of SEQ ID NO: 64. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 60 and the light chain amino acid sequence of SEQ ID NO: 65. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 60 and the light chain amino acid sequence of SEQ ID NO: 66.

[0286] In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 47 and the light chain amino acid sequence of SEQ ID NO: 61. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 48 and the light chain amino acid sequence of SEQ ID NO: 61. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 49 and the light chain amino acid sequence of SEQ ID NO: 61. In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 60 and the light chain amino acid sequence of SEQ ID NO: 61.

[0287] In some embodiments, the anti-PSMA antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 60 and the light chain amino acid sequence of SEQ ID NO: 65.

[0288] In any of the antibodies discussed above, the heavy chain amino acid sequence may not have the C-terminal lysine.

[0289] In several embodiments, amino acid substitutions can be made while retaining the binding affinity and / or specificity of an antibody disclosed herein and / or to provide one or more additional beneficial properties, for example, by making one or more changes to the framework, constant domain and / or CDR sequences. In Petition 870260065905, dated 03 / 07 / 2026, p. 209 / 1400 206 / 650 In some embodiments, the substitutions are of single residues. For example, in some embodiments, anti-PSMA antibodies comprise a human IgG1 Fc domain comprising amino acid substitutions to reduce binding to an FcyR compared to an antibody containing an IgG1 Fc domain with a wild-type IgG1 Fc domain. In some embodiments, anti-PSMA antibodies comprise a mutated human IgG1 Fc domain comprising the L234A, L235A, P238S, H268Q, and K274Q substitutions. Insertions will generally be on the order of about 1 to about 20 amino acid residues, although considerably larger insertions may be tolerated as long as biological function is maintained (e.g., binding to a PSMA). Deletions generally range from about 1 to about 20 amino acid residues, although in some cases deletions may be much larger.Substitutions, deletions, insertions, or any combination thereof can be used to arrive at a final derivative or variant. Generally, these changes are made to a few amino acids to minimize alteration of the molecule, particularly the immunogenicity and specificity of the antigen-binding protein. However, larger changes may be tolerated under certain circumstances. Conservative substitutions are generally made according to the following chart shown in Table 15. Table 15. Examples of conservative substitutions Original Residue Exemplary Substitutions Ala Ser Arg Lys Asn Gln, His Asp Glu Cys Ser Gln Asn Glu Asp Petition 870260065905, dated 03 / 07 / 2026, page 210 / 1400 207 / 650 Table 15. Examples of conservative substitutions (continued) Original Residue Exemplary Substitutions Gly Pro His Asn, Gln Ile Leu, Val Leu Ile, Val Lys Arg, Gln, Glu Met Leu, Ile Phe Met, Leu, Tyr Ser Thr Thr Ser Trp Tyr Tyr Trp, Phe Val Ile, Leu

[0290] In various embodiments where variant antibody sequences are used in an ADC, the variants may exhibit the same qualitative biological activity and elicit the same immune response, although the variants may also be selected to modify the characteristics of the antigen-binding proteins as needed. For example, the anti-PSMA antibodies provided in this document may comprise a human IgG1 Fc domain that is mutated to reduce binding to an FcyR compared to an antibody containing IgG1 Fc with a wild-type IgG1 Fc domain. Alternatively, the variant may be engineered so that the biological activity of the antigen-binding protein is altered.

[0291] Any of the anti-PSMA antibodies and antigen-binding fragments disclosed herein may be used as a conjugate, for example, with a detectable agent and / or another therapeutic agent. In some embodiments, the anti-PSMA antibody or fragment of Petition 870260065905, dated 03 / 07 / 2026, p. 211 / 1400 208 / 650 antigen binding can be used in an antibody-drug conjugate (ADC), for example, any of the ADCs disclosed herein, preferably to target the drug in the ADC to a cancer cell. As shown above, the toxin-binding ADCs disclosed herein are surprisingly effective with the anti-PSMA antibodies also disclosed herein. These antibodies can be used with the ligands and toxin (e.g., Compound 1) disclosed herein. Binders

[0292] In several embodiments, the anti-PSMA antibodies and antigen-binding fragments disclosed in this document can be joined to a chemical moiety of a drug (e.g., a cytotoxic payload, e.g., Compound 1) by a linker to create an antibody-drug conjugate (ADC).

[0293] In some embodiments, the ligand in an ADC is sufficiently stable extracellularly to be therapeutically effective. In some embodiments, the ligand is stable outside a cell, so that the ADC remains intact when present under extracellular conditions (e.g., prior to transport or delivery into a cell). The term “intact,” used in the context of an ADC, means that the antibody chemical portion remains attached to the drug chemical portion (e.g., Compound 1).As used in this document, stable, in the context of a ligand or ADC comprising a ligand, means that no more than about 20%, no more than about 15%, no more than about 10%, no more than about 5%, no more than about 3%, or no more than about 1% of the ligands (or any percentage therebetween) in an ADC sample are cleaved (or in the case of an overall ADC not intact) when the ADC is present under extracellular conditions when assessed over a defined period of time. In some embodiments, the ligands in ADCs disclosed in this document are chosen to remain stable for more than about 48 hours. Petition 870260065905, dated 03 / 07 / 2026, p. 212 / 1400 209 / 650 more than about 60 hours, more than about 72 hours, more than about 84 hours, or more than about 96 hours.

[0294] Determining whether a ligand is extracellularly stable can be done, for example, by including an ADC in plasma for a predetermined period of time (e.g., 2, 4, 6, 8, 16, or 24 hours) and then quantifying the amount of free drug moiety present in the plasma. Stability can allow the ADC time to localize to target tumor cells and prevent premature drug release, which could reduce the therapeutic index of the ADC by indiscriminately damaging normal and tumor tissues. In some embodiments, the ligand is stable outside a target cell and releases the drug moiety of the ADC once inside the cell, so that the drug moiety can bind to its target (e.g., STING).Thus, an effective ligand will: (i) maintain the specific binding properties of the antibody chemical portion; (ii) allow distribution, for example, intracellular distribution, of the drug chemical portion through stable binding to the antibody chemical portion; (iii) remain stable and intact until the ADC is transported or delivered to its target site; and (iv) allow the therapeutic effect, for example, cytotoxic effect, of the drug chemical portion after cleavage.

[0295] Ligands can impact the physicochemical properties of an ADC. Since many cytotoxic agents are hydrophobic in nature, their binding to the antibody with an additional hydrophobic chemical portion can lead to aggregation. ADC aggregates are insoluble and often limit the achievable drug loading on the antibody, which can negatively affect the potency of the ADC. Protein aggregates of biological products, in general, have also been associated with increased immunogenicity. As shown below, the ligands disclosed in this document result in ADCs with low levels of aggregation and desirable levels of drug loading. In several embodiments, a ligand is conjugated to the antibody or antigen-binding fragment via a Petition 870260065905, dated 03 / 07 / 2026, p. 213 / 1400 210 / 650 cysteine. In several embodiments, a ligand is conjugated to the antibody or antigen-binding fragment via a lysine. Suitable methods for conjugating ligands of the present disclosure to an antibody include technologies for targeted binding to a lysine in an antibody heavy chain, to a cysteine ​​in an antibody heavy chain, and to a cysteine ​​in an antibody light chain, for example, as disclosed in PCT applications WO 2017 / 213267, WO 2017 / 106643 and WO 2016 / 205618, and in Junutula et al. (2008) Journal of Immunological Methods 332:41-52, all of which are incorporated herein by reference in their entirety. In some embodiments, a ligand is conjugated to the antibody or antigen-binding fragment on the light chain, for example, on a cysteine ​​in the light chain, for example, on cysteine-80 in the light chain.In some embodiments, a ligand is conjugated to the antibody or antigen-binding fragment on the heavy chain, for example, on a cysteine ​​in the heavy chain, for example, on cysteine-118 in the heavy chain.

[0296] A ligand used in this document may be cleavable or non-cleavable (Ducry and Stump, Bioconjugate Chem. (2010) 21:5-13). Cleavable ligands are designed to release the drug when subjected to certain environmental factors, for example, when internalized into the target cell, while non-cleavable ligands generally depend on the degradation of the antibody chemical portion itself.

[0297] In some embodiments, the ligand is a non-cleavable ligand. In some embodiments, the drug chemical portion of the ADC is released by degradation of the antibody chemical portion.

[0298] In some embodiments, the ligand is cleavable. Cleavable ligands are designed to release the drug when subjected to certain environmental factors, for example, when internalized into the target cell. A cleavable ligand refers to any ligand that comprises a cleavable chemical moiety. As used in this document, the term cleavable chemical moiety refers to any chemical bond that can be cleaved. Chemical bonds Petition 870260065905, dated 03 / 07 / 2026, page 214 / 1400 Suitable cleavable linkers are known in the art and include, but are not limited to, labile acid linkages, labile protease / peptidase linkages, photolabile linkages, disulfide linkages, and labile esterase linkages. Linkages comprising a cleavable moiety may allow the release of the drug chemical portion from the ADC via cleavage at a specific site on the linker.

[0299] In some embodiments, the ligand is cleavable under intracellular conditions, such that cleavage of the ligand sufficiently releases the drug chemical portion of the antibody from the antibody chemical portion into the intracellular environment to activate the drug and / or render the drug therapeutically effective. In some embodiments, the drug chemical portion is not cleaved from the antibody chemical portion until the ADC enters a cell expressing an antigen specific to the antibody chemical portion of the ADC, and the drug chemical portion is cleaved from the antibody chemical portion upon entry into the cell. In some embodiments, the ligand comprises a cleavable chemical portion that is positioned such that no part of the ligand or the antibody chemical portion remains bound to the drug chemical portion after cleavage.Examples of cleavable ligands include acid-labile ligands, protease / peptidase-sensitive ligands, photolabile ligands, and ligands containing dimethyl, disulfide, or sulfonamide groups.

[0300] In some embodiments, the linker is cleavable by a cleavage agent, for example, an enzyme, which is present in the intracellular environment (e.g., within a lysosome, endosome, or caveolae). The linker may be, for example, a peptide linker that is cleaved by an intracellular peptidase or protease enzyme, including, but not limited to, a lysosomal or endosomal protease. In some embodiments, the linker is a cleavable peptide linker. As used herein, a cleavable peptide linker refers to any linker comprising a cleavable peptide chemical moiety. The term “cleavable peptide chemical moiety” refers to any chemical bond linking amino acids (derived from natural or synthetic amino acids) that can be cleaved by an agent that is Petition 870260065905, dated 03 / 07 / 2026, page 215 / 1400 212 / 650 present in the intracellular environment. In some embodiments, a cleavable peptide ligand is more stably conjugated with an antibody disclosed in this document compared to an acid-labile ligand.

[0301] In some embodiments, the linker is an enzyme-cleavable linker and a cleavable peptide chemical portion in the linker is cleavable by the enzyme. In some embodiments, the cleavable peptide chemical portion is cleavable by a lysosomal enzyme, for example, cathepsin or legumain (also known as asparaginyl endopeptidase or vacuolar processing enzyme). In some embodiments, the linker is a cathepsin-cleavable linker. In some embodiments, the linker is a legumain-cleavable linker. In some embodiments, the cleavable peptide portion in the ligand is cleavable by a lysosomal cysteine ​​cathepsin, such as cathepsin B, C, F, H, K, L, O, S, V, X, or W. In some embodiments, the cleavable peptide chemical portion is cleavable by cathepsin B. An exemplary dipeptide that can be cleaved by cathepsin B is valine-citrulline (Val-Cit). See, for example, Dubowchik et al. (2002) Bioconjugate Chem. 13:855-69.Another example of a dipeptide that can be cleaved by cathepsin B is valine-alanine (Val-Ala). See, for example, Fu and Ho (2002) Antib. Ther. 1(2):33-43.

[0302] In some embodiments, the cleavable peptide chemical portion in the ligand is cleavable by a lysosomal cysteine ​​endopeptidase, such as legumain. An example monopeptide that can be cleaved by legumain is asparagine (Asn). Another example monopeptide that can be cleaved by legumain is aspartic acid (Asp).

[0303] In some embodiments, the ligand or cleavable peptide chemical portion in the ligand comprises an amino acid unit. In some embodiments, the amino acid unit allows cleavage of the ligand by a protease, thus facilitating the release of the drug chemical portion from the ADC upon exposure to one or more intracellular proteases, such as one or more lysosomal enzymes. See, for example, Doronina et al. (2003) Nat. Biotechnol. 21:778-84; and Dubowchik and Walker (1999) Pharm. Therapeutics Petition 870260065905, dated 03 / 07 / 2026, p. 216 / 1400 213 / 650 83:67-123. Exemplary amino acid units include, but are not limited to, monopeptides, dipeptides, tripeptides, tetrapeptides, and pentapeptides. Exemplary monopeptides include, but are not limited to, asparagine (Asn) and aspartic acid (Asp). Examples of dipeptides include, but are not limited to, valine-citrulline (Val-Cit), alanine-asparagine (Ala-Asn), alanine-phenylalanine (Ala-Phe), phenylalanine-lysine (Phe-Lys), alanine-lysine (AlaLys), alanine-valine (Ala-Val), valine-alanine (Val-Ala), valine-lysine (Val-Lys), lysine-lysine (Lys-Lys), phenylalanine-citrulline (Phe-Cit), leucine-citrulline (Leu-Cit), isoleucine-citrulline (Ile-Cit), tryptophan-citrulline (Trp-Cit), and phenylalanine-alanine (Phe-Ala).Exemplary tripeptides include, but are not limited to, alanine-asparagine (Ala-Ala-Asn), glycine-valine-citrulline (Gly-Val-Cit), glutamic acid-valine-citrulline, glycine-glycine-glycine (Gly-Gly-Gly), phenylalanine-lysine (Phe-Phe-Lys), alanine-phenylalanine-lysine (Ala-Phe-Lys), glycine-valine-alanine (Gly-Val-Ala), and glycine-phenylalanine-lysine (Gly-Phe-Lys). Exemplary tetrapeptides include, but are not limited to, glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly (SEQ ID NO: 141)). Other exemplary amino acid units include, but are not limited to, Gly-Phe-Leu-Gly (SEQ ID NO: 142), Ala-Leu-Ala-Leu (SEQ ID NO: 143), Phe-N9-tosyl-Arg and PheN9-Nitro-Arg, as described in, for example, U.S. Patent No. 6,214,345. In some embodiments, an amino acid unit may comprise amino acid residues comprising at least one methyl group, for example, a monomethyl or dimethyl group.Exemplary amino acid units comprising amino acid residues containing at least one methyl group include, but are not limited to, N-methylated alanine ((NMe)Ala), methylated aspartic acid (Asp(OMe)), and dimethylated lysine (Val-Lys(Me)2). In some embodiments, the amino acid unit in the linker comprises Val-Ala. In some embodiments, the amino acid unit in the linker comprises Val-Cit. An amino acid unit may comprise unnaturally occurring amino acid residues and / or minor amino acids and / or unnaturally occurring amino acid analogs, such as citrulline. The units of... Petition 870260065905, dated 03 / 07 / 2026, p. 217 / 1400 214 / 650 amino acids can be designed and optimized for enzymatic cleavage by a particular enzyme, for example, a tumor-associated protease, a lysosomal protease, such as legumain or cathepsin B, C, D, or S.

[0304] In some embodiments, the linker in an ADC disclosed herein may comprise an antibody-binding chemical moiety. An antibody-binding chemical moiety may be used, for example, to link the antibody chemical moiety to the linker, which, in turn, may bind to the drug chemical moiety, for example, indirectly through a cleavable chemical moiety (e.g., a cleavable peptide).

[0305] In some embodiments, the linker comprises an antibody-binding chemical moiety comprising a maleimide (Mal) chemical moiety. The term maleimide chemical moiety, as used herein, means a compound containing a maleimide group that is reactive with a sulfhydryl group, for example, a sulfhydryl group of a cysteine ​​residue in the antibody chemical moiety. Other functional groups that are reactive with sulfhydryl (thiol) groups and may therefore be used instead of a Mal include, but are not limited to, iodoacetamide, bromoacetamide, vinyl pyridine disulfide, pyridyl disulfide, isocyanate, and isothiocyanate.

[0306] In some embodiments, the ligand binds to the antibody or antigen-binding fragment via a Mal chemical moiety. In some embodiments, the Mal chemical moiety is reactive with a cysteine ​​residue on the antibody or antigen-binding fragment. In some embodiments, the Mal chemical moiety is attached to the antibody or antigen-binding fragment via the cysteine ​​residue.

[0307] In some embodiments, the Mal chemical moiety is a maleimidocaproyl (MC) chemical moiety. In some embodiments, the ligand binds to the antibody or antigen-binding fragment via an MC chemical moiety. In some embodiments, the MC chemical moiety is reactive with a cysteine ​​residue on the antibody or antigen-binding fragment. In some embodiments, the MC chemical moiety is attached to the antibody or Petition 870260065905, dated 03 / 07 / 2026, p. 218 / 1400 215 / 650 antigen-binding fragment via cysteine ​​residue.

[0308] In some embodiments, the linker comprises a Mal chemical moiety and a cleavable peptide chemical moiety. In some embodiments, the cleavable peptide chemical moiety comprises an amino acid unit. In some embodiments, the amino acid unit comprises Val-Cit. In some embodiments, the amino acid unit comprises ValAla. In some embodiments, the Mal chemical moiety links the antibody chemical moiety to the cleavable peptide chemical moiety in the linker. In some embodiments, the cleavable peptide chemical moiety comprises an amino acid unit. In some embodiments, the amino acid unit comprises Val-Cit. In some embodiments, the amino acid unit comprises ValAla. In some embodiments, the linker comprises Mal-Val-Cit. In some embodiments, the linker comprises Mal-Val-Ala.

[0309] In some embodiments, the linker comprises a chemical portion of MC and a chemical portion of cleavable peptide. In some embodiments, the cleavable peptide chemical portion comprises an amino acid unit. In some embodiments, the amino acid unit comprises Val-Cit. In some embodiments, the amino acid unit comprises ValAla. In some embodiments, the MC chemical portion links the antibody chemical portion to the cleavable peptide chemical portion in the linker. In some embodiments, the cleavable peptide chemical portion comprises an amino acid unit. In some embodiments, the amino acid unit comprises Val-Cit. In some embodiments, the amino acid unit comprises ValAla. In some embodiments, the linker comprises MC-Val-Cit. In some embodiments, the linker comprises MC-Val-Ala.

[0310] In some embodiments, any of the linkers in ADCs disclosed in this document may comprise at least one spacer unit that links the antibody chemical portion to the drug chemical portion. In some embodiments, the spacer unit links a cleavage site (e.g., a cleavable peptide chemical portion) in the linker to Petition 870260065905, dated 03 / 07 / 2026, p. 219 / 1400 216 / 650 antibody chemical moiety. In some embodiments, the spacer unit links a cleavage site (e.g., a cleavable peptide chemical moiety) in the ligand to the drug chemical moiety. In some embodiments, the ligand and / or spacer unit in the ligand is substantially hydrophilic. In some embodiments, the ligand includes one or more polyethylene glycol (PEG) chemical moieties, for example, 1, 2, 3, or 4 PEG chemical moieties. In some embodiments, the ligand includes one or more alkyl chemical moieties, for example, 1, 2, 3, 4, or 5 alkyl chemical moieties.

[0311] In some embodiments, the spacer unit in the ligand comprises one or more PEG chemical moieties. In some embodiments, the spacer unit comprises -(PEG)m-, where m is an integer from 1 to 10. In some embodiments, m ranges from 1 to 4; or from 2 to 4. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4. In some embodiments, the spacer unit comprises (PEG)2, (PEG)3, or (PEG)4. In some embodiments, the spacer unit comprises PEG2-Lys(e-PEGe-OMe)-PEG2.

[0312] In some embodiments, the spacer unit in the ligand comprises an alkyl chemical moiety. In some embodiments, the spacer unit comprises -(CH2)n- and n is an integer from 1 to 10 (i.e., n can be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10). In some embodiments, n is 3, 4, or 5. In some embodiments, the spacer unit comprises (CH2)3, or (CH2)4, or (CH2)5. In some embodiments, the spacer unit comprises CH2-CH2.

[0313] In some embodiments, the spacer unit comprises the . In some embodiments, the spacer unit comprises O and (PEG)2. In some embodiments, the unit Petition 870260065905, dated 03 / 07 / 2026, page 220 / 1400 217 / 650 spacer comprises θ coupled with (PEG)2. In some embodiments, the spacer unit comprises N OO Formula (II).

[0314] In some embodiments, the ligands disclosed herein may be used in LD constructs with other D chemical moieties. In some embodiments, the use of a ligand comprising a spacer unit comprising Formula (II) may provide benefits for several D chemical moieties, including, for example, improved conjugation stability, improved plasma stability, and / or in vivo antitumor activity compared with other ligands comprising alternative spacer units. In some embodiments, without being bound by theory, the benefits of using a ligand comprising Formula (II) with a STING agonist disclosed herein, for example, a compound of Formula (III), Formula (IV), or Table 18, for example, Compound 1, may include improved conjugation stability, improved plasma stability, and / or in vivo antitumor activity.In some embodiments, a ligand comprising Formula (II) and a payload comprising a STING agonist disclosed herein, for example, a compound of Formula (III), Formula (IV) or Table 18, demonstrates superior properties when conjugated with an anti-PSMA antibody disclosed herein. Exemplary evidence of the superior benefits of such LD and antibody-drug conjugates is shown in Examples 4, 9, 12 and 15.

[0315] A spacer unit can be used, for example, to link the antibody chemical portion to the drug chemical portion, directly or indirectly. In some embodiments, the spacer unit links the antibody chemical portion to the drug chemical portion directly. In some embodiments, the antibody chemical portion and the drug chemical portion are Petition 870260065905, dated 03 / 07 / 2026, p. 221 / 1400 218 / 650 linked by means of a spacer unit comprising one or more alkyl chemical moieties (e.g., (CH2)3, or (CH2)4, or (CH2)5). In some embodiments, the antibody chemical moiety and the drug chemical moiety are linked by means of a spacer unit comprising one or more PEG chemical moieties (e.g., (PEG)2 or (PEG)3 or (PEG)4). In some embodiments, the antibody chemical moiety and the drug chemical moiety are linked by means of a spacer unit comprising Formula (II). In some embodiments, the spacer unit links the antibody chemical moiety to the drug chemical moiety indirectly.In some embodiments, the spacer unit links the antibody chemical moiety to the drug chemical moiety indirectly through a cleavable chemical moiety (e.g., a cleavable peptide) and / or an antibody-binding chemical moiety to link the spacer unit to the antibody chemical moiety, for example, a maleimide chemical moiety or a carbobenzoxy-L-glutaminyl-glycine chemical moiety.

[0316] In some embodiments, the spacer unit binds to the antibody chemical portion (i.e., the antibody or antigen-binding fragment) via a maleimide (Mal) chemical portion. A spacer unit that binds to the antibody or antigen-binding fragment via a Mal is referred to herein as a “Mal spacer unit.” In some embodiments, the Mal spacer unit is reactive with a cysteine ​​residue in the antibody or antigen-binding fragment. In some embodiments, the Mal spacer unit is attached to the antibody or antigen-binding fragment via the cysteine ​​residue. In some embodiments, the Mal spacer unit comprises a PEG chemical portion. In some embodiments, the Mal spacer unit comprises an alkyl chemical portion. In some embodiments, the Mal spacer unit comprises Formula (II).In some embodiments, the spacer unit binds to the antibody chemical portion (i.e., the antibody or antigen-binding fragment) via a maleimidocaproyl (MC) chemical portion. A. Petition 870260065905, dated 03 / 07 / 2026, page 222 / 1400 219 / 650 a spacer unit that binds to the antibody or antigen-binding fragment via a MC is referred to herein as an “MC spacer unit”. In some embodiments, the MC spacer unit is reactive with a cysteine ​​residue in the antibody or antigen-binding fragment. In some embodiments, the MC spacer unit is attached to the antibody or antigen-binding fragment via the cysteine ​​residue. In some embodiments, the MC spacer unit comprises a PEG chemical moiety. In some embodiments, the MC spacer unit comprises an alkyl chemical moiety. In some embodiments, the MC spacer unit comprises Formula (II).

[0317] In some embodiments, the linker comprises a Mal spacer unit or an MC spacer unit and a cleavable peptide chemical moiety. In some embodiments, the cleavable peptide chemical moiety comprises an amino acid unit. In some embodiments, the amino acid unit comprises Val-Cit. In some embodiments, the amino acid unit comprises Val-Ala. In some embodiments, the linker comprises a Mal spacer unit or an MC spacer unit and an amino acid unit. In some embodiments, the linker comprises Mal(CH2)n and an amino acid unit, wherein n is 3 to 5, or 3, 4, or 5. In some embodiments, the linker comprises MC-(CH2)n and an amino acid unit, wherein n is 3 to 5, or 3, 4, or 5.

[0318] In some embodiments, the linker comprises Mal(PEG)m and an amino acid unit, where m is 2 to 4, or 2, 3, or 4. In some embodiments, the linker comprises MC-(PEG)m and an amino acid unit, where m is 2 to 4, or 2, 3, or 4. In some embodiments, the linker further comprises a cleavable dipeptide, for example, Val-Cit or ValAla. In some embodiments, the linker comprises Mal-(PEG)n-Val-Cit, where n is any number between 1 and 10. In some embodiments, the linker comprises Mal-(PEG)n-Val-Ala, where n is any number between 1 and 10. In some embodiments, the linker comprises MC-(PEG)n-Val-Cit, where n is Petition 870260065905, dated 03 / 07 / 2026, p. 223 / 1400 220 / 650 any number between 1 and 10. In some embodiments, the linker comprises MC-(PEG)n-Val-Ala, where n is any number between 1 and 10.

[0319] In some embodiments, the linker comprises MalFormula (II) and an amino acid unit. In some embodiments, the linker comprises a cleavable dipeptide, for example, Val-Cit or Val-Ala. In some embodiments, the linker comprises MalFormula (II)-Val-Cit. In some embodiments, the linker comprises MalFormula (II)-Val-Ala.

[0320] In some embodiments, the Mal spacer unit or MC spacer unit links the antibody chemical portion (i.e., the antibody or antigen-binding fragment) to the cleavable chemical portion in the ligand. In some embodiments, the Mal spacer unit or MC spacer unit links the antibody or antigen-binding fragment to a cleavable peptide chemical portion. In some embodiments, the cleavable peptide chemical portion comprises an amino acid unit. In some embodiments, the ligand comprises a Mal spacer unit-amino acid unit. In some embodiments, the Mal spacer unit comprises a PEG chemical portion. In some embodiments, the Mal spacer unit comprises an alkyl chemical portion. In some embodiments, the Mal spacer unit comprises Formula (II). In some embodiments, the ligand comprises MC spacer unit-amino acid unit. In some embodiments, the MC spacer unit comprises a PEG chemical portion.In some embodiments, the MC spacer unit comprises an alkyl chemical moiety.

[0321] In several embodiments, the cleavable chemical moiety in the ligand is directly attached to the drug chemical moiety and / or the antibody chemical moiety. In other embodiments, a spacer unit is used to link the cleavable chemical moiety in the ligand to the drug chemical moiety and / or the antibody chemical moiety. In several embodiments, the drug chemical moiety can be any STING agonist drug chemical moiety disclosed in this document, for example, a compound of Formula (III), Formula (IV) Petition 870260065905, dated 03 / 07 / 2026, p. 224 / 1400 221 / 650 or a compound disclosed in Table 18 below. In several embodiments, the drug chemical portion is linked to the cleavable chemical portion in the ligand by a spacer unit. In several embodiments, the drug chemical portion is Compound 1. In several embodiments, the chemical portion of Compound 1 is linked to the cleavable chemical portion in the ligand by a spacer unit. In some embodiments, the drug chemical portion, for example, Compound 1, is linked to the cleavable chemical portion in the ligand by a self-immolating unit. In some embodiments, the drug chemical portion, for example, Compound 1, is linked to the cleavable chemical portion in the ligand by a self-immolating unit, the cleavable chemical portion comprising an amino acid unit and an additional spacer unit, for example, comprising one or more alkyl or PEG chemical portions or Formula (II), links the cleavable chemical portion to the antibody chemical portion.In some embodiments, the drug chemical moiety, for example, Compound 1, is linked to an anti-PSMA antibody via a Mal spacer unit in the ligand linked to a cleavable peptide chemical moiety and a pAB or pABC autoimmolating unit. In some embodiments, the drug chemical moiety, for example, Compound 1, is linked to an anti-PSMA antibody via an MC spacer unit in the ligand linked to a cleavable peptide chemical moiety and a pAB or pABC autoimmolating unit.

[0322] A spacer unit can be “self-immolating” or “non-self-immolating.” A “non-self-immolating” spacer unit is one in which part or all of the spacer unit remains bound to the drug chemical moiety after ligand cleavage. Examples of non-self-immolating units include, but are not limited to, a glycine spacer unit and a glycine-glycine spacer unit. Non-self-immolating units may eventually degrade over time, but do not readily release a fully bound native drug under cellular conditions. A “self-immolating” unit comprises any structure that allows the release of the native drug chemical moiety after administration to an individual, by Petition 870260065905, dated 03 / 07 / 2026, page 225 / 1400 222 / 650 example, under intracellular conditions. A “native drug” is one in which no part of the spacer unit or other chemical modification remains after cleavage / degradation of the spacer unit.

[0323] Self-immolation chemistry is known in the art and can be readily selected for the disclosed ADCs. In several embodiments, the spacer unit linking the chemical moiety in the ligand to the drug chemical moiety (e.g., Compound 1) is self-immolating and undergoes self-immola...

Claims

1. Humanized prostate-specific membrane antigen (PSMA) antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment is characterized in that it binds specifically to human PSMA, and wherein the antibody or antigen-binding fragment comprises (i) three HCDRs comprising amino acid sequences of SEQ ID NO: 21 (HCDR1), SEQ ID NO: 22 (HCDR2) and SEQ ID NO: 27 (HCDR3); and three LCDRs comprising SEQ ID NO: 32 (LCDR1), SEQ ID NO: 35 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the Kabat numbering system; or (ii) three HCDRs comprising amino acid sequences of SEQ ID NO: 21 (HCDR1), SEQ ID NO: 22 (HCDR2) and SEQ ID NO: 27 (HCDR3); and three LCDRs comprising SEQ ID NO: 33 (LCDR1), SEQ ID NO: 36 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the Kabat numbering system;or (iii) three HCDRs comprising amino acid sequences of SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2) and SEQ ID NO: 30 (HCDR3); and three LCDRs comprising SEQ ID NO: 38 (LCDR1), SEQ ID NO: 39 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the IMGT numbering system.

2. Anti-PSMA antibody or antigen-binding fragment according to claim 1, wherein the antibody or antigen-binding fragment is characterized in that it comprises (i) three HCDRs comprising amino acid sequences of SEQ ID NO: 21 (HCDR1), SEQ ID NO: 22 (HCDR2) and SEQ ID NO: 27 (HCDR3); and three LCDRs comprising SEQ ID NO: 32 (LCDR1), SEQ ID NO: 35 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the Kabat numbering system; or (ii) three HCDRs comprising amino acid sequences of Petition 870260065905, dated 03 / 07 / 2026, p. 655 / 1400 2 / 47 SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2) and SEQ ID NO: 30 (HCDR3); and three LCDRs comprising SEQ ID NO: 38 (LCDR1), SEQ ID NO: 39 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the IMGT numbering system.

3. Anti-PSMA antibody or antigen-binding fragment according to claim 1, wherein the antibody or antigen-binding fragment is characterized in that it comprises (i) a variable heavy chain region comprising an amino acid sequence of SEQ ID NO: 1 and a variable light chain region comprising an amino acid sequence of SEQ ID NO: 15; or (ii) a variable heavy chain region comprising an amino acid sequence of SEQ ID NO: 2 and a variable light chain region comprising an amino acid sequence of SEQ ID NO: 15; or (iii) a variable heavy chain region comprising an amino acid sequence of SEQ ID NO: 3 and a variable light chain region comprising an amino acid sequence of SEQ ID NO: 15;or (iv) a variable heavy chain region comprising an amino acid sequence from SEQ ID NO: 14 and a variable light chain region comprising an amino acid sequence from SEQ ID NO: 15; or (v) a variable heavy chain region comprising an amino acid sequence from SEQ ID NO: 14 and a variable light chain region comprising an amino acid sequence from SEQ ID NO: 19.; 4. Anti-PSMA antibody or antigen-binding fragment, according to any one of claims 1 to 3, wherein the antibody or antigen-binding fragment is characterized in that it comprises a variable heavy chain region comprising an amino acid sequence of SEQ ID NO: 14 and a variable light chain region comprising an amino acid sequence of SEQ ID NO:

19.

5. Anti-PSMA antibody or antigen-binding fragment, according to any one of claims 1 to 4, wherein the antibody or antigen-binding fragment is characterized in that it comprises a constant region of human IgG heavy chain.

6. Anti-PSMA antibody or antigen-binding fragment, according to any one of claims 1 to 5, wherein the antibody or antigen-binding fragment is characterized in that it comprises a constant region of human IgG1 heavy chain.

7. Anti-PSMA antibody or antigen-binding fragment, according to any one of claims 1 to 6, wherein the antibody or antigen-binding fragment is characterized in that it comprises a constant region of human Ig kappa light chain.

8. Anti-PSMA antibody or antigen-binding fragment, according to any one of claims 1 to 4, characterized in that the antigen-binding fragment has a melting temperature (Tm) > 80 °C, wherein optionally the antigen-binding fragment is a Fab.

9. Anti-PSMA antibody or antigen-binding fragment, according to any one of claims 1 to 8, wherein the antibody or antigen-binding fragment is characterized in that it is bound to at least one ligand, wherein optionally the at least one ligand is cleavable.

10. Anti-PSMA antibody or antigen-binding fragment, according to claim 9, characterized in that at least one ligand is conjugated with a detectable cytotoxic agent or reagent.

11. Ligand-payload conjugate characterized in that it comprises LD, wherein L is a ligand covalently bonded to D, wherein D comprises a compound according to one of the following formulas: Petition 870260065905, dated 03 / 07 / 2026, page.657 / 1400 4 / 47 Formula (III), Formula (IV), an isomer thereof, a deuterated derivative of the compound or isomer; or a salt of the compound, isomer or deuterated derivative; wherein, independently for each occurrence, each of Pa and Pb, when not racemic, is independently selected from stereochemistry (F?) and stereochemistry (S); each of Qa and Qb is independently selected from NH and O; each of Va and Vb is independently selected from F and OH; W is selected from H and NH2; each of Xa and Xb is independently selected from OH and SH; each of Ya and Yb is independently selected from O and S; each of Za and Zb is independently selected from CH2, O and NH; and means that the bond is selected from a single bond (—), a double bond (=) of configuration (E) or (Z), or a triple bond (=); provided that at least one of Za and Zb is NH or at least one of Xa and Xb is SH.

12. Conjugate binder-payload, according to claim 11, Petition 870260065905, dated 03 / 07 / 2026, page 658 / 1400 5 / 47 characterized in that Pa is of configuration (S) and Pb is of configuration (R).

13. Conjugate binder-payload, according to claim 11, characterized in that Pa is of configuration (R) and Pb is of configuration (R).

14. Conjugate binder-payload, according to any one of claims 11 to 13, characterized in that Qa and Qb are O.

15. Conjugate binder-payload, according to any one of claims 11 to 14, characterized in that Va and Vb are OH.

16. Conjugate binder-payload, according to any one of claims 11 to 14, characterized in that Va and Vb are F.

17. Conjugate binder-payload, according to any one of claims 11 to 16, characterized in that W is H.

18. Conjugate binder-payload, according to any one of claims 11 to 17, characterized in that at least one of Za and ZbéNH.

19. Conjugate ligand-payload, according to any one of claims 11 to 18, characterized in that Za and Zb are NH.

20. Conjugate bond-payload, according to any one of claims 11 to 19, characterized in that it comprises a double bond (=) of configuration (E) or (Z).

21. A coupled bonding-payload system, according to any one of claims 11 to 19, characterized in that the bridge has an H-structure or 22. Conjugate ligand-payload, according to any one of claims 11 to 21, characterized in that at least one of Ya and YbéO.

23. Conjugate binder-payload, according to any of claims 11 to 22, characterized by the fact that Ya and Yb are O.

24. Conjugate binder-payload, according to any one of claims 11 to 23, characterized in that at least one of Xa and Xb is SH.

25. Conjugate binder-payload, according to any one of claims 11 to 24, characterized in that Xa and Xb are SH.

26. Conjugate ligand-payload, according to any one of claims 11 to 25, characterized in that D comprises a compound of Formula (III).

27. Conjugate ligand-payload, according to claim 11, characterized in that D comprises a compound of Formula (III) selected from: Compound 1 Petition 870260065905, dated 03 / 07 / 2026, page 660 / 1400 7 / 47 ο Compound 2 and salts thereof.

28. Conjugate-payload according to claim 11 or 27, characterized in that D comprises a compound of Formula (III) selected from: Petition 870260065905, dated 03 / 07 / 2026, page 661 / 1400 8 / 47 Compound 1 Compound 2 and salts thereof.

29. Conjugate ligand-payload, according to claim 27 or 28, characterized in that D comprises Compound 1.

30. Conjugate ligand-payload, according to claim 27 or 28, characterized in that D comprises Compound 2.

31. Conjugate ligand-payload, according to any one of claims 11 to 30, characterized in that at least one of Xa and Xb is SH and L is linked to D through a sulfur atom on sulfur S-2 or sulfur S-14.

32. Conjugate ligand-payload, according to claim 31, characterized in that Xb is SH and L is bonded to D on sulfur S-2.

33. Conjugate ligand-payload, according to claim 31, characterized in that Xa is SH and L is bonded to D on sulfur S-14.

34. Conjugate ligand-payload, according to any one of claims 11 to 30, characterized in that at least one of Za and Zb is NH and L is linked to D through a nitrogen atom at nitrogen N-34 or nitrogen N-39.

35. Conjugate ligand-payload, according to claim 34, characterized in that Zb is NH and L is bonded to D on nitrogen N-34. Petition 870260065905, dated 03 / 07 / 2026, page 662 / 1400 9 / 47 36. Conjugate ligand-payload, according to claim 34, characterized in that Za is NH and L is bonded to D on nitrogen N-39.

37. Conjugate binder-payload, according to any one of claims 11 to 36, characterized in that L is a cleavable binder.

38. Ligand-payload conjugate, according to claim 37, characterized in that the cleavable ligand comprises a cleavable peptide chemical moiety.

39. Ligand-payload conjugate, according to claim 38, characterized in that the cleavable peptide chemical portion is cleavable by a protease, optionally wherein the protease is a cathepsin or a legumain.

40. Ligand-payload conjugate, according to claim 38 or 39, characterized in that the cleavable peptide chemical portion comprises an amino acid unit.

41. Linker-payload conjugate, according to claim 40, characterized in that the amino acid unit comprises Val-Ala, Val-Cit, Val-Lys, Ala-Ala-Asn, Ala-(NMe)Ala-Asn, Asn, Gly-Gly-Phe-Gly, Glu-ValAla or Gly-Val-Ala.

42. Conjugate binder-payload, according to any one of claims 37 to 41, characterized in that the cleavable binder comprises Val-Ala.

43. Conjugate ligand-payload, according to any one of claims 11 to 42, characterized in that the ligand comprises a chemical moiety of maleimide (Mal).

44. Ligand-payload conjugate, according to claim 43, characterized in that the chemical moiety of Mal comprises maleimidocaproyl (MC).

45. Ligand-payload conjugate, according to claim 43 or 44, characterized in that the chemical portion of Mal is attached to an antibody or antigen-binding fragment by means of a cysteine ​​residue in the antibody or antigen-binding fragment.

46. ​​A binder-payload coupling, according to any one of claims 11 to 45, characterized in that the binder additionally comprises at least one spacer unit.

47. Conjugate binder-payload, according to claim 46, characterized in that at least one spacer unit comprises at least one polyethylene glycol (PEG) chemical moiety.

48. Conjugate ligand-payload, according to claim 47, characterized in that at least one PEG chemical moiety comprises -(PEG)m- where is an integer from 1 to 10.

49. Conjugate-payload ligand according to claim 48, characterized in that m is an integer from 2 to 8.

50. Conjugate binder-payload, according to claim 48 or 49, characterized in that m is an integer from 2 to 5.

51. Conjugate binder-payload, according to any one of claims 48 to 50, characterized in that m is 2.

52. Conjugate binder-payload, according to claim 46 or 47, characterized in that at least one spacer unit comprises PEG2-Lys(s-PEG8-OMe)-PEG2.

53. Bonding-payload coupling, according to claim 46, characterized in that at least one spacer unit comprises O.

54. Conjugate binder-payload, according to claim 46 or 53, characterized in that at least one spacer unit comprises OO Formula (II).

55. Binder-payload conjugate, according to any one of claims 11 to 54, characterized in that the binder additionally comprises at least one self-immolating unit.

56. A binder-payload conjugate, according to claim 55, characterized in that the binder comprises a first self-immolating unit.

57. A ligand-payload conjugate, according to claim 56, characterized in that the ligand has the capacity to be removed from D after cleavage of the ligand by self-immolation of the first self-immolating unit.

58. Ligand-payload conjugate, according to claim 56 or 57, characterized in that the first self-immolating unit comprises a p-aminobenzyl (pAB) optionally substituted by 1-3 substituents chosen from methyl, fluorine, chlorine, trifluoromethyl, aryl and heteroaryl.

59. Ligand-payload conjugate, according to claim 58, characterized in that the first self-immolating unit comprises a p-aminobenzyl (pAB).

60. Binder-payload conjugate, according to any one of claims 55 to 59, characterized in that the binder comprises MC-Val-Ala-pAB.

61. Ligand-payload conjugate, according to any one of claims 56 to 59, characterized in that the first self-immolating unit comprises a p-aminobenzyloxycarbonyl (pABC).

62. A binder-payload conjugate, according to any one of claims 56 to 61, characterized in that the binder additionally comprises a second self-immolating unit.

63. A ligand-payload conjugate, according to claim 62, characterized in that the ligand has the capacity to be removed from D after cleavage of the ligand by self-immolation of the first self-immolating unit and / or self-immolation of the second self-immolating unit.

64. Conjugate binder-payload, according to claim 62 or Petition 870260065905, dated 03 / 07 / 2026, page 665 / 1400 12 / 47 63, characterized in that the binder is removed from D after the binder is cleaved in a stepwise manner by self-immolation of the first self-immolating unit and then self-immolation of the second self-immolating unit.

65. A binder-payload conjugate, according to any one of claims 11 to 41 and 43 to 64, characterized in that the binder comprises a cleavable binder, a first self-immolating unit and a second self-immolating unit.

66. Conjugate binder-payload, according to claim 65, characterized in that the cleavable binder comprises Val-Ala.

67. Conjugate binder-payload, according to claim 65, characterized in that the cleavable binder comprises Val-Cit.

68. Conjugate binder-payload, according to any one of claims 65 to 67, characterized in that the cleavable binder comprises Formula (II).

69. Ligand-payload conjugate, according to claim 65, characterized in that the second self-immolating unit comprises one of the following chemical moieties: Table 1 Second Self-Immolating Unit Chemical Structure Unit 1 (MEC) 1 0 Unit 2 Unit 3 1 0 Unit 4 1 0 Petition 870260065905, dated 03 / 07 / 2026, page 666 / 1400 13 / 47 Table 1 (continued) Second Self-Immolating Unit Chemical Structure Unit 5 1 0 Unit 6 4^ | / \ 11 0 Unit 7 -°γί H 0 Unit 8 / ' o Unit 9 N-\ Άι- / F ß Unit 10 F N-\ 0 Unit 11 FFN—\ 0 Unit 12 ^F Petition 870260065905, dated 03 / 07 / 2026, page 667 / 1400 14 / 47 Table 1 (continued) Second Self-Immolating Unit Chemical Structure Unit 13 FN—( 0 or an isomer thereof.

70. Conjugate ligand-payload, according to claim 65, characterized in that the cleavable ligand comprises Val-Ala and in that the second self-immolating unit comprises one of the following chemical moieties: Table 2 Second Self-Imolating Unit Chemical Structure Unit 1 (MEC) o Unit 2 -I-N^ o Unit 3 0 Unit 4 I -V 0 Unit 5 0 Unit 6 '4^ Unit 7 IH 0 Petition 870260065905, dated 03 / 07 / 2026, page. 668 / 1400 15 / 47 Table 2 (continued) Second Self-Immolating Unit Chemical Structure Unit 8 o, N~\ Vl· Unit 9 N—( V 0 Unit 10 FN—( 0 Unit 11 FFN—( V 0 Unit 12 / ^FN—< 0 Unit 13 F \ / ~F N-\ V 0 or an isomer thereof.

71. Conjugate ligand-payload, according to any one of claims 62 to 70, characterized in that the second self-immolating unit comprises a chemical moiety of Unit 1 (MEC).

72. Conjugate ligand-payload, according to any of claims 62 to 70, characterized in that the second self-immolating unit comprises a chemical portion of Unit 8.

73. Conjugate ligand-payload, according to any one of claims 62 to 70, characterized in that the second self-immolating unit comprises a chemical moiety of Unit 11.

74. Conjugate ligand-payload, according to any one of claims 62 to 70, characterized in that the second self-immolating unit comprises a chemical moiety of Unit 9.

75. Conjugate ligand-payload, according to claim 70, characterized in that the ligand comprises a chemical moiety of Val-Ala-pABC-MEC.

76. Conjugate ligand-payload, according to claim 70, characterized in that the ligand comprises a chemical moiety of MC-Val-Ala-pABC-MEC.

77. Conjugate binder-payload, according to claim 11, characterized in that the LD comprises LP1: O 78. Conjugate ligand-payload, according to claim 69, Petition 870260065905, dated 03 / 07 / 2026, page 670 / 1400 17 / 47, characterized in that the ligand comprises a chemical moiety of Val-Cit-pABC-MEC.

79. Ligand-payload conjugate, according to claim 69, characterized in that the ligand comprises a chemical moiety of MC-Val-Cit-pABC-MEC.

80. Conjugate binder-payload, according to claim 69, characterized in that the LD comprises MC-Val-Cit-pABC-MECCom post 1.

81. Conjugate ligand-payload, according to claim 70, characterized in that the ligand comprises a chemical moiety of Val-Ala-pABC-Unit 8.

82. Conjugate ligand-payload, according to claim 70, characterized in that the ligand comprises a chemical moiety of MC-Val-Ala-pABC-Unit 8.

83. Conjugate binder-payload, according to claim 11, characterized in that the LD comprises LP16:

84. Conjugate ligand-payload, according to claim 69, characterized in that the ligand comprises a chemical moiety of Val-Cit-pABC-Unit 8.

85. Conjugate ligand-payload, according to claim 69, characterized in that the ligand comprises a chemical moiety of MC-Val-Cit-pABC-Unit 8. Petition 870260065905, dated 03 / 07 / 2026, page 671 / 1400 18 / 47 86. Conjugate binder-payload, according to claim 69, characterized in that the LD comprises MC-Val-Cit-pABC-Unit 8Com post 1.

87. Conjugate ligand-payload, according to claim 70, characterized in that the ligand comprises a chemical moiety of Val-Ala-pABC-Unit 11.

88. Conjugate ligand-payload, according to claim 70, characterized in that the ligand comprises a chemical moiety of MC-Val-Ala-pABC-Unit 11.

89. Conjugate binder-payload, according to claim 11, characterized in that the LD comprises LP28: II O-------------------------------------------P 'SH 90. Conjugate ligand-payload, according to claim 69, characterized in that the ligand comprises a chemical moiety of Val-Cit-pABC-Unit 11.

91. Conjugate ligand-payload, according to claim 69, characterized in that the ligand comprises a chemical moiety of MC-Val-Cit-pABC-Unit 11.

92. Conjugate ligand-payload, according to claim 69, characterized in that the LD comprises MC-Val-Cit-pABC-Unit 11-Compound 1.

93. Conjugate ligand-payload, according to claim 70, characterized in that the ligand comprises a chemical portion of Petition 870260065905, dated 03 / 07 / 2026, page 672 / 1400 19 / 47 Val-Ala-pABC-Unit 9.

94. Conjugate ligand-payload, according to claim 70, characterized in that the ligand comprises a chemical moiety of MC-Val-Ala-pABC-Unit 9.

95. Conjugate binder-payload, according to claim 11, characterized in that the LD comprises LP20:

96. Conjugate ligand-payload, according to claim 69, characterized in that the ligand comprises a chemical moiety of Val-Cit-pABC-Unit 9.

97. Conjugate ligand-payload, according to claim 69, characterized in that the ligand comprises a chemical moiety of MC-Val-Cit-pABC-Unit 9.

98. Conjugate binder-payload, according to claim 69, characterized in that the LD comprises MC-Val-Cit-pABC-Unit 9Com post 1.

99. Conjugate ligand-payload, according to claim 69, characterized in that the ligand comprises Formula (H)-Val-Cit-pABC.

100. Conjugate ligand-payload, according to claim 69, characterized in that the ligand comprises a chemical moiety of Formula (H)-Val-Cit-pABC-MEC.

101. Conjugate ligand-payload, according to claim 69, characterized in that the ligand comprises a chemical portion of Petition 870260065905, dated 03 / 07 / 2026, page 673 / 1400 20 / 47 Mal-Formula (II)-Val-Cit-pABC-MEC.

102. Conjugate ligand-payload, according to claim 69, characterized in that the LD comprises Mal-Formula (II)-Val-CitpABC-MEC-Compound 1.

103. Conjugate ligand-payload, according to claim 69, characterized in that the ligand comprises a chemical moiety of Formula (II)-Val-Cit-pABC-Unit 8.

104. Conjugate ligand-payload, according to claim 69, characterized in that the ligand comprises a chemical moiety of Mal-Formula (II)-Val-Cit-pABC-Unit 8.

105. Conjugate ligand-payload, according to claim 69, characterized in that the LD comprises Mal-Formula (II)-Val-CitpABC-Unit 8-Compound 1.

106. Conjugate ligand-payload, according to claim 69, characterized in that the ligand comprises a chemical moiety of Formula (II)-Val-Cit-pABC-Unit 11.

107. Conjugate ligand-payload, according to claim 69, characterized in that the ligand comprises a chemical moiety of Mal-Formula (II)-Val-Cit-pABC-Unit 11.

108. Conjugate ligand-payload, according to claim 69, characterized in that the LD comprises Mal-Formula (II)-Val-CitpABC-Unit 11-Compound 1.

109. Conjugate ligand-payload, according to claim 69, characterized in that the ligand comprises a chemical moiety of Formula (II)-Val-Cit-pABC-Unit 9.

110. Conjugate ligand-payload, according to claim 69, characterized in that the ligand comprises a chemical moiety of Mal-Formula (II)-Val-Cit-pABC-Unit 9.

111. Conjugate binder-payload, according to claim 69, characterized in that the LD comprises Mal-Formula (II)-Val-Cit Petition 870260065905, dated 03 / 07 / 2026, page 674 / 1400 21 / 47 pABC-Unit 9-Compound 1.

112. Conjugate binder-payload, according to claim 70, characterized in that the binder comprises Formula (II)-Val-Ala-pABC.

113. Conjugate ligand-payload, according to claim 70, characterized in that the ligand comprises a chemical moiety of Formula (II)-Val-Ala-pABC-MEC.

114. Conjugate ligand-payload, according to claim 70, characterized in that the ligand comprises a chemical moiety of Mal-Formula (II)-Val-Ala-pABC-MEC.

115. Conjugate binder-payload, according to claim 70, characterized in that the LD comprises Mal-Formula (II)-Val-AlapABC-MEC-Compound 1.

116. Conjugate ligand-payload, according to claim 70, characterized in that the ligand comprises a chemical moiety of Formula (II)-Val-Ala-pABC-Unit 8.

117. Conjugate ligand-payload, according to claim 70, characterized in that the ligand comprises a chemical moiety of Mal-Formula (II)-Val-Ala-pABC-Unit 8.

118. Conjugate binder-payload, according to claim 70, characterized in that the LD comprises Mal-Formula (II)-Val-AlapABC-Unit 8-Compound 1.

119. Conjugate ligand-payload, according to claim 70, characterized in that the ligand comprises a chemical moiety of Formula (II)-Val-Ala-pABC-Unit 11.

120. Conjugate ligand-payload, according to claim 70, characterized in that the ligand comprises a chemical moiety of Mal-Formula (II)-Val-Ala-pABC-Unit 11.

121. Conjugate binder-payload, according to claim 70, characterized in that the LD comprises Mal-Formula (II)-Val-AlapABC-Unit 11-Compound 1. Petition 870260065905, dated 03 / 07 / 2026, p. 675 / 1400 22 / 47 122. Conjugate ligand-payload, according to claim 70, characterized in that the ligand comprises a chemical moiety of Formula (II)-Val-Ala-pABC-Unit 9.

123. Conjugate ligand-payload, according to claim 70, characterized in that the ligand comprises a chemical moiety of Mal-Formula (II)-Val-Ala-pABC-Unit 9.

124. Conjugate binder-payload, according to claim 70, characterized in that the LD comprises Mal-Formula (II)-Val-AlapABC-Unit 9-Compound 1.

125. Conjugate linker-payload, according to claim 69, characterized in that the linker comprises Formula (II)-Val-Cit-pAB.

126. Conjugate ligand-payload, according to claim 69, characterized in that the ligand comprises chemical moiety of Formula (II)-Val-Cit-pAB-Unit 9.

127. Conjugate binder-payload, according to claim 69, characterized in that the binder comprises Mal-Formula (II)-Val-CitpAB.

128. Conjugate ligand-payload, according to claim 69, characterized in that the ligand comprises a chemical moiety of Mal-Formula (II)-Val-Cit-pAB-Unit 9.

129. Conjugate ligand-payload, according to claim 69, characterized in that the LD comprises Mal-Formula (II)-Val-Cit-pABUnit 9-Compound 1.

130. Conjugate binder-payload, according to claim 70, characterized in that the binder comprises Formula (II)-Val-Ala-pAB.

131. Conjugate ligand-payload, according to claim 70, characterized in that the ligand comprises a chemical moiety of Formula (II)-Val-Ala-pAB-Unit 9.

132. Conjugate binder-payload, according to claim 70, characterized in that the binder comprises Mal-Formula (II)-Val-Ala Petition 870260065905, dated 03 / 07 / 2026, page 676 / 1400 23 / 47 pAB.

133. Conjugate ligand-payload, according to claim 70, characterized in that the ligand comprises a chemical moiety of Mal-Formula (H)-Val-Ala-pAB-Unit 9.

134. Conjugate binder-payload, according to claim 11, characterized in that the LD comprises LP25:

135. Conjugate ligand-payload, according to claim 69, characterized in that the ligand comprises a chemical moiety of Formula (H)-Val-Cit-pAB-Unit 11.

136. Conjugate ligand-payload, according to claim 69, characterized in that the ligand comprises a chemical moiety of Mal-Formula (H)-Val-Cit-pAB-Unit 11.

137. Conjugate ligand-payload, according to claim 69, characterized in that the LD comprises Mal-Formula (H)-Val-Cit-pABUnit 11-Compound 1.

138. Conjugate ligand-payload, according to claim 70, characterized in that the ligand comprises a chemical moiety of Formula (H)-Val-Ala-pAB-Unit 11.

139. Conjugate ligand-payload, according to claim 70, characterized in that the ligand comprises a chemical moiety of Mal-Formula (H)-Val-Ala-pAB-Unit 11.

140. Conjugate binder-payload, according to claim 11, characterized in that the LD comprises LP26: Petition 870260065905, dated 03 / 07 / 2026, page 677 / 1400 24 / 47 141. Antibody-drug conjugate of Formula (I): Ab-(LD)p (I) characterized in that Ab is an anti-PSMA antibody or antigen-binding fragment thereof, as defined in any one of claims 1 to 8; LD is a ligand-payload conjugate as defined in any one of claims 11 to 140; ep is an integer from 1 to 20.

142. Antibody-drug conjugate, according to claim 141, characterized in that p is an integer from 1 to 12, preferably where p is an integer from 2 to 8.

143. Antibody-drug conjugate, according to claim 141 or 142, characterized in that p is an integer from 2 to 4.

144. Antibody-drug conjugate, according to any one of claims 141 to 143, characterized in that the ligand comprises a cleavable chemical portion that is positioned so that no part of the ligand or antibody or antigen-binding fragment remains bound to D by cleavage.

145. Antibody-drug conjugate, as defined in any one of claims 141 to 144, characterized in that the ligand-payload conjugate binds to the antibody or antigen-binding fragment via a Mal chemical moiety, wherein the Mal chemical moiety is attached to the antibody or antigen-binding fragment via a cysteine ​​residue in the antibody or antigen-binding fragment.

146. Antibody-drug conjugate, according to claim 145, characterized in that the cysteine ​​residue is in the light chain of the antibody or antigen-binding fragment.

147. Antibody-drug conjugate, according to claim 145, characterized in that the cysteine ​​residue is in the heavy chain of the antibody or antigen-binding fragment.

148. Antibody-drug conjugate, according to any one of claims 141 to 147, characterized in that the antibody or antigen-binding fragment comprises three HCDRs comprising amino acid sequences of SEQ ID NO: 21 (HCDR1), SEQ ID NO: 22 (HCDR2) and SEQ ID NO: 27 (HCDR3); and three LCDRs comprising amino acid sequences of SEQ ID NO: 32 (LCDR1), SEQ ID NO: 35 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the Kabat numbering system.

149. Antibody-drug conjugate, according to any one of claims 141 to 147, characterized in that the antibody or antigen-binding fragment comprises three HCDRs comprising amino acid sequences of SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2) and SEQ ID NO: 30 (HCDR3); and three LCDRs comprising amino acid sequences of SEQ ID NO: 38 (LCDR1), SEQ ID NO: 39 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the IMGT numbering system.

150. Antibody-drug conjugate, according to claim 148 or 149, characterized in that the antibody or antigen-binding fragment comprises a variable heavy chain region comprising an amino acid sequence of SEQ ID NO: 14 and a variable light chain region comprising an amino acid sequence of SEQ ID NO:

19.

151. Antibody-drug conjugate, according to any one of claims 141 to 150, characterized in that LD comprises LP16, LP20, LP26 or LP28.

152. Antibody-drug conjugate, according to any one of claims 141 to 151, characterized in that the LD comprises LP16:

153. Antibody-drug conjugate, according to any one of claims 141 to 151, characterized in that the LD comprises LP20:

154. Antibody-drug conjugate, according to any one of claims 141 to 151, characterized in that the LD comprises LP26: Petition 870260065905, dated 03 / 07 / 2026, p. 680 / 1400 27 / 47 155. Antibody-drug conjugate, according to any one of claims 141 to 151, characterized in that the LD comprises LP28:

156. Pharmaceutical composition characterized in that it comprises the antibody or antigen-binding fragment, as defined in any one of claims 1 to 10, the ligand-payload conjugate, as defined in any one of claims 11-140, or the antibody-drug conjugate, as defined in any one of claims 14-155, and a pharmaceutically acceptable carrier.

157. Composition characterized in that it comprises multiple copies of an antibody-drug conjugate of Formula (I): Ab-(LD)p (I) wherein Ab is an anti-PSMA antibody or antigen-binding fragment thereof, as defined in any one of claims 1 to 8; Petition 870260065905, dated 03 / 07 / 2026, p. 681 / 1400 28 / 47 LD is a ligand-payload conjugate as defined in any one of claims 11 to 140; ep is the average number of LD chemical moieties per Ab, wherein the average op of the antibody-drug conjugates in the composition is from about 2 to about 8.

158. Composition according to claim 157, characterized in that the antibody or antigen-binding fragment comprises three HCDRs comprising amino acid sequences of SEQ ID NO: 21 (HCDR1), SEQ ID NO: 22 (HCDR2) and SEQ ID NO: 27 (HCDR3); and three LCDRs comprising SEQ ID NO: 32 (LCDR1), SEQ ID NO: 35 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the Kabat numbering system; or three HCDRs comprising amino acid sequences of SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2) and SEQ ID NO: 30 (HCDR3); and three LCDRs comprising SEQ ID NO: 38 (LCDR1), SEQ ID NO: 39 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the IMGT numbering system; and the LD comprises LP16:

159. Composition according to claim 157, characterized in that the antibody or antigen-binding fragment comprises three HCDRs comprising amino acid sequences of SEQ ID NO: 21 (HCDR1), SEQ ID NO: 22 (HCDR2) and SEQ ID NO: 27 (HCDR3); and three LCDRs comprising SEQ ID NO: 32 (LCDR1), SEQ ID NO: 35 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the Kabat numbering system; or three HCDRs comprising amino acid sequences of SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2) and SEQ ID NO: 30 (HCDR3); and three LCDRs comprising SEQ ID NO: 38 (LCDR1), SEQ ID NO: 39 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the IMGT numbering system; and the LD comprises LP20: the 160. Composition according to claim 157, characterized in that the antibody or antigen-binding fragment comprises three HCDRs comprising amino acid sequences of SEQ ID NO: 21 (HCDR1), SEQ ID NO: 22 (HCDR2) and SEQ ID NO: 27 (HCDR3); and three LCDRs comprising SEQ ID NO: 32 (LCDR1), SEQ ID NO: 35 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the Kabat numbering system; or three HCDRs comprising amino acid sequences of SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2) and SEQ ID NO: 30 (HCDR3); and three LCDRs comprising SEQ ID NO: 38 (LCDR1), SEQ ID NO: 39 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the IMGT numbering system; and the LD comprises LP26: Petition 870260065905, dated 03 / 07 / 2026, page 683 / 1400 30 / 47 161. Composition according to claim 157, characterized in that the antibody or antigen-binding fragment comprises three HCDRs comprising amino acid sequences of SEQ ID NO: 21 (HCDR1), SEQ ID NO: 22 (HCDR2) and SEQ ID NO: 27 (HCDR3); and three LCDRs comprising SEQ ID NO: 32 (LCDR1), SEQ ID NO: 35 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the Kabat numbering system; or three HCDRs comprising amino acid sequences of SEQ ID NO: 28 (HCDR1), SEQ ID NO: 29 (HCDR2) and SEQ ID NO: 30 (HCDR3); and three LCDRs comprising SEQ ID NO: 38 (LCDR1), SEQ ID NO: 39 (LCDR2) and SEQ ID NO: 37 (LCDR3), as defined by the IMGT numbering system; and the LD comprises LP28:

162. Composition, according to any one of claims 157 to 161, characterized in that the antibody or antigen-binding fragment comprises a variable heavy chain region comprising an amino acid sequence of SEQ ID NO: 14 and a variable light chain region comprising an amino acid sequence of SEQ ID NO:

19.

163. A method for treating a patient who has or is at risk of having cancer, characterized in that it comprises administering to the patient a therapeutically effective amount of the antibody or antigen-binding fragment, as defined in any one of claims 1 to 10, the ligand-payload conjugate, as defined in any one of claims 11 to 140, the antibody-drug conjugate, as defined in any one of claims 141 to 155, the pharmaceutical composition, as defined in claim 156, or the composition, as defined in any one of claims 157 to 162.

164. A method for reducing or inhibiting the growth of a cancer, characterized in that it comprises administering a therapeutically effective amount of an antibody or antigen-binding fragment, as defined in any one of claims 1 to 10, of the ligand-payload conjugate, as defined in any one of claims 11 to 140, of the antibody-drug conjugate, as defined in any one of claims 141 to 155, of the pharmaceutical composition, as defined in claim 156, or of the composition, as defined in any one of claims 157 to 162.

165. Use of an antibody or antigen-binding fragment, as defined in any one of claims 1 to 10, of the ligand-payload conjugate, as defined in any one of claims 11 to 140, of the antibody-drug conjugate, as defined in any one of claims 141 to 155, of the pharmaceutical composition, as defined in claim 156, or of the composition, as defined in any one of claims 157 to 162, characterized in that it is in the manufacture of a medicament for the treatment of cancer.

166. Use of an antibody or antigen-binding fragment, as defined in any one of claims 1 to 10, of the ligand-payload conjugate, as defined in any one of claims 11 to 140, of the antibody-drug conjugate, as defined in any one of claims 141 to 155, of the pharmaceutical composition, as defined in claim 156, or of the composition, as defined in any one of claims 157 to 162, characterized in that it is in the treatment of a cancer.

167. Method according to claim 163 or 164, or use according to claim 165 or 166, characterized in that the cancer expresses PSMA.

168. Method according to claim 163 or 164, or use according to claim 165 or 166, characterized in that the cancer is prostate cancer.

169. Method for producing the antibody-drug conjugate, as defined in any one of claims 141 to 155, or composition, as defined in any one of claims 157 to 162, characterized in that it comprises reacting an antibody or antigen-binding fragment, as defined in any one of claims 1 to 8, with a ligand-payload conjugate, as defined in any one of claims 11 to 140.

170. Antibody-drug conjugate characterized in that it is produced according to the method as defined in claim 169.

171. Method for producing an LD (V) conjugate: Petition 870260065905, dated 03 / 07 / 2026, page 686 / 1400 33 / 47 wherein the method is characterized in that it comprises reacting a compound of Formula (III), as defined in claim 11: or a salt thereof with an activated ligand comprising a suitable ligand having the following structure: ° ίΎN°2 Ligand for producing the LD (V) conjugate, wherein Zb is NH.

172. Method according to claim 171, characterized in that Pb has (S) configuration, and the activated ligand reacts preferentially with Zb.

173. Method for producing an LD (VI) conjugate: Petition 870260065905, dated 03 / 07 / 2026, page 687 / 1400 34 / 47 wherein the method is characterized in that it comprises reacting a compound of Formula (III), as defined in claim 11: or a salt thereof with an activated ligand comprising a suitable ligand having the following structure: to produce the LD (VI) conjugate, wherein Zb is NH.

174. Method according to claim 173, characterized in that Pb has (S) configuration, and the activated ligand reacts preferentially with Zb. Petition 870260065905, dated 03 / 07 / 2026, p. 688 / 1400 35 / 47 175. Method according to any one of claims 171 to 174, characterized in that the compound of Formula (III) is Compound 1.

176. Ligand-drug conjugate characterized in that it is produced by the method as defined in any one of claims 171 to 175.

177. Method for producing an antibody-drug conjugate, wherein the method is characterized in that it comprises conjugating the antibody or antigen-binding fragment, as defined in any one of claims 1 to 8, with the LD conjugate, as defined in any one of claims 11 to 140, under suitable binding conditions.

178. Composition characterized in that it comprises the binder-payload conjugate, as defined in any one of claims 11 to 140.

179. Composition characterized in that it comprises a binder-payload conjugate produced according to the method as defined in any one of claims 171 to 175.

180. Bonding-payload combination according to claim 11, wherein the bonding-payload combination is characterized in that it is selected from the following bonding-payload combinations:

Images